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Laboratory results play an important role in assessment of one’s health status including detection 
of sub-clinical disease. Reference intervals (RIs) have been shown to vary across different 
populations due to various reasons including ethnic and racial differences, differences in reference 
populations and statistical approaches used in deriving the RIs. The International Federation of 
Clinical Chemistry committee on reference intervals and decision limits has been carrying out a 
global study aimed at harmonizing RIs. Kenya is the only country in East Africa that participated 
in this study and therefore the derived RIs will serve as a reference point for laboratories in the 
region. It is also important to identify what factors cause variations in RIs and whether partitioning 
based on age or sex will make them more specific. We subsequently compared our RIs with those 
from South Africa also derived as part of the global RI study. 
Methods 
Recruitment of study participants in Kenya was carried out between January and October 2015 in 
several counties after obtaining informed consent. Inclusion of participants was limited to healthy 
adults aged 18-65 years stratified into 4 age groups: 18-29, 30-39, 40-49 and 50-65 years. 
Haematology tests were performed at the PathCare laboratories in Nairobi, Kenya while all other 
analysis was done at the PathCare reference laboratory in Cape Town, South Africa. For purposes 
of the global RI study, all participating laboratories received a panel of sera that had assigned 
values to enable recalibration of reference values (RVs) and alignment across different countries. 
RIs were determined using both parametric and non-parametric methods before and after applying 
the latent abnormal values exclusion (LAVE) method.  
Results 
Out of 596 volunteers, 533 met the inclusion criteria: 260 (48.8%) males and 273 (51.2%) females. 
The prevalence of metabolic syndrome (MetS) was 25.6% and less than 1% of participants had 
reduced estimated glomerular filtration rate (eGFR). Sex-specific RIs were required for uric acid, 
creatinine, total bilirubin (TBil), total cholesterol (TC), transaminases, transferrin, transferrin 
saturation and immunoglobulin-M. Age-specific RIs were required for glucose and triglyceride for 
both sexes, and for urea, magnesium (Mg), TC, HDL-cholesterol ratio, alkaline phosphatase 
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(ALP), and ferritin for females. Kenyan RIs were comparable to those of other countries 
participating in the global study with a few exceptions such as higher ULs for TBil and c-reactive 
protein (CRP). South African RIs for uric acid, TC, low density lipoptotein cholesterol, alanine 
transaminase, lactate dehydrogenase, ALP, albumin, Mg, thyroid stimulating hormone and 
prostate specific antigen were lower than the Kenyan RIs. 
Conclusion 
Kenyan RIs for several analytes were established using a harmonized protocol from well-defined 
reference individuals. Given the rigour with which the study was conducted, the derived RIs will 
provide a useful reference for laboratories in sub-Saharan Africa that are looking for RIs for 
common haematology and biochemistry tests. For most analytes, harmonization of RIs between 
Kenyans and South Africans of African ancestry was not possible as they could result in 
misclassification of individuals as either diseased or healthy given the differences seen. 
  





Laboratorium uitslae speel ‘n belangrike rol in die behandeling en diagnose van onderliggende 
siektes in pasiente.  Normale reikwydtes (NW) vertoon verskillend oor bevolkingsgroepe om 
verskeie redes: etniese- en verwysings polulasie verskille asook verskillende statistiese metodes 
wat gebruik word.  Die Internationale Federasie van Kliniese Chemie se kommitee vir reikwydtes 
en bepalings limiete koördineer ‘n globale projek om te bepaal of NW geharmoniseer kan word of 
nie.  Kenya was die enigste land in Oos Afrika wat aan die globale projek deegeneem het.  Kenya 
NW’s kan dien as verwysingsraamwerk vir ander laboratoria in die streek.  Dit is belangrik in 
studies van hierdie aard om te bepaal watter faktore variasies in NW sal veroorsaak en die 
noodsaklikheid om ‘n skeiding te maak in NW om dit spesifiek te maak vir ouderdom en geslag.  
Hierdie studie het die NW van Kenya met die van Suid Afrika (RSA) vergelyk wat ook deegeneem 
het aan die globale projek. 
Metode 
Werwing van deelnemers in diè studie was gedoen in verskeie graafskappe in Kenya tussen 
Januarie en Oktober 2015 met ingeligte toestemming.  Gesonde deelnemers was toegelaat om deel 
te neem tussen 18 – 65 jarige ouderdom, met verdere subverdeel in 4 verskillende 
ouderdomsgroepe: 18 – 29, 30 – 39, 40 – 49 en 50 – 65.  Haematologiese analise van 
bloedmonsters was gedoen by PathCare Laboratorium in Nairobi, Kenya.  Alle ander analise was 
gedoen was by PathCare se Verwysingslaboratorium in Kaapstad, RSA.  Vir die doeleindes van 
die globale studie het alle deelnemende lande ‘n paneel sera ontvang met voorafbepaalde waardes 
wat hulle moes analiseer.  Diè waardes was gebruik om verwysingswaardes te herkalibeer asook 
om waardes van die verskillende lande te kombineer en harmoniseer.  Parametiese – asook nie-
parametiese statisiek metodes was gebruik om NW te bepaal voor en na latente abnormale waarde 
uitskakelings (LAVE) toegepas was.   
Resultate 
596 deelenemers het deelgeneem; daar slegs 533 oor na toepassing van streng kriteria waarvan 
260 (48.8%) mans en 273 (51.2%) vrouens was. Metaboliese sindroom (MetS) voorkoms onder 
deelnemers was 25.6%.  < 1% van deelnemers het ‘n verminderde geskatte glomulêre filtrasie 
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tempo (eGFR) gehad.  Geslag spesifieke NW was nodig vir uriensuur, kreatinien, totale bilirubin 
(TBil), totale cholesterol (TC), transaminases, transferrien, transferrien saturasie en 
immunoglobulien – M.  Ouderdom spesifieke NW was nodig vir glukose en trigliseriede vir beide 
geslagte.  NW vir vroulike deelnemers vir ureum, magnesium, TC, HDL-cholesterol verhouding, 
alkaliese phosfatase (ALP) en ferritien.  NW vir Kenya kon vergelyk word met ander lande wat 
deelgeneem het met etlike uitsonderings vir boonste limiet waardes vir TBil en c-reaktiewe protein 
(CRP).  Die NW van Suid Afrika vir uriensuur, lae densiteit lipoprotein cholesterol, alanine 
transaminase, laktaat dehidrogenase, ALP, albumien, magnesium, tiroïd stumulerings hormoon en 
prostaat spesifieke antigeen was laer as die NW van Kenya. 
Konklusie 
NW vir Keyna was bepaal deur ‘n geharmoniseerde protokol met goed gedefiniheerde 
verwysingsraamwerk en kan dien as verwysingsraamwerk vir ander laboratoria in die streek asook 
vir sub-Sahara Afrika lande vir algemene haematologiese – en kliniese chemie toetse.  Kenya en 
RSA se NW’s kon nie geharmoniseer word nie; dit kan lei tot misklassifikasie van pasiente as óf 
gesond óf met onderliggende siektetoestande. 
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OUTLINE OF THE DISSERTATION 
The dissertation is organized into eight chapters. Chapter 1 is a general introduction that surmises 
the importance of deriving population specific reference intervals for laboratory tests, study 
justification, hypotheses, research questions and objectives. Chapter 2 is the literature review that 
highlights the variation of reference intervals across populations, various statistical methods used 
in deriving RIs, review of clinical decision limits, biochemical abnormalities in a reference 
population and assessment of renal dysfunction in asymptomatic individuals. Chapter 3 is a 
published manuscript on the prevalence of metabolic syndrome in adult reference individuals 
recruited from Kenya as part of the global study on reference intervals. This study also proposes 
optimal cut-offs for the different components of metabolic syndrome for the Kenyan population. 
Chapter 4 is a published manuscript on comparison of equations for estimating glomerular 
filtration rate in screening for chronic kidney disease in healthy Kenyan adults recruited as part of 
the global study on reference intervals. Chapter 5 is a published manuscript on reference intervals 
for complete blood count parameters for the Kenyan population and comparison with similar 
studies from Africa and North America highlighting similarities and differences. Chapter 6 is a 
published manuscript on reference intervals for clinical chemistry and immunoassay tests for the 
Kenyan adult population and comparison with similar studies carried out by the committee of 
reference intervals and decision limits (C-RIDL) of the International Federation of Clinical 
Chemistry (IFCC). Chapter 7 is a yet to be published manuscript that compares reference intervals 
between Kenya and South Africa. It also explores sources of variation in reference values including 
age, sex and BMI. Chapter 8 is an integrated summary of the key findings and recommendations 
on what needs to be done with regards to reference interval determination. Each chapter has its 
own references which have all been formatted in a common style across all chapters to provide 
consistency. However, some chapters retain some formatting aspects unique to the journal 
requirements. The last part of the dissertation is the appendix which has copies of study approvals, 
consent form and questionnaire.  
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CHAPTER 1:  GENERAL INTRODUCTION 
1.1. Introduction 
Laboratory results play an important role in assessment of one’s health status including detection 
of sub-clinical disease and ruling in or ruling out clinical diagnosis. In order to make laboratory 
test results more reliable, harmonization of all levels of the testing cycle is required (Miller, Tate, 
Barth, & Jones, 2014). Harmonization in laboratory testing goes beyond standardization of the 
analytical process, it includes standardizing pre-analytical processes such as sample collection 
and processing as well as post analytical processes such as use of appropriate reference intervals 
(RIs) and interpretive comments. It has been argued that RIs are the most common decision 
support tool used for interpretation of quantitative laboratory results and that the quality of the 
RIs may be as important as the quality of the result itself (G. Jones & Barker, 2008). It has been 
shown that the variation in RIs across laboratories for some tests may be much greater than the 
analytical accuracy of their measurements (G. R. D. Jones, Barker, Tate, Lim, & Robertson, 
2004). This implies that the same patient result obtained by two laboratories that use the same 
assay but different RIs can result in different clinical interpretation and possibly initiate a 
cascade of testing that is unnecessary. 
 
In Europe, in-vitro diagnostic companies are required by law to provide RIs for healthy and 
diseased individuals where appropriate for the test values determined using their equipment as 
this aids in better interpretation of the generated values (EU, 2017). The International 
Organization for Standardization (ISO) 15189 standard for medical laboratories states that “a 
laboratory shall define the biological reference intervals or clinical decision values, document the 
basis for the reference intervals or decision values and communicate this information to users” 
(ISO, 2012). The Clinical Laboratory Standards Institute (CLSI) has also published guidelines 
that guide the establishment of reference intervals in clinical laboratories in order to standardize 
the process of determining RIs. These guidelines are modelled around discussions of an expert 
panel of the International Federation of Clinical Chemistry (IFCC) on reference intervals that 
were published as 6 papers from as far back as 1986 (Dybkœr & Solberg, 1987; PetitClerc & 
Solberg, 1987; Solberg, 1984, 1987; Solberg & PetitClerc, 1988; Solberg & Stamm, 1991). The 
best method for deriving RIs is a formal study where samples are collected from a reference 
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group comprising a minimum of 120 individuals identified from a reference population through 
probability sampling (CLSI, 2010). CLSI recommends verification of RIs as an option in the 
event that establishing population specific RIs is not possible. In-vitro diagnostic companies also 
recommend local validation of the RIs reported in their reagent inserts. Even though verification 
is an affordable alternative, formal derivation of RIs should be attempted where possible. 
 
RIs have been shown to vary across different populations due to various reasons including ethnic 
and racial differences, differences in reference populations including differences in body mass 
index (BMI), and differences in statistical approaches used in deriving RIs (Ichihara et al., 2008; 
Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017). Despite these known sources of variation in RIs, 
many countries in sub-Saharan Africa (SSA) adopt manufacturer proposed RIs which are largely 
derived from a Caucasian population and some of these RIs may not be appropriate. For 
instance, it is known that Africans in SSA have low absolute neutrophil counts compared to 
individuals of European ancestry (Karita et al., 2009). This lower neutrophil count is thought to 
be an adaptation that is related to the presence of a null genotype of the duffy antigen receptor 
complex (DARC) which confers resistance to infection by Plasmodium vivax (Haddy, Rana, & 
Castro, 1999; Thobakgale & Ndung'u, 2014). In Tanzania, RI upper limits for lactate 
dehydrogenase (LDH), creatine kinase (CK) and total bilirubin (TBil) were found to be double 
that of similar RIs from the United States of America (USA) (Saathoff et al., 2008). Despite the 
well-established evidence of such differences, there is reluctance by many laboratories in SSA to 
adopt RIs derived from their own populations possibly due to a paucity of high quality studies 
carried out using universally approved and accepted guidelines for RI derivation.  
 
The International Federation of Clinical Chemistry (IFCC) committee on reference intervals and 
decision limits (C-RIDL) has been carrying out a global study aimed at harmonizing RIs. A key 
strategy for this study is the use of harmonized protocols for the pre-analytical, analytical and 
post-analytical processes (Ozarda, Ichihara, Barth, & Klee, 2013). This will enable comparison 
of reference values and RIs across different geographical jurisdictions and exploration of sources 
of variation such as age, sex and BMI. A critical component of this process is ensuring that 
reference individuals who are recruited are reflective of a healthy population enabling the 
extrapolation of results to the community. Unfortunately, given the subjectivity associated with 
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defining health (Petitclerc, 2004), it is not always a guarantee that people who define themselves 
as healthy are free of sub-clinical disease given that some medical conditions are preceded by a 
prolonged asymptomatic period. This has been a major confounder in the derivation of RIs.  
 
It has been demonstrated that the association between BMI and health risks varies across races 
and ethnicities and that the prevalence of conditions such diabetes and hypertension vary across 
races even for the same BMI categories. Across races, increasing BMI is associated with 
increased health risks (Stommel & Schoenborn, 2010). The presence of conditions such as 
metabolic syndrome (MetS) and elevated BMI have been associated with variation in reference 
values necessitating their consideration when deriving RIs (Ichihara, Ozarda, Barth, Klee, Qiu, et 
al., 2017). Therefore, it is important to know the BMI of reference individuals and the prevalence 
of conditions such as MetS in your reference population in order to better understand their 
association with reference values. 
 
Early chronic kidney disease (CKD) is often times asymptomatic and could be present in 
individuals who are subjectively healthy including those who would volunteer as reference 
individuals in a RI study. In such individuals, screening for CKD is dependent on determining 
their glomerular filtration rate (KDIGO, 2013). It is recommended that routine reporting of 
estimated glomerular filtration rate (eGFR) with every request for serum creatinine be adopted to 
enhance awareness of CKD, early detection of CKD and the institution of early interventions to 
slow its progression. There is value in determining the prevalence of reduced eGFR in reference 
individuals as this would affect RIs derived for renal function tests. However, there is 
controversy on which equation should be used in determining eGFR in an asymptomatic 
population given that serum creatinine based equations derived from Caucasian populations have 
been shown to be inappropriate for other races (Hans Pottel, Hoste, Delanaye, Cavalier, & 
Martens, 2012). Furthermore, the issue of whether to correct for race when screening 
asymptomatic Africans for CKD is yet to be settled.  
 




The IFCC recommends that population specific RIs should be determined in recognition of 
variations that may arise due to various reasons including ethnic, racial, diet and environmental 
differences. There is a need for RIs for haematology and biochemistry laboratory tests derived 
using well standardized guidelines for the Kenyan and East African population. Most of the 
studies carried out in the East Africa region were carried out by the Center for Disease control 
(CDC) and International Aids and Vaccine Initiative (IAVI) either as part of disease surveillance 
or prior to the roll out of HIV related clinical trials. Many of these studies were not meticulous in 
identifying reference populations and often times recruited reference individuals who would not 
suffice as being representative of a healthy population. Kenya is the only country in East Africa 
that participated in the global RI study and therefore the derived RIs will serve as a reference 
point for laboratories in the region in the short term but can also provide leadership in this field 
so that intra-regional differences in RIs can be determined. The determination and use of RIs that 
are specific to Kenya and by extension the wider East African region will ensure that diagnosis, 
prognosis, treatment, follow up and disease surveillance is done based on appropriate laboratory 
cut-offs.  
 
It is also important to identify what factors cause variations in RIs in the Kenyan population and 
whether partitioning of RIs based on age or sex will make them more specific. The magnitude of 
the effect of these variables on the distribution of reference values in different populations is not 
necessarily the same. We have no data from Kenya or the East African region on how RIs for 
certain analytes vary with age or sex and the effect of BMI. Furthermore, the use of clinical 
decision limits (CDLs) to guide diagnosis of diseases like diabetes or to influence treatment of 
dyslipidemia requires consideration of local RIs for the respective tests.  
 
Few studies have been carried out in Kenya looking at the prevalence of MetS or renal 
dysfunction adjudged by reduced estimated glomerular filtration rate (eGFR) in the general 
population and in particular healthy adults. The prevalence of these conditions which often times 
are sub-clinical may impact derivation of RIs and more importantly can inform public health 
interventions aimed at reducing their prevalence given the associated morbidity and mortality if 
not addressed. 




In order to investigate the potential influence of environmental factors such as geographical 
location, diet, physical activity, alcohol intake and smoking on RIs, the derived Kenyan RIs were 
compared to South African RIs derived from a similar study carried out using the same 




1. Kenyan RIs for common haematology and biochemical tests differ from those proposed by 
in-vitro diagnostic companies and published studies 
2. Kenyan RIs vary with age, sex and BMI 
3. Kenyan RIs differ from South African RIs 
 
1.4. Research questions 
1. Are CLSI/IFCC protocol derived RIs for common haematology and biochemical analytes in 
healthy adult Kenyan subjects different from those stated in manufacturer reagent inserts or 
published studies? 
2. Are such derived RIs affected by age, sex or BMI? 
3. Will such RIs derived from a Kenyan population be different from those derived from a 
South African population? 
4. Would such healthy populations identified through a questionnaire and physical examination 
have metabolic syndrome or renal dysfunction? 
5. Which equation for estimating eGFR is most appropriate to use in assessing renal 
dysfunction in healthy Kenyan adults? 
 
1.5. Objectives 
1. To establish age and sex specific haematology and chemistry RIs for an adult Kenyan 
population 
2. To determine the association between age, sex, BMI and RIs in the Kenyan population 
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3. To determine whether there is a difference in RIs between Kenya and South Africa 
4. To determine the prevalence of metabolic syndrome and reduced estimated glomerular 
filtration rate in healthy Kenyan adults 
5. To evaluate various equations for eGFR determination in subjectively healthy Kenyan adults 
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CHAPTER 2:  LITERATURE REVIEW 
2.1 Variation of reference intervals in different populations  
There have been several attempts to derive RIs in various continents. The Nordic Reference 
Interval Project (NORIP) was one of the landmark studies whose aim was to establish common 
adult Nordic RIs for 25 clinical biochemical tests frequently measured in serum and plasma. 
Recruitment of reference individuals above the age of 18 years, collection of samples and 
analyses was done in 102 medical laboratories in 5 Nordic countries using a common protocol. 
The results showed no significant differences for the included tests  across the 5 countries and 
subsequently common RIs were adopted (Rustad et al., 2009). The upper reference limits for 
alanine transaminase (ALT), aspartate transaminase (AST), creatinine kinase (CK) and gamma-
glutamyl transferase (GGT) were found to be higher compared to the ones recommended by the 
IFCC. The study also demonstrated increase in total cholesterol (TC) and low density lipoprotein 
cholesterol (LDL-C) with increase in age for both males and females. High density lipoprotein 
cholesterol (HDL-C) was found to be lower in males than in females which is in keeping with 
what has been published (Burtis, Ashwood, & Bruns, 2005). One interesting finding was the lack 
of a significant difference in the RI upper limit for potassium between serum and plasma 
samples. Potassium levels are usually higher in serum as a result of cellular leakage that occurs 
during clot formation. A reference clinical chemistry text book recommends a RI of 3.5-5.1 
mmol/L for serum and 3.4-4.4 mmol/L for plasma (Burtis et al., 2005). For the NORIP study, 
RIs for serum and plasma were 3.6-4.6 mmol/L and 3.5-4.4 mmol/L respectively.  
 
Several RI studies have been published from the Asian continent including one that derived RIs 
for selected serum proteins in 6 Asian countries from adults aged 20-60 years. Despite analysis 
being performed in a central laboratory to reduce chances of variation due to different 
measurement procedures and adjustment done for age, sex, and lifestyle variables, marked 
regional variations were still seen between the participating countries  for some proteins like c-
reactive protein (CRP), complement 3 (C3) and immunoglobulin G (IgG) (Ichihara et al., 2008). 
These differences were thought to be due to genetic or environmental differences. A more recent 
study reported on RIs for 31 standardized tests in both males and females aged 20-65 years from 
Japan and a few other countries in South East Asia. Despite all attempts to standardize 
recruitment so as to have a fairly homogeneous population, it was surprising that significant 
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regional variation was seen for HDL-C, IgG, C3, complement 4 (C4), and CRP. However, when 
data was analyzed for Japan only, there were no significant age and gender variations hence 
common RIs were calculated without age and sex stratification (Ichihara, Ceriotti, Tam, et al., 
2013). The hypothesis suggested for the increase in inflammatory markers seen in these 2 Asian 
studies is increased exposure to infectious agents as you move closer to the equator.  
 
In Turkey, a RI study enrolled 3066 healthy individuals in the age group 20-65 years from 7 
regions in the country. This study found gender related differences in 10 analytes; uric acid 
(UA), urea nitrogen (UN), total bilirubin (TBIL), creatinine, triglycerides (TG), HDL-C, ALT, 
AST, CK, and GGT), and age-related differences in 7 analytes (albumin (ALB), UN, TG, Low 
Density Lipoprotein cholesterol (LDL-C), total cholesterol, glucose and alkaline phosphatase. 
The study showed no major differences between the selected regions within the country and 
therefore proposed common RIs for the selected tests. A secondary exclusion of individuals with 
a BMI >28 kg/m2 resulted in narrower RIs for UA, GLU, TG, HDL-C, LDL-C, ALT and GGT. 
This shows that BMI is an important covariate for specific RIs in particular those associated with 
metabolic syndrome (MetS). Of note, the upper limit for RIs for glucose, TC, HDL-C, LDL-C 
and TGs were higher than the well-recognized clinical decision limits (CDLs). For example, the 
upper limit for TC was determined to be 6.45 mmol/L which is significantly higher than the CDL 
of 5 mmol/L. The authors hypothesized that this could be due to the presence of sub-clinical 
disease such as MetS or pre-diabetes in the individuals enrolled for the study (Ozarda et al., 
2014). 
 
Regional variations in RIs even within the same country have been described especially for 
haematological parameters. Ozarda et al carried out a multicentre study in Turkey to establish 
RIs for haematological parameters and found regional differences for red blood cells (RBC), 
haemoglobin (HB), hematocrit (HCT), unsaturated iron binding capacity (UIBC), and total iron 
binding capacity (TIBC). Not surprisingly, there was an association between altitude and HB, 
HCT and ferritin in males, and RBC, HB, HCT, and TIBC in females with higher values found 
in areas with high altitude (Ozarda et al., 2017).   
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In Africa, there are several published studies on RIs from different countries (Karita et al., 2009; 
Miri-Dashe et al., 2014; Segolodi et al., 2014). Many of the studies have been driven by the need 
for robust population specific RIs required for clinical trials where patient follow up and 
laboratory monitoring of adverse events is essential. Using RIs derived from reference 
populations that are not similar to the local population where the clinical trial is being carried out 
may result in inappropriate exclusion or inclusion of potential trial volunteers and makes 
laboratory assessment of adverse events challenging. Karita et al carried out a cross sectional, 
observational study of healthy adults aged 18-60 years in multiple African research centers in 
Kenya, Uganda, Zambia and Rwanda from December 2004 to October 2006. Compared to RIs 
from the United States of America (USA), the study found lower HCT and HB levels which 
were more pronounced in women, lower total white blood cell (WBC) and neutrophil counts, and 
lower amylase levels (Karita et al., 2009). Genetic deletion of the Duffy antigen receptor for 
chemokines (DARC-null genotype) is thought to contribute to the neutropenia seen in Africans 
and African-Americans. DARC is thought to be a receptor for Plasmodium vivax malaria and the 
null genotype may have been positively selected among Africans (Thobakgale & Ndung'u, 
2014). Both sexes showed elevated eosinophil counts, IgG, total and direct bilirubin, lactate 
dehydrogenase (LDH) and CK. Most volunteers with elevated LDH had normal liver function 
tests ruling out underlying hepatic disease as a possible cause. There was significant variability 
in some analytes between the different study sites. For example, the lower limit for HB from the 
coastal site in Kilifi, Kenya was less than 8 g/dL which would normally be considered anaemic. 
The lower limit of the consensus RI for the 5 countries was 9.5 g/dL. It was hypothesized that the 
low haemoglobin seen in women was most likely due to iron deficiency anaemia. This study 
further went on to evaluate how many of the healthy volunteers would have been classified as 
having a laboratory adverse event (AE) according to the 2004 grading criteria provided by 
Division of AIDS, National Institute of Allergy and Infectious Diseases, of the U.S. National 
Institutes of Health (DAIDS). Based on the US cut-offs used as the comparison RI in this study 
(Kratz, Ferraro, Sluss, & Lewandrowski, 2004), a total of 744 out of 2105 (35.3%) healthy 
volunteers would have been classified as having at least one laboratory-based AE at the time of 
recruitment. Three volunteers would have been classified as having a grade 4 (‘‘life 
threatening’’) AE (Karita et al., 2009). This would result in unnecessary exclusion of individuals 
from the vaccine trials due to misclassification. 




The question that arises when examining RIs derived from people being screened as part of a 
HIV clinical trial is whether such volunteers are truly representative of the health status of the 
reference population and whether any RIs derived are generalizable. Participants who volunteer 
in such clinical trials have different motivations which can result in a selection bias hence 
compromising the external validity of the study results. Individual gain is a major motivator 
especially access to free medical care as reported by Townsend et al who interviewed 39 
individuals who had previously participated in clinical trials in Canada (Townsend & Cox, 
2013). There is reason to believe that individuals who volunteer to participate in vaccine trials 
may be more representative of the population who would benefit from the trial intervention 
rather than the general healthy population. 
 
2.2 Statistical methods and reference intervals 
The main source of post analytical variation in RIs is the adoption of different statistical methods 
when analyzing reference values. Computation of RIs can be done using parametric or non-
parametric methods. Parametric methods assume that the distribution of data can be predicted by 
a standard statistical distribution. For non-parametric methods no such assumption is made. CLSI 
recommends the use of non-parametric methods without the exclusion of outliers as a simple 
way of deriving RIs (CLSI, 2010). It is recommended that confidence intervals should be 
determined around the upper and lower limits of the RI which is usually done using a 
bootstrapping method to give an estimate of error around each limit. Generally, the parametric 
method gives narrower confidence intervals for the lower and upper limits of the RI (Ichihara & 
Boyd, 2010). Parametric computations can be done on transformed or untransformed data. Data 
transformation is done to normalize data especially when the distribution of the reference values 
is skewed or has kurtosis. Several power transformation methods can be used but the one most 
commonly used in RI calculations is a modification of the original Box-Cox transformation (Box 
& Cox, 1964). Testing for normality can be done using graphical methods like box plots and 
histograms, numerical methods like kurtosis and skewness indices or formal normality tests. 
Graphical methods are good but they do not give conclusive evidence of normality. Razali et al 
evaluated the performance of four standard normality tests namely Shapiro-Wilk, Kolmogorov-
Smirnov, Lilliefors and Anderson-Darling. Shapiro-Wilk was shown to have the highest power 
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to determine normality followed by Andrerson-Darling (Razali & Wah, 2011). However, the 
Anderson-Darling method is preferred for large data sets and is optimized to look for normality 
at both ends of the data distribution which is important when determining RIs. A study by Pavlov 
et al used 3 different methods to calculate RIs from the same set of data for 33 analytes and 
demonstrated that the larger your data set the lower the likelihood that it will be normally 
distributed. In his study, none of the data sets with more than 240 values achieved normality. 
This basically implies that the number of reference individuals recruited for a RI study will 
impact on the approach used to calculate RIs. 
 
Partitioning of RIs is commonly done in order to make them more specific if statistically 
significant differences exist between different groups. There are several methods that can be used 
to determine whether there is a significant difference in RIs between sub-groups. For univariate 
analysis, the t-test or analysis of variance (ANOVA) can be used depending on whether the data 
is normally distributed and the number of groups being compared. Ichihara et al argues that 
being observational in nature, RI studies potentially have many confounders that may affect the 
distribution of reference values and as such multiple regression analysis (MRA) models may be 
more appropriate when assessing the contribution of different variables on the distribution of 
reference values (Ichihara, 2014). After identifying major sources of variation, it is worth 
determining whether there is a need to stratify the reference values depending on the magnitude 
of the contribution of each source of variation. Different methods can be used to determine this 
magnitude and include Harris-Boyd, Lahti, Fraser and Ichihara methods. After partitioning and 
normalizing data, parametric methods require that outlier reference values are removed. This can 
be done using various methods such as Tukey’s or the Dixon’s method which consider outliers in 
analytes independently as opposed to looking for outliers in groups of related analytes. The latent 
abnormal value exclusion (LAVE) method developed by Ichihara considers multiple related 
analytes when determining whether to exclude a reference individual’s values from analysis. The 
rationale for this approach is that one may have a normal value for one analyte like glucose but 
out of range values for a different but related analyte such as TGs or HDL-C as seen in MetS. In 
a RI study, it is thought that this approach would help weed out  individuals who may have 
subclinical disease (Ichihara, 2014). This approach has been used in several studies and has been 
shown to be quite efficient in reducing the impact of MetS, anaemia and inflammation on RIs for 
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analytes that are associated with these conditions (Borai et al., 2016; Evgina et al., 2020; Omuse 
et al., 2018; Ozarda et al., 2017). The CLSI guideline recommends that outliers should not be 
deleted as there isn’t a generally applicable method of outlier detection (CLSI, 2010). 
 
Selection of appropriate statistical methods when determining RIs is important as it contributes 
to the variability seen even after standardizing pre–analytic and analytic processes. In order to 
compare RIs across different regions, age and sex stratifications, the same statistical analysis 
method needs to be used as different statistical analysis on the same dataset can result in very 
different RIs (Ichihara, 2014). 
 
2.3 Clinical decision limits and reference intervals 
Certain biochemical tests have known CDLs that are used in diagnosis, risk stratification or 
follow up of patients. Fasting plasma glucose (FPG), TGs, TC, HDL-C and LDL-C are common 
analytes for which CDLs have been defined by expert panels and committees to guide practice 
(Alberti et al., 2009; American Diabetes Association, 2014; NCEP, 2001).  
 
The third report of the expert panel on detection, evaluation, and treatment of high blood 
cholesterol in adults (ATP III) has published guidelines for cholesterol treatment targets. The 
optimal or desirable levels for TC, LDL-C and HDL-C levels are < 5.17 mmol/L, < 2.59 mmol/L 
and > 1.03 mmol/L respectively (NCEP, 2001). These CDLs have replaced RIs and have 
generally been adopted by laboratories in the USA to guide interpretation of lipid test results 
based on individual patient risk. The2013 American College of Cardiology (ACC)/American 
Heart Association (AHA) guidelines on the treatment of blood cholesterol in adults recommends 
that individuals with primary, severe elevations of LDL-C (> 4.91 mmol/L) should receive 
treatment even as early as 21 years of age. This is because of increased risk of atherosclerotic 
cardiovascular disease (Stone et al., 2014). 
 
A recent RI study carried out in Turkey derived a RI for LDL-C that had upper limits that were 
significantly higher than the CDLs. For males and females aged 20-29 years, the RI was 1.47-
3.92 mmol/L. For females above 50 years and above the RI was 1.78-4.91 mmol/L (Ozarda et 
al., 2014). The upper limit of 4.91 mmol/L is equivalent to the level that would prompt 
Stellenbosch University  https://scholar.sun.ac.za
15 
 
immediate treatment in a young adult with a primary cause for elevation. In the NORIP study, 
LDL-C RIs for adults 18-29 years was 1.2-4.3 mmol/L, 1.4-4.7 mmol/L for those aged 30-49 
years and 2.0-5.3 mmoI/L for those ≥ 50 years. In the wake of well accepted CDLs, it is unlikely 
that these RIs would be adopted despite the possibility that the predictive values of a common 
cut off could differ significantly across different populations thereby affecting the diagnostic 
accuracy of the CDLs. Population specific RIs can however serve as a baseline to inform local 
cholesterol treatment guidelines. 
 
The American Diabetes Association (ADA) defines a FPG level of 5.6-6.9 to diagnose pre-
diabetes and a value ≥ 7.0 mmol/L or a 2 hour plasma glucose value (2hPG)  ≥ 11.1 mmol/L  
post a 75g glucose load to define diabetes (American Diabetes Association, 2014). Some studies 
have however shown that these cut offs are inappropriate in some populations. For example, in 
an Australian cohort, the levels that best correlated with increased risk of diabetic retinopathy 
were FPG ≥ 7.1 mmol/L, 2hPG ≥ 13.1 mmol/L and HbA1c 6.1% (Tapp et al., 2006). The 
appropriateness of the 2hPG of 11.1 mmol/L in this population is therefore questionable. 
Similarly, in a Chinese cohort, significant increase in retinopathy occurred among individuals 
with FPG ≥ 7.2 mmol/l, 2hPG ≥ 10.5 mmol/L and HbA1c ≥ 6.4% (Xin et al., 2012).  
 
The ADA recommends testing adults to assess risk for future diabetes in asymptomatic people 
who are overweight or obese and who have one or more additional risk factors for diabetes. It 
also recommends testing of all patients, particularly those who are overweight or obese and this 
should begin at 45 years of age (American Diabetes Association, 2010).  The idea of testing for 
pre-diabetes which includes impaired fasting glucose (IFG) and/or impaired glucose tolerance 
(IGT) is due to its association with increased risk of developing diabetes. The FPG CDL for pre-
diabetes is 5.6-6.9 mmol/L. Some of the studies done as part of the global RI study have derived 
FPG upper limits that are higher than the widely adopted CDLs. For example, in Turkey, the RI 
for FPG was 3.96-5.88 mmol/L suggesting a good number of individuals have higher values 
compared to the ADA criteria (Ozarda et al., 2014). The adoption of this higher upper limit to 
define normality would reduce the number of people classified as pre-diabetic in Turkey. 
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The Japanese Society of Gout and Nucleic Acid Metabolism defines hyperuricaemia as a UA 
level above 416 µmol/L (7 mg/dL). It has published guidelines for the management of 
hyperuricaemia and gout which recommends urate-lowering therapy for asymptomatic 
hyperuricaemia greater than 476 µmol/L (8 mg/dL) especially in individuals with complications 
such as hypertension, ischemic heart disease, diabetes mellitus, and metabolic syndrome, which 
are considered risk factors for renal disorders, including urinary calculus, and cardiovascular 
disorders (Yamanaka, Japanese Society of, & Nucleic Acid, 2011). The definition of 
hyperuricaemia varies across different populations and men usually have higher levels than 
women. The National Health and Nutrition Examination Survey (NHANES) uses cut offs of 416 
µmol/L (7 mg/dl) and 339 µmol/L (5.7 mg/dl) to define hyperuricaemia in men and women 
respectively (Zhu, Pandya, & Choi, 2011). In Turkey, the RI for men was determined to be 226-
458 µmol/L for men and 166-345 µmol/L for women (Ozarda et al., 2014). In the US, the RIs for 
men are 150-480 and 90-360 for women (Kratz et al., 2004). In Asia, the RIs were 223-471 
µmol/L in men and 153-344 µmol/L in women (Ichihara, Ceriotti, Tam, et al., 2013). These 
differences in UA RIs suggest that the same cut-off to determine hyperuricaemia across different 
populations will not be ideal. There is paucity of data on UA RIs from Africa but it has been 
documented that UA levels are higher in urban populations compared to semi-urban and rural 
populations (Reimann, Schutte, Malan, Huisman, & Malan, 2008). A study in South Africa also 
showed lower levels of UA in black Africans compared to Caucasians with no obvious 
explanation for this difference (Palmer, Schutte, & Huisman, 2010; Palmer et al., 2007).  
 
The differences seen in RIs for analytes whose interpretation is based on CDLs emphasizes the 
point that a single cut off for a CDL may perform differently across different populations and 
therefore their appropriateness should be evaluated before adaptation. RI studies can provide 
evidence for the need to validate CDLs especially if there are significant differences in RIs 
between a reference population and the population where the CDLs were derived. 
 
2.4 Biochemical abnormalities in a reference population 
Despite all attempts at ensuring that only healthy individuals are included in a RI study, this can 
never be achieved due to the presence of subclinical disease. Reference individuals are quite 
heterogeneous in their state of health and there isn’t a perfect standard to define health or 
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normality (Petitclerc, 2004). A study in Turkey revealed that BMI levels are clearly associated 
with test results for UA, GLU, TG, HDL-C, LDL-C, ALT and GGT either in males and/ or 
females. It was found that RIs derived for these analytes were wider compared with RIs derived 
after excluding reference values from individuals with a BMI ≥ 28 kg/m2. Despite this secondary 
exclusion, it was found that upper reference limits for TC, LDL-C, TG, ALT, GGT and GLU 
were higher than published CDLs. The authors concluded that this was due to the presence of 
latent diseases such as MetS in the reference population (Ozarda et al., 2014). The observed 
prevalence of the MetS in the National Health and Nutrition Examination Survey (NHANES) 
was 5% among the subjects of normal weight, 22% among the overweight, and 60% among the 
obese (Park et al., 2003). This raises the question whether BMI should be included as part of the 
exclusion criteria in a RI study. 
 
In order to minimize the recruitment of individuals with possible latent diseases, IFCC have 
provided fairly strict inclusion and exclusion criteria to be used in the global RI study (Ozarda et 
al., 2013). Some RI studies have gone even further and carried out secondary exclusion based on 
BMI to further reduce the likelihood of including reference values from individuals with sub 
clinical disease like MetS. According to the USA “Clinical Guidelines on the Identification, 
Evaluation, and Treatment of Overweight and Obesity in Adults” published in 1998, all 
overweight and obese adults are at an increased risk for developing diseases such as 
hypertension, elevated cholesterol, type 2 diabetes and coronary heart disease (NHLBI Obesity 
Education Initiative Expert Panel, 1998). Stommel et al used data from the National Health 
Interview Survey (NHIS) to determine the prevalence of hypertension, diabetes, CHD and 
asthma in 4 racial and ethnic groups, and the influence of BMI on the prevalence of these 
diseases. It was clearly demonstrated that increasing BMI levels are associated with higher levels 
of chronic disease burden in the four major racial and ethnic groups represented namely 
Hispanics, non-Hispanic whites, non-Hispanic blacks and East Asians. This association persisted 
even after adjusting for possible confounders such as smoking, physical activity and alcohol 
consumption. A notable observation was that even small 1 unit kg/m2 increments in BMI values 
were associated with increased prevalence of the four chronic diseases (Stommel & Schoenborn, 
2010). Initial results of RI studies carried out in Japan, China, Turkey, Saudi Arabia and USA as 
part of the global study being conducted by the IFCC have shown that there is an increase in the 
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levels of TG, ALT and GGT as BMI increases while HDL decreases. This association was also 
seen for glucose, UA, TC, and LDL-C. In order to compare RIs across the different regions and 
populations, there may be need to correct the RIs for BMI (Ichihara, 2014). The pattern of 
reduced HDL-C, increased TG and glucose with increasing BMI suggests the presence of MetS 
in some of the reference populations. 
 
2.5 Assessment of renal dysfunction in asymptomatic individuals 
The increasing prevalence of chronic kidney disease (CKD) and its associated morbidity and 
mortality has necessitated the development of interventions geared at reducing its prevalence as 
well as reducing the rate of progression from early to late stage disease (Levey, Atkins, et al., 
2007). One of the interventions from a public health perspective is the routine reporting of 
estimated glomerular filtration rate (eGFR) for every serum creatinine request. The purpose of 
this is to create awareness of CKD and more importantly, identify early cases of CKD which are 
invariably asymptomatic. A key component of determining RIs for a general population is 
ensuring that recruited individuals are free from disease including sub-clinical conditions such as 
early CKD. Renal dysfunction will impact on RIs especially those used in assessing renal 
function. Determination of eGFR is a useful tool in identifying individuals who would pass off as 
healthy but have underlying CKD. Part of the challenge with eGFR determination is the lack of 
consensus on the issue of correction for race in black Africans. Studies carried out in the USA 
clearly demonstrated the need to correct for race when determining eGFR in black Americans 
due to greater muscle mass (Levey et al., 2009). Similar studies carried out in sub-Saharan Africa 
have suggested that correction for race is not necessary. A study carried out in South Africa 
compared eGFR with and without correction for race to measured GFR (mGFR) and concluded 
that the bias was less when the correction factor for race was excluded. Specifically, the 
correction factor of 1.212 as established for African Americans resulted in a median positive bias 
of 13.1 (95% CI 5.5 to 18.3) mL/min/1.73m2 for eGFR determined using the 4-variable modified 
diet in renal disease formula (4-v MDRD). Without the ethnicity factor, the median bias was 1.9 
(95% CI_0.8 to 4.5) mL/min/1.73m2. However, one of the major criticisms of this study is that 
the population recruited comprised individuals with CKD or risk factors for CKD of whom 20% 
had HIV/AIDS (van Deventer, George, Paiker, Becker, & Katz, 2008). The findings from this 
study can therefore not be directly extrapolated to an asymptomatic or subjectively healthy black 
Stellenbosch University  https://scholar.sun.ac.za
19 
 
African population. It has also been demonstrated that serum creatinine based eGFR equations 
derived from a Caucasian population may not be appropriate for other populations (Hans Pottel 
et al., 2012). This highlights the need for the evaluation of the various proposed equations in 
order to determine their appropriateness or derivation of population specific eGFR equations to 
enable screening for CKD in asymptomatic black Africans. 
 
In order to evaluate which equation best estimates GFR in healthy individuals, the ideal 
methodology would be to compare eGFR to GFR measured using exogenous filtration markers 
such as inulin. Measurement of GFR is technically challenging, expensive and not practical for 
routine clinical practice. There are also ethical issues around subjecting healthy individuals with 
no known risk factors for CKD to such an invasive test. Alternative ways of evaluating equations 
for eGFR determination and their appropriateness for routine use in screening for CKD in 
asymptomatic individuals need to be developed and evaluated. 
 
2.6 References 
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., . 
. . Smith, S. C. (2009). Harmonizing the metabolic syndrome: a joint interim statement of 
the International Diabetes Federation Task Force on Epidemiology and Prevention; 
National Heart, Lung, and Blood Institute; American Heart Association; World Heart 
Federation; International. Circulation, 120(16), 1640-1645. 
doi:10.1161/CIRCULATIONAHA.109.192644 
American Diabetes Association. (2010). Diagnosis and classification of diabetes mellitus. 
Diabetes Care, 33 Suppl 1(Supplement_1), S62-69. doi:10.2337/dc10-S062 
American Diabetes Association. (2014). Classification and Diagnosis of Diabetes. Diabetes 
Care, 38(Supplement_1), S8-S16. doi:10.2337/dc15-S005 
Borai, A., Ichihara, K., Al Masaud, A., Tamimi, W., Bahijri, S., Armbuster, D., . . . Abdelaal, M. 
(2016). Establishment of reference intervals of clinical chemistry analytes for the adult 
population in Saudi Arabia: A study conducted as a part of the IFCC global study on 
reference values. Clinical Chemistry and Laboratory Medicine, 54(5), 843-855. 
doi:10.1515/cclm-2015-0490 
Stellenbosch University  https://scholar.sun.ac.za
20 
 
Box, G. E. P., & Cox, R. D. (1964). An Analysis of Transformations. Journal of the Royal 
Statistical Society. Series B (Methodological), 26(2), 211-252.  
Burtis, C., Ashwood, E., & Bruns, D. (2005). Tietz Textbook of Clinical Chemistry and 
Molecular Diagnostics. 
CLSI. (2010). EP28-A3C: Defining, Establishing, and Verifying Reference Intervals in the 
Clinical Laboratory; Approved Guideline (Third ed.): Clinical Laboratory Standards 
Institute. 
Evgina, S., Ichihara, K., Ruzhanskaya, A., Skibo, I., Vybornova, N., Vasiliev, A., . . . Emanuel, 
V. (2020). Establishing reference intervals for major biochemical analytes for the Russian 
population: a research conducted as a part of the IFCC global study on reference values. 
Clin Biochem, 81, 47-58. doi:10.1016/j.clinbiochem.2020.04.001 
Ichihara, K. (2014). Statistical considerations for harmonization of the global multicenter study 
on reference values. Clinica Chimica Acta, 432, 108-118. doi:10.1016/j.cca.2014.01.025 
Ichihara, K., & Boyd, J. C. (2010). An appraisal of statistical procedures used in derivation of 
reference intervals. Clinical Chemistry and Laboratory Medicine, 48(11), 1537-1551. 
doi:10.1515/CCLM.2010.319 
Ichihara, K., Ceriotti, F., Tam, T. H., Sueyoshi, S., Poon, P. M. K., Thong, M. L., . . . Panteghini, 
M. (2013). The Asian project for collaborative derivation of reference intervals: (1) 
strategy and major results of standardized analytes. Clinical Chemistry and Laboratory 
Medicine, 51(7), 1429-1442. doi:10.1515/cclm-2012-0421 
Ichihara, K., Itoh, Y., Lam, C. W. K., Poon, P. M. K., Kim, J.-H., Kyono, H., . . . Muliaty, D. 
(2008). Sources of variation of commonly measured serum analytes in 6 Asian cities and 
consideration of common reference intervals. Clinical Chemistry, 54(2), 356-365. 
doi:10.1373/clinchem.2007.091843 
Karita, E., Ketter, N., Price, M. A., Kayitenkore, K., Kaleebu, P., Nanvubya, A., . . . Kamali, A. 
(2009). CLSI-derived hematology and biochemistry reference intervals for healthy adults 
in eastern and southern Africa. PLOS ONE, 4(2), e4401. 
doi:10.1371/journal.pone.0004401 
Kratz, A., Ferraro, M., Sluss, P. M., & Lewandrowski, K. B. (2004). Case records of the 
Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory 
Stellenbosch University  https://scholar.sun.ac.za
21 
 
reference values. The New England Journal of Medicine, 351(15), 1548-1563. 
doi:10.1056/NEJMcpc049016 
Levey, A. S., Atkins, R., Coresh, J., Cohen, E. P., Collins, A. J., Eckardt, K. U., . . . Eknoyan, G. 
(2007). Chronic kidney disease as a global public health problem: approaches and 
initiatives - a position statement from Kidney Disease Improving Global Outcomes. 
Kidney Int, 72(3), 247-259. doi:10.1038/sj.ki.5002343 
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F., Feldman, H. I., . . . 
Coresh, J. (2009). A new equation to estimate glomerular filtration rate. Annals of 
Internal Medicine, 150(9), 604-612. doi:10.7326/0003-4819-150-9-200905050-00006 
Miri-Dashe, T., Osawe, S., Tokdung, M., Daniel, N., Choji, R. P., Mamman, I., . . . Morkve, O. 
(2014). Comprehensive Reference Ranges for Hematology and Clinical Chemistry 
Laboratory Parameters Derived from Normal Nigerian Adults. PLOS ONE, 9(5), e93919-
e93919. doi:10.1371/journal.pone.0093919 
NCEP. (2001). Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285(19), 2486-2497. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/11368702 
NHLBI Obesity Education Initiative Expert Panel. (1998). Clinical Guidelines on the 
Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Retrieved 
from http://www.ncbi.nlm.nih.gov/books/NBK2003/ 
Omuse, G., Maina, D., Mwangi, J., Wambua, C., Radia, K., Kanyua, A., . . . Erasmus, R. (2018). 
Complete blood count reference intervals from a healthy adult urban population in 
Kenya. PLOS ONE, 1-19.  
Ozarda, Y., Ichihara, K., Aslan, D., Aybek, H., Ari, Z., Taneli, F., . . . Degirmen, E. (2014). A 
multicenter nationwide reference intervals study for common biochemical analytes in 
Turkey using Abbott analyzers. Clinical Chemistry and Laboratory Medicine (CCLM), 
52(12). doi:10.1515/cclm-2014-0228 
Ozarda, Y., Ichihara, K., Bakan, E., Polat, H., Ozturk, N., Baygutalp, N. K., . . . Eker, P. (2017). 
A nationwide multicentre study in Turkey for establishing reference intervals of 
haematological parameters with novel use of a panel of whole blood. Biochemia Medica, 
27(2), 350-377. doi:10.11613/BM.2017.038 
Stellenbosch University  https://scholar.sun.ac.za
22 
 
Ozarda, Y., Ichihara, K., Barth, J. H., & Klee, G. (2013). Protocol and standard operating 
procedures for common use in a worldwide multicenter study on reference values. 
Clinical Chemistry and Laboratory Medicine (CCLM), 51(5), 1027-1040. 
doi:10.1515/cclm-2013-0249 
Palmer, I. M., Schutte, A. E., & Huisman, H. W. (2010). Uric acid and the cardiovascular profile 
of African and Caucasian men. J Hum Hypertens, 24(10), 639-645. 
doi:10.1038/jhh.2010.1 
Palmer, I. M., Schutte, A. E., Huisman, H. W., Van Rooyen, J. M., Schutte, R., Malan, L., & 
Malan, N. T. (2007). A comparison of uric acid levels in Black African vs Caucasian 
women from South Africa: the POWIRS study. Ethn Dis, 17(4), 676-681. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/18072378 
Park, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. 
(2003). The metabolic syndrome: prevalence and associated risk factor findings in the US 
population from the Third National Health and Nutrition Examination Survey, 1988-
1994. Archives of Internal Medicine, 163(4), 427-436. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3146257&tool=pmcentrez&r
endertype=abstract 
Petitclerc, C. (2004). Normality: the unreachable star? Clinical Chemistry and Laboratory 
Medicine, 42(7), 698-701. doi:10.1515/CCLM.2004.119 
Pottel, H., Hoste, L., Delanaye, P., Cavalier, E., & Martens, F. (2012). Demystifying ethnic/sex 
differences in kidney function: Is the difference in (estimating) glomerular filtration rate 
or in serum creatinine concentration? Clinica Chimica Acta, 413(19), 1612-1617. 
doi:10.1016/j.cca.2012.04.034 
Razali, N. M., & Wah, Y. B. (2011). Power comparisons of Shapiro-Wilk, Kolmogorov-
Smirnov, Lilliefors, and Anderson-Darling test. Journal of Statistical Modeling and 
Analytics, 2(1), 21-33.  
Reimann, M., Schutte, A. E., Malan, L., Huisman, H. W., & Malan, N. T. (2008). 
Hyperuricaemia is an independent factor for the metabolic syndrome in a sub-Saharan 
African population: a factor analysis. Atherosclerosis, 197(2), 638-645. 
doi:10.1016/j.atherosclerosis.2007.09.011 
Stellenbosch University  https://scholar.sun.ac.za
23 
 
Rustad, P., Felding, P., Franzson, L., Kairisto, V., Lahti, A., Mårtensson, A., . . . Uldall, A. 
(2009). The Nordic Reference Interval Project 2000: recommended reference intervals 
for 25 common biochemical properties. Scandinavian Journal of Clinical and Laboratory 
Investigation. Retrieved from 
http://www.tandfonline.com/doi/abs/10.1080/00365510410006324 
Segolodi, T. M., Henderson, F. L., Rose, C. E., Turner, K. T., Zeh, C., Fonjungo, P. N., . . . 
Paxton, L. A. (2014). Normal laboratory reference intervals among healthy adults 
screened for a HIV pre-exposure prophylaxis clinical trial in Botswana. PLOS ONE, 9(4), 
e93034-e93034. doi:10.1371/journal.pone.0093034 
Stommel, M., & Schoenborn, C. A. (2010). Variations in BMI and Prevalence of Health Risks in 
Diverse Racial and Ethnic Populations. Obesity, 18(9), 1821-1826. 
doi:10.1038/oby.2009.472 
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., 
. . . Wilson, P. W. F. (2014). 2013 ACC/AHA Guideline on the Treatment of Blood 
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the 
American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Circulation, 129(25 Suppl 2), S1-S45. 
doi:10.1161/01.cir.0000437738.63853.7a 
Tapp, R. J., Zimmet, P. Z., Harper, C. A., de Courten, M. P., McCarty, D. J., Balkau, B., . . . 
Shaw, J. E. (2006). Diagnostic thresholds for diabetes: the association of retinopathy and 
albuminuria with glycaemia. Diabetes Research and Clinical Practice, 73(3), 315-321. 
doi:10.1016/j.diabres.2006.02.008 
Thobakgale, C. F., & Ndung'u, T. (2014). Neutrophil counts in persons of African origin. 
Current Opinion in Hematology, 21(1), 50-57. doi:10.1097/MOH.0000000000000007 
Townsend, A., & Cox, S. M. (2013). Accessing health services through the back door: a 
qualitative interview study investigating reasons why people participate in health research 
in Canada. BMC Medical Ethics, 14(1), 40-40. doi:10.1186/1472-6939-14-40 
van Deventer, H. E., George, J. A., Paiker, J. E., Becker, P. J., & Katz, I. J. (2008). Estimating 
glomerular filtration rate in black South Africans by use of the modification of diet in 
renal disease and Cockcroft-Gault equations. Clinical Chemistry, 54(7), 1197-1202. 
doi:10.1373/clinchem.2007.099085 
Stellenbosch University  https://scholar.sun.ac.za
24 
 
Xin, Z., Yuan, M.-X., Li, H.-X., Hua, L., Feng, J.-P., Shi, J., . . . Yang, J.-K. (2012). Evaluation 
for fasting and 2-hour glucose and HbA1c for diagnosing diabetes based on prevalence of 
retinopathy in a Chinese population. PLOS ONE, 7(7), e40610-e40610. 
doi:10.1371/journal.pone.0040610 
Yamanaka, H., Japanese Society of, G., & Nucleic Acid, M. (2011). Japanese guideline for the 
management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic 
Acids, 30(12), 1018-1029. doi:10.1080/15257770.2011.596496 
Zhu, Y., Pandya, B. J., & Choi, H. K. (2011). Prevalence of gout and hyperuricemia in the US 
general population: the National Health and Nutrition Examination Survey 2007-2008. 




Stellenbosch University  https://scholar.sun.ac.za
25 
 
CHAPTER 3:  METABOLIC SYNDROME AND ITS PREDICTORS IN 
AN URBAN POPULATION IN KENYA: A CROSS SECTIONAL 
STUDY 
Omuse, G., Maina, D., Hoffman, M., Mwangi, J., Wambua, C., Kagotho, E., . . . Erasmus, R. 
(2017). Metabolic syndrome and its predictors in an urban population in Kenya: A cross 
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The metabolic syndrome (MetS) is a clustering of interrelated risk factors which doubles the risk 
of cardio-vascular disease (CVD) in 5-10 years and increases the risk of type 2 diabetes 5 fold. 
The identification of modifiable CVD risk factors and predictors of MetS in an otherwise healthy 
population is necessary in order to identify individuals who may benefit from early interventions. 
We sought to determine the prevalence of MetS as defined by the harmonized criteria and its 
predictors in subjectively healthy black Africans from various urban centres in Kenya. 
Method 
We used data collected from healthy black Africans in Kenya as part of a global study on 
establishing reference intervals for common laboratory tests. We determined the prevalence of 
MetS and its components using the 2009 harmonized criterion. Receiver operator characteristic 
(ROC) curve analysis was used to determine the area under the curves (AUC) for various 
predictors of MetS. Youden index was used to determine optimum cut-off for quantitative 
measurements such as waist circumference (WC). 
Results 
A total of 528 participants were included in the analysis. The prevalence of MetS was 25.6% 
(95% CI: 22.0%-29.5%). Among the surrogate markers of visceral adiposity, lipid accumulation 
product was the best predictor of MetS with an AUC of 0.880 while triglyceride was the best 
predictor among the lipid parameters with an AUC of 0.816 for all participants. The optimal WC 
cut-off for diagnosing MetS was 94cm and 86 cm respectively for males and females. 
Conclusions 
The prevalence of MetS was high for a healthy population highlighting the fact that one can be 
physically healthy but have metabolic derangements indicative of an increased CVD risk. This is 
likely to result in an increase in the cases of CVD and type 2 diabetes in Kenya if interventions 
are not put in place to reverse this trend. We have also demonstrated the inappropriateness of the 
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WC cut-off of 80 cm for black African women in Kenya when defining MetS and recommend 
adoption of 86 cm.  
Key words 
Metabolic syndrome, waist circumference, visceral adiposity, cardiovascular risk, Kenya, Africa 
 
3.2 Background 
The non-communicable disease (NCD) burden is expected to increase globally by 17% and by 
27% in the African region in the next 10 years. NCDs are projected to overtake communicable 
diseases as the major cause of morbidity in sub Saharan Africa by the year 2030 (Mathers & 
Loncar, 2006). Smoking, hypertension, abdominal obesity, diabetes mellitus and elevated 
Apolipoprotein B/A-1 ratio have been shown to account for up to 90% of the risk for a first 
myocardial infarction in Africa according to the INTERHEART study (Steyn et al., 2005). 
Unfortunately, the prevalence of these risk factors continues to increase as urbanization takes 
root in the African continent (Vorster, 2002).  
 
The metabolic syndrome (MetS) is a clustering of interrelated risk factors which doubles the risk 
of cardio-vascular disease (CVD) in 5-10 years and increases the risk of type 2 diabetes 5 fold 
(Alberti et al., 2009). The identification of modifiable CVD risk factors and predictors of MetS 
in an otherwise healthy population is necessary in order to identify individuals who may benefit 
from early interventions. It has been shown that subjectively healthy individuals may have 
biochemical abnormalities in keeping with the presence of MetS (Gami et al., 2007). A study 
carried out in the US showed that 23.5% of normal-weight adults were metabolically abnormal 
and conversely, 51.3% of overweight adults and 31.7% of obese adults were metabolically 
healthy (Wildman et al., 2008). Metabolic derangements may be an early indicator of increased 
CVD risk even in normal weight or subjectively healthy individuals. Initial results of reference 
interval (RI) studies carried out in Japan, China, Turkey, Saudi Arabia and USA have shown that 
the levels of fasting plasma glucose (FPG), triglycerides (TGs), alanine aminotransferase (ALT) 
and gamma-glutamyl transferase (GGT) increase while high density lipoprotein cholesterol 
(HDL-C) decreases as body mass index (BMI) increases. This pattern of reduced HDL-C, 
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increased TG and FPG suggests the presence of MetS in some of the reference individuals 
recruited despite adherence to a strict inclusion criteria designed to exclude unhealthy 
individuals. This has raised the question whether RIs should be further stratified according to 
BMI for those analytes where it is a major source of variation (Ichihara, 2014).  
 
Whereas increasing levels of waist circumference (WC) and BMI have been associated with 
increased CVD risk, there is a continuous search for robust predictors of MetS. Both BMI and 
WC do not distinguish between visceral adipose tissue (VAT) and subcutaneous adipose tissue 
(SAT). VAT plays a significant role in the pathogenesis of CVD due to its association with 
insulin resistance and increased levels of VAT has been associated with increased cardio-
metabolic risk and coronary artery calcification regardless of BMI (Reilly, 2003; R. V. Shah et 
al., 2014). One of the emerging surrogate markers of visceral adiposity and predictor of MetS yet 
to be extensively studied in a black African population is the lipid accumulation product (LAP), 
a parameter whose calculation is based on WC and serum TG levels (Kahn, 2005). LAP has been 
shown to have a strong association with the presence of MetS in healthy adults, an accurate 
predictor of MetS in those aged 50 years and above, as well as an association with diabetes in 
studies carried out in Europe and Asia (Chiang & Koo, 2012; Taverna, Martinez-Larrad, 
Frechtel, & Serrano-Rios, 2011; Tellechea et al., 2009; Wakabayashi & Daimon, 2014).  
 
Visceral adiposity index (VAI) is another emerging parameter that indirectly expresses visceral 
fat function and has been found to be independently associated with coronary heart disease, 
myocardial infarction, transient ischemic attack and ischemic stroke. The calculation of VAI is 
based on WC, BMI, triglycerides, and HDL cholesterol and hence includes both physical and 
metabolic parameters (Amato et al., 2010). In China, VAI was shown to be positively associated 
with type 2 diabetes and was a better predictor of diabetes than BMI, WC and waist to height 
ratio (Chen et al., 2014). VAI was derived from an Italian cohort largely comprising of 
Caucasians and hence needs validation in a black African population. 
 
Hypertriglyceridaemia and low HDL-C are the only lipid parameters included in the harmonized 
MetS criterion (Alberti et al., 2009). There is controversy as to the specific role elevated TGs 
play in atherogenesis. Whereas increased TGs have been associated with increased risk of CVD, 
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it is thought that they are a surrogate marker for cholesterol remnants which play a direct role in 
atheromatous plaque formation (Jorgensen et al., 2013). Varbo et al demonstrated in a Danish 
population that non-fasting cholesterol remnants are a risk factor for ischaemic heart disease 
independent of HDL-C levels with an increase of 1 mmol/L associated with a 2.8 fold increase in 
risk (Varbo et al., 2013). The utility of cholesterol remnants in determination of CVD risk or 
MetS in healthy black Africans is unknown. 
 
The prevalence of MetS in any population is influenced by many factors including the specific 
criteria adopted to define it. For example, in a rural population in Ghana, the overall prevalence 
of MetS defined by the International Diabetic Federation (IDF) and the National Cholesterol 
Education Programme Adult Treatment Panel III (ATP III) criteria was 35.9% and 15.0% 
respectively (Gyakobo, Amoah, Martey-Marbell, & Snow, 2012). In 2009, a harmonized 
criterion for diagnosing MetS was developed whose components included abdominal obesity, 
dyslipidemia, hyperglycemia, and hypertension (Alberti et al., 2009). Using the harmonized 
definition, the prevalence of MetS in an urban population in Kenya was reported as 34.6% with 
the prevalence being significantly higher in women at 40.2%. However, this study was only 
limited to one constituency in the capital city of Nairobi which limits the generalizability of the 
results despite the use of random sampling when identifying participants (Kaduka et al., 2012). 
Furthermore, this study didn’t explore the utility of LAP and VAI as predictors of MetS in a 
black African population. 
  
We sought to determine the prevalence of MetS as defined by the harmonized criteria in 
subjectively healthy black Africans from various urban centres in Kenya. We also determined the 
ability of various lipid parameters, LAP, VAI, WC and BMI to predict the presence of MetS. 
 
3.3 Methods 
We used data from 533 healthy black Africans participating in a global RI study in Kenya. This 
study is part of an initiative by the Committee of Reference Intervals and Decision Limits (C-
RIDL) under the auspices of the International Federation of Clinical Chemistry (IFCC). Kenya is 
one of 3 participating countries in Africa, the other ones being Nigeria and South Africa. 
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Majority of recruited participants in Kenya were urban dwellers from the capital city Nairobi and 
its environs, Kisii County in the western part of Kenya and Nakuru town based in the Great Rift 
valley. Recruitment was mainly done by seeking adult volunteers aged 18-65 years of age 
through use of posters in public areas including churches, universities, colleges, hospitals and 
companies. Social media and word of mouth were also used. This was done between January and 
October 2015 and written informed consent was sought from each participant after giving a 
written and verbal explanation of the study.  
Inclusion criteria 
Inclusion was limited to healthy adults 18-65 years of age and was stratified into 4 age groups: 
18-29, 30-39, 40-49 and 50-65 years with a similar distribution of males and females in each age 
strata.  
Exclusion criteria 
Exclusion criteria included participants with a BMI greater than 35 kg/m2, consumption of 
ethanol greater than or equal to 70g per day [equivalent to 5 alcoholic drinks], smoking more 
than 20 tobacco cigarettes per day, taking regular medication for a chronic disease (diabetes 
mellitus, hypertension, hyperlipidemia, allergic disorders, depression), recent (less than 15 days) 
recovery from acute illness, injury or surgery requiring hospitalization, known carrier state of 
hepatitis B, hepatitis C or human Immunodeficiency virus, pregnant or within one year after 
childbirth. Individuals with any chronic disease were excluded except for the age group 50-65 
years where those with well controlled hypertension were recruited. Towards the end of the 
study, a few individuals with a BMI greater than 35 kg/m2 but less than 40 kg/m2 were recruited 
due to difficulties in recruiting healthy participants in the older age groups. The exclusion criteria 
were defined in the questionnaire filled by the participants and those who were excluded didn’t 
have blood samples taken.  
Measurements 
All participants had measurements of blood pressure (BP), WC and body mass index (BMI) 
done. A single measurement of BP was performed in a sitting position after at least 15 minutes of 
rest using a calibrated OMRON M3 automated BP monitor (Omron Healthcare, Kyoto, Japan) 
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that uses an upper arm cuff. A repeat BP measurement was done if the initial reading was 
consistent with hypertension. If the initial and second reading were in agreement then the first 
reading was adopted. If there was a discrepancy in terms of BP status then a third reading was 
done as a tie breaker. WC was measured using a tape measure over light clothing at the level of 
the umbilical cord to ensure a consistent reference point while BMI was automatically calculated 
after measuring the participants’ height and weight using a Seca 703 weighing scale digital 
column with height meter scale (Seca, Hamburg, Germany). On average, measuring WC over 
light clothing increased the measurement by approximately 1cm which was subsequently 
deducted. Height was measured after removal of shoes to the nearest 0.5cm, WC to the nearest 
1cm and weight to the nearest 0.1kg after removal of shoes and bulky clothing.  
Sample handling 
All participant samples were collected after obtaining informed consent and filling of a 
questionnaire. All participants had an overnight fast as per the study protocol. Samples were 
collected and centrifuged within 4 hours after collection and stored at -80oc until shipment on dry 
ice to the reference laboratory in South Africa. All the sample analysis for the biochemistries and 
immunoassays were performed in the Pathcare reference laboratory in Cape Town, South Africa 
which is an International Organization for Standardization (ISO) 15189 accredited laboratory. 
Thawing was only done once before sample analysis. As part of the RI study, all participating 
laboratories used a common panel of sera with assigned values to ensure accuracy of reported 
results and alignment of values if any biases were identified. All the listed tests were carried out 
on a Beckman Coulter AU5800. The analytical methods for the various tests are shown in Table 
3.1.  
  




Table 3.1: List of tests, methodologies and coefficient of variation 
Test Method Between 
run CV 
UA Enzymatic colour 0.1% 
TC Enzymatic colour calibrated to CDC Reference Method (Abell-Kendall) 0.3% 
LDL-C Enzymatic colour calibrated to US CDC  0.4% 
TGs Enzymatic colour 0.4% 
HDL-C Enzymatic colour calibrated to US CDC  0.3% 
Glucose Enzymatic UV test (hexokinase method) 0.1% 
hsCRP Immuno-turbidimetric 0.8% 
ALP Kinetic colour IFCC 0.1% 
ALT Kinetic UV IFCC 0.8% 
AST Kinetic UV IFCC 0.4% 
GGT Kinetic colour IFCC 0.4% 
Key: ALP-Alkaline phosphatase, ALT-Alanine aminotransferase, AST-Aspartate aminotransferase, CDC-Centre of Disease 
Control, CV-Coefficient of variation, GGT-Gama glutamyl transferase, HDL-C-High density lipoprotein cholesterol, hsCRP-
Highly sensitive C-reactive protein, IFCC-International Federation of Clinical Chemistry, LDL-C-Low density lipoprotein 
cholesterol, TGs-Triglycerides, UA-Uric acid, US-United States 
MetS diagnosis 
The 2009 harmonized definition was used to diagnose MetS which requires the presence of any 3 
of the following: increased WC (men: ≥ 94 cm, women: ≥ 80 cm), low HDL-C (men: <40 mg/dl 
(1 mmol/l), women: <50 mg/dl (1.3 mmol/l)), hypertriglyceredimia ≥150 mg/dl (1.7 mmol/l), 
elevated BP (systolic BP ≥ 130 mmHg and/or diastolic ≥ 85 mmHg or drug treatment for 
hypertension) and elevated blood sugar (FPG ≥ 100 mg/dl (5.6 mmol/l) or diabetes mellitus 
(Alberti et al., 2009).  
CVD risk calculation 
The 10 year CVD risk was calculated using the Framingham risk calculation (Blom, 2011). 
Family history of CVD was not included as this information wasn’t captured in the questionnaire 
used for the study. 
LAP calculation 
LAP was calculated as (WC [cm] − 65) × (TG [mmol/L]) for males, and (WC [cm] − 58) × (TG 
[mmol/L]) for females (Kahn, 2005). 




VAI was calculated as (WC[cm] / (39.68 + (1.88 x BMI))) x (TG / 1.03) x (1.31 / HDL-C 
[mmol/L]) for males and (WC[cm] / (36.58 + (1.89 x BMI))) x (TG / 0.81) x (1.52 / HDL-C 
[mmol/L]) for females (Amato et al., 2010).  
Non HDL-C 
Non HDL-C was calculated as fasting total cholesterol minus HDL-C. 
Cholesterol remnants 
Cholesterol remnants were calculated as fasting total cholesterol minus HDL-C minus LDL-C. 
Statistical analysis 
The prevalence of MetS was presented as a percentage with 95% confidence intervals (CI). 
Descriptive statistics for continuous variables were presented as medians with interquartile 
ranges (IQRs). The Mann Whitney U test was used to compare the distribution pattern of 
continuous variables between males and females and those with and without. Where the 
distribution patterns were similar, medians were compared using the independent samples 
median test. Mean ranks were compared where the distribution patterns not similar. Binary 
logistic regression was used to determine the association between cardio-metabolic risk factors 
and MetS presence. Adjusted odds ratios (ORs) were subsequently determined in a model that 
excluded the MetS components. For hs-CRP, uric acid and GGT, the median value was used to 
as a cut-off to classify individuals as having increased or normal levels. Binary logistic 
regression was also used to determine the strength of association between MetS and CVD risk. 
Chi-square was used to compare cardio-metabolic factors between male and female participants 
as well as between individuals with a BMI < 25 kg/m2 and those with BMIs ≥ 25 kg/m2.  A p-
value < 0.05 was considered statistically significant. Receiver operator characteristic (ROC) 
curves were created and area under the curve (AUC) determined in order to compare lipid 
parameters, LAP, VAI, WC and BMI as predictors of MetS. An AUC ≥ 0.90 was considered 
excellent; 0.80 - 0.90, good; 0.70 - 0.80, fair; and 0.70 - 0.50, poor test performance. The 
Youden’s index was calculated and used to determine the cut-offs that gave the best combination 
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of sensitivity and specificity. Statistical analysis was carried out using IBM SPSS Statistics for 
Windows, Version 20.0 (Armonk, NY: IBM Corp). 
 
3.4 Results 
A total of 533 participants met the inclusion criteria and subsequently had samples collected and 
analysed. However, 5 participants didn’t have FPG results due to sample insufficiency and were 
excluded from this analysis leaving 528 participants, 255 (48.3%) males and 273 (51.7%) 
females. BMI was higher in female participants while WC and BP were higher in males. The 
difference in total cholesterol (TC) between male and female participants was not statistically 
significant but TGs were significantly higher in males and HDL-C lower in females. FPG levels 
and liver enzymes were higher in male participants as shown in Table 3.2. Only 2 (0.7%) 
women were smokers compared to 13 (5.1%) men, a difference that was statistically significant 
(p = 0.003). 
  




Key: ALP-Alkaline phosphatase, ALT-Alanine aminotransferase, AST-Aspartate aminotransferase, BMI-Body Mass Index, BP-
Blood pressure, CVD-Cardiovascular disease, DBP-Diastolic blood pressure, F-Female, FPG-Fasting plasma glucose, GGT-
Gama glutamyl transferase, HDL-C-High density lipoprotein cholesterol, hsCRP-Highly sensitive C-reactive protein, LAP-Lipid 
accumulation product, cLDL-C-calculated low density lipoprotein cholesterol, mLDL-C-measured low density lipoprotein 
cholesterol, M-Male, SBP-Systolic blood pressure, TGs-Triglycerides, VAI-Visceral adiposity index, UA-Uric acid, WC-Waist 
circumference, *comparison of medians, †comparison of mean ranks 
 
The overall prevalence of MetS was 25.6% (95% CI: 22.0%-29.5%). The prevalence increased 
with increase in age and BMI. The most prevalent component of the MetS was increased WC 
which was present in 294 (55.7%) participants while the least prevalent was elevated FPG which 
was found in 83 (15.7%) participants. Having GGT or UA values above the median more than 
doubled the odds of having MetS as shown in Table 3.3. Only 2 out of 135 (1.5%) participants 
with MetS were smokers compared to 13 out of 393 (3.3%) with no MetS (p = 0.375). Those 
who consumed alcohol were 26.7% (36/135) and 34.6% (136/393) for those with and without 
MetS respectively (p = 0.110). A comparison of ALT (U=17197.0, p=0.000), AST (U=22805.0, 
p=0.015) and ALP (U=21887.5, p=0.002) mean ranks in participants with and without Mets 










Age (years) 38 (19) 20-65 39 (21) 18-64 39 (20) 18-65 0.986*
BMI (kg/m
2
) 24.87 (5.66) 16.29-34.94 26.10 (6.25) 17.10-38.05 25.46 (5.96) 16.29-38.05 0.000†
LAP 29.52 (40.95) 0.00-388.87 23.97 (29.69) 3.30-205.54 26.94 (35.96) 0.00-388.87 0.055*
VAI 1.51 (1.45) 0.26-21.66 1.35 (1.13) 0.42-20.42 1.43 (1.22) 0.26-21.66 0.163*
WC (cm) 90 (15) 65-124 86 (16) 64-115 89 (17) 64-124 0.000†
SBP (mmHg) 127 (18) 94-167 118 (20) 77-194 123.5 (20) 77-194 0.000†
DBP (mmHg) 81 (12) 56-101 79 (14) 57-112 80 (14) 56-112 0.003†
FPG (mmol/L) 4.9 (0.8) 3.0-15.6 4.8 (0.7) 3.3-19.5 4.9 (0.8) 3.0-19.5 0.022†
TC (mmol/L) 4.7 (1.2) 2.3-8.2 4.6 (1.2) 2.6-7.7 4.6 (1.1) 2.3-8.2 0.732*
HDL-C (mmol/L) 1.1 (0.3) 0.5-2.0 1.2 (0.3) 0.3-2.4 1.1 (0.3) 0.3-2.4 0.000†
cLDL-C (mmol/L) 2.9 (1.1) 1.0-5.8 2.9 (1.0) 1.1-5.4 2.9 (1.0) 1.0-5.8 0.650*
mLDL-C (mmol/L) 2.9 (1.1) 0.9-5.8 2.8 (1.0) 1.3-5.2 2.8 (1.1) 0.9-5.8 0.141*
TG (mmol/L) 1.2 (0.90) 0.32-10.51 0.9 (0.61) 0.33-4.78 1.05 (0.75) 0.32-10.51 0.000†
UA (mmol/L) 0.35 (0.10) 0.18-0.64 0.27 (0.08) 0.13-0.47 0.31 (0.11) 0.13-0.64 0.000†
ALP (U/L) 86 (35) 34-179 84 (38) 31-191 85 (37) 31-191 0.497*
ALT (U/L) 21 (14) Aug-96 14 (9) 6-123 18 (11) 6-123 0.000†
AST (U/L 25 (8) 14-73 21 (6) 11-102 23 (7) 11-102 0.000†
GGT (U/L) 31 (24) 9-701 21 (12) 7-211 25 (19) 7-701 0.000†
hsCRP (mg/L) 0.99 (2.05) 0.20-36.25 1.65 (3.19) 0.20-60.75 1.31 (2.63) 0.20-60.80 0.000†
Male (n=254) Female (n=274) Total (n=528)
Table 3.2: Descriptive characteristics of participants 
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Table 3.3: Association between cardio-metabolic risk factors and metabolic syndrome 
 
Key: BMI-Body Mass Index, BP-Blood pressure, CI-Confidence interval, CVD-Cardiovascular disease, DBP-Diastolic BP, F-Female, FPG-Fasting plasma glucose, GGT-
Gamma-glutamyl transferase, HDL-C-High density lipoprotein cholesterol, hsCRP-highly sensitive C-reactive protein, M-Male, OR-Odds Ratio, SBP-Systolic BP, TGs-
Triglycerides, UA-uric acid, WC-Waist circumference, * Indicates reference category, **Components of MetS excluded in the multivariate analysis 
Variable Categories Number
Present-No. (%) Absent-No. (%) p-value Crude OR (95% CI) p-value Adjusted OR (95% CI)
Gender Male* 255 64 (25.1%) 191 (74.9%)
Female 273 71 (26.0%) 202 (74.0%) 0.811 1.05 (0.71-1.55) 0.523 1.20 (0.68-2.13)
Age (years) 18-29* 134 6 (4.5%) 128 (95.5%)
30-39 136 23 (16.9%) 113 (83.1%) 0.002 4.34 (1.71-11.04) 0.051 2.64 (1.00-6.99)
40-49 131 45 (34.4%) 86 (65.6%) 0.000 11.16 (4.56-27.31) 0.000 6.06 (2.35-15.60)
50-65 127 61 (48.0%) 66 (52.0%) 0.000 19.72 (8.10-48.00) 0.000 11.74 (4.61-29.88)
BMI (kg/m
2
) < 25.00* 242 19 (7.9%) 223 (92.1%)
25.00-29.99 198 76 (38.4%) 122 (61.6%) 0.000 7.31 (4.22-12.66) 0.000 5.08 (2.80-9.22)
30.00-39.99 88 40 (45.5%) 48 (54.5%) 0.000 9.78 (5.22-18.34) 0.000 5.23 (2.57-10.66)
WC (cm) < 94 (M) OR < 80 (F)* 234 4 (1.7%) 230 (98.3%)
≥ 94 (M) OR ≥ 80 (F) 294 131 (44.6%) 163 (55.4%) 0.000 46.21 (16.75-127.50)
TGs (mmol/L) < 1.7* 437 63 (14.4%) 374 (85.6%)
≥ 1.7 91 72 (79.1%) 19 (20.9%) 0.000 22.50 (12.70-39.85)
HDL-C (mmol/L) ≥ 1(M) OR ≥ 1.3 (F)* 304 38 (12.5%) 266 (87.5%)
< 1(M) OR < 1.3 (F) 224 97 (43.3%) 127 (56.7%) 0.000 5.35 (3.48-8.22)
BP (mmHg) SBP < 130 OR DBP < 85* 287 21 (7.3%) 266 (92.7%)
SBP ≥ 130 OR DBP ≥ 85 241 114 (47.3%) 127 (52.7%) 0.000 11.37 (6.82-18.96)
FPG (mmol/L) < 5.6* 445 65 (14.6%) 380 (85.4%)
≥ 5.6 83 70 (84.3%) 13 (15.7%) 0.000 31.48 (16.47-60.16)
hsCRP (mg/L) < 1.3* 262 44 (16.8%) 218 (83.2%)
≥ 1.3 266 91 (34.2%) 175 (65.8%) 0.000 2.58 (1.71-3.89) 0.620 1.14 (0.686-1.880)
GGT (IU/L) < 25* 263 45 (17.1%) 218 (82.9%)
≥ 25 265 90 (34.0%) 175 (66.0%) 0.000 2.491 (1.654-3.752) 0.003 2.173 (1.295-3.648)
UA (mmol/L) < 0.31* 252 47 (18.7%) 205 (18.3%)
≥ 0.31 276 88 (31.9%) 188 (68.1%) 0.000 2.042 (1.361-3.063) 0.000 2.042 (1.361-3.063)
Metabolic syndrome status Univariate **Multivariate
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The prevalence of MetS was higher in females though the difference was not statistically 
significant. There was a statistically significant difference in the prevalence of each component 
of the MetS when comparing male and female participants except for FPG. The commonest 
component of the MetS that was present in male participants was elevated BP (53.3%) while in 
females it was increased WC (71.8%). No female participant had a 10 year CVD risk > 10% 
based on their Framingham risk score compared to 10.6% of males as shown in Table 3.4.  
 
Table 3.4: Gender comparison of metabolic syndrome component prevalence 





BMI (kg/m2) < 25.00 132 (51.8%) 110 (40.3%) 0.001 
  25.00-29.99 95 (37.3%) 103 (37.7%)   
  30.00-39.99 28 (11.0%) 60 (22.0%)   
WC (cm) < 94 (M) OR < 80 (F) 157 (61.6%) 77 (28.2%) 0.000 
  ≥ 94 (M) OR ≥ 80 (F) 98 (38.4%) 196 (71.8%)   
TGs (mmol/L) < 1.7 194 (76.1%) 243 (89.0%) 0.000 
  ≥ 1.7 61 (23.9%) 30 (11.0%)   
HDL-C (mmol/L) ≥ 1(M) OR ≥ 1.3 (F) 179 (70.2%) 125 (45.8%) 0.000 
  < 1(M) OR < 1.3 (F) 76 (29.8%) 148 (54.2%)   
BP (mmHg) SBP < 130 OR DBP < 85 119 (46.7%) 168 (61.5%) 0.001 
  SBP ≥ 130 OR DBP ≥ 85 136 (53.3%) 105 (38.5%)   
FPG (mmol/L) < 5.6 212 (83.1%) 233 (85.3%) 0.486 
  ≥ 5.6 43 (16.9%) 40 (14.7%)   
10 year CVD risk (%) ≤ 10% 228 (89.4%) 273 (100.0%) 0.000 
  > 10% 27 (10.6%) 0 (0.0%)   
Key: BMI-Body Mass Index, BP-Blood pressure, CVD-Cardiovascular disease, DBP-Diastolic BP, FPG-Fasting plasma glucose, 
F-Female, HDL-C-High density lipoprotein cholesterol, M-Male, SBP-Systolic BP, TGs-Triglycerides, WC-Waist circumference 
 
The prevalence of each component of the MetS was significantly higher in those with a BMI 
greater ≥ 25 kg/m2 compared to those with a BMI < 25 kg/m2 as shown in Table 3.5.  
 
  




Table 3.5: Comparison of metabolic syndrome component prevalence in different BMI 
categories 
Variable Categories BMI < 25.00 
(n=242) No. (%) 
BMI ≥ 25.00 
(n=286) No. (%) 
p-value 
WC (cm) < 94 (M) OR < 80 (F) 188 (77.7%) 46 (16.1%) 0.000 
  ≥ 94 (M) OR ≥ 80 (F) 54 (22.3%) 240 (83.9%)   
TGs (mmol/L) < 1.7 223 (92.1%) 214 (74.8%) 0.000 
  ≥ 1.7 19 (7.9%) 72 (25.2%)   
HDL-C (mmol/L) ≥ 1(M) OR ≥ 1.3 (F) 157 (64.9%) 147 (51.4%) 0.002 
  < 1(M) OR < 1.3 (F) 85 (35.1%) 139 (48.6%)   
BP (mmHg) SBP < 130 OR DBP < 85 152 (62.8%) 135 (47.2%) 0.000 
  SBP ≥ 130 OR DBP ≥ 85 90 (37.2%) 151 (52.8%)   
FPG (mmol/L) < 5.6 230 (95.0%) 215 (75.2%) 0.000 
  ≥ 5.6 12 (5.0%) 71 (24.8%)   
Key: BMI-Body Mass Index, BP-Blood pressure, DBP-Diastolic BP, FPG-Fasting plasma glucose, F-Female, HDL-C-High 
density lipoprotein cholesterol, M-Male, SBP-Systolic BP, TGs-Triglycerides, WC-Waist circumference 
 
ROC analysis of LAP, VAI, WC and BMI ability to predict the presence of MetS showed LAP 
as having the highest AUC at 0.880. When male and female data were analysed separately, the 
AUC for the 4 parameters were higher in males with WC, LAP and VAI having excellent AUCs. 
With the exception of VAI, all other optimum cut-offs were lower in females as shown in Table 
3.6. Using a WC cut-off of 86 cm reduced the prevalence of MetS in female participants from 
26.0% to 23.4%. 
 
Table 3.6: Summary of ROC curve and Youden Index analysis for BMI, WC, VAI and 
LAP as predictors of MetS 
Gender Variable AUC (95% CI) YI Cut-off Sensitivity Specificity 
Males & Females 
  
  
BMI 0.766 (0.725-0.808) 0.457 26.23 0.770 0.687 
WC 0.825 (0.789-0.862) 0.518 89.5 0.867 0.651 
VAI 0.858 (0.818-0.897) 0.599 2.057 0.726 0.873 





BMI 0.841 (0.789-0.892) 0.587 25.71 0.859 0.728 
WC 0.913 (0.879-0.947) 0.759 93.5 0.957 0.806 
VAI 0.905 (0.859-0.951) 0.697 1.727 0.922 0.775 





BMI 0.702 (0.638-0.765) 0.363 24.99 0.873 0.49 
WC 0.766 (0.710-0.821) 0.453 85.5 0.859 0.594 
VAI 0.814 (0.752-0.876) 0.529 2.065 0.648 0.881 
LAP 0.822 (0.764-0.879) 0.502 30.56 0.775 0.728 
Key: AUC-Area under the curve, BMI-Body mass index, CI-Confidence intervals, LAP-Lipid accumulation product, WC-Waist 
circumference, VAI-Visceral adiposity index, YI-Youden Index 




The lipid parameter that best predicted MetS was TG with AUCs of 0.816, 0.887 and 0.770 for 
all participants, male and female participants respectively. Measured LDL-C (mLDL-C) was 
consistently better than calculated LDL-C (cLDL-C) at predicting MetS. Non-HDL-C and 
cholesterol remnants performed better in males compared to females as shown in Table 3.7. 
 
Table 3.7: ROC curve analysis for lipid parameters as predictors of MetS 
Gender Variable AUC (95% CI) YI Cut-off Sensitivity Specificity 




TG 0.816 (0.769-0.862) 0.517 1.27 0.726 0.791 
HDL-C 0.721 (0.669-0.774) 0.318 1.1 0.756 0.562 
mLDL-C 0.660 (0.605-0.714) 0.268 3.0 0.652 0.616 
cLDL-C 0.578 (0.520-0.636) 0.146 3.2 0.459 0.687 
TC 0.648 (0.592-0.704) 0.258 5.0 0.548 0.710 
non HDL-C 0.706 (0.654-0.759) 0.342 3.4 0.785 0.557 





TG 0.887 (0.841-0.933) 0.645 1.68 0.734 0.911 
HDL-C 0.722 (0.642-0.803) 0.395 0.9 0.594 0.801 
mLDL-C 0.719 (0.650-0.789) 0.346 2.8 0.828 0.518 
cLDL-C 0.613 (0.532-0.693) 0.190 2.8 0.703 0.487 
TC 0.731 (0.660-0.802) 0.358 4.9 0.688 0.670 
non HDL-C 0.778 (0.714-0.843) 0.456 3.5 0.891 0.565 





TG 0.770 (0.697-0.843) 0.471 1.25 0.620 0.851 
HDL-C 0.752 (0.684-0.820) 0.412 1.1 0.704 0.708 
mLDL-C 0.605 (0.525-0.685) 0.214 3.1 0.521 0.693 
cLDL-C 0.547 (0.464-0.629) 0.123 3.5 0.296 0.827 
TC 0.572 (0.490-0.654) 0.173 5.0 0.465 0.708 
non HDL-C 0.645 (0.567-0.722) 0.264 3.4 0.690 0.574 
CholRem 0.712 (0.642-0.782) 0.307 0.7 0.451 0.856 
Key: AUC-Area under the curve, CholRem-Cholesterol remnants, cLDL-C-calculated LDL cholesterol, CI-Confidence intervals, 




The prevalence of MetS of 25.6% found in this study is quite high given the strict inclusion and 
exclusion criteria used for the RI study. This sample was meant to be representative of a healthy 
black African population in Kenya and as such the percentage of individuals with MetS was 
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expected to be much lower. Several studies have reported the prevalence of MetS in Africa. 
These studies are quite heterogeneous by way of individuals included and MetS definitions used 
hence limiting direct comparisons. Ogbera reported a MetS prevalence of 86% using the 2009 
harmonized definition in diabetic patients in Lagos, Nigeria (Ogbera, 2010). This high 
prevalence in a diabetic population is expected given the known association between  MetS and 
increased risk of developing type 2 diabetes (Marott, Nordestgaard, Tybjærg-Hansen, & Benn, 
2016).  In Ethiopia, Tran et al reported a prevalence of 12.5% and 17.9% using the ATP III and 
IDF definitions respectively in a presumably healthy population comprising working class 
individuals in Addis Ababa (Tran et al., 2011). This prevalence is much lower than what we have 
found in our study. Of, note is that the prevalence of overweight and obese individuals was lower 
in the Ethiopian population which we hypothesize may be attributed to genetic and/or 
environmental differences. Kaduka et al reported a prevalence of 34.6% in an urban population 
in Nairobi, Kenya. This study was however limited to one constituency in Nairobi hence limiting 
the generalizability of the findings. The inclusion criteria was also not as strict as what we used 
in our study and this could partly explain the higher reported prevalence (Kaduka et al., 2012). 
 
The most prevalent component of the MetS was increased WC which was present in 294 (55.7%) 
participants followed by elevated BP found in 241 (45.6%) of study participants. This is 
consistent with what has been found in other studies carried out in sub-Saharan Africa (SSA) 
(Kaduka et al., 2012; Tran et al., 2011). However, the most common MetS component in males 
was hypertension (53.3%) and increased WC (71.8%) in females. In South Africa, HDL-C < 1.3 
mmol/L was found to be the most prevalent of the MetS components in black African women at 
70.1% closely followed by increased WC at 69.3% compared to 54.2% and 71.8% for low HDL-
C and increased WC respectively in our study (Crowther & Norris, 2012). WC is a measure of 
both VAT and SAT. Increased visceral adiposity contributes to the insulin resistance that is 
central to the pathogenesis of MetS and is associated with the production of adipocytokines 
which contribute to the chronic low grade inflammation seen in MetS. WC was a better predictor 
of MetS than BMI in our study but had a lower AUC than both LAP and VAI. Chen et al found 
that VAI was better than BMI and WC in predicting the presence of diabetes in a Chinese cohort 
(Chen et al., 2014). Gender specific ROC curve analysis in our study showed that WC was a 
better predictor of MetS in males than in females and was superior to VAI. A WC greater than 
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93.5 cm in male participants had a sensitivity of 95.7%, specificity of 80.6% and AUC of 0.913 
which is excellent for a simple measurement that can be carried out in any clinical setting. It is 
interesting that the optimum WC cut-off of 93.5 cm is similar to the proposed European cut-off 
for abdominal obesity of 94 cm that is used in the MetS 2009 harmonized criterion for men. The 
women cut-off of 85.5 cm is much higher than the European cut-off of 80 cm highlighting the 
need to adopt population specific cut-offs (Alberti et al., 2009). The use of the 80 cm cut-off in 
black African women may be misclassifying many of them as having abdominal obesity. A study 
carried out in Johannesburg, South Africa derived an optimal cut-off to diagnose MetS in urban 
black African women of 91.5 cm. The prevalence of MetS in this population was 42.1% and the 
WC was measured at the smallest girth above the umbilicus (Crowther & Norris, 2012). This 
suggests that the optimal cut-off would have been higher if measured at the level of the 
umbilicus like we did in our study. Further longitudinal studies are required to validate the WC 
cut-offs we have proposed and assess their ability to predict CVD risk in a black African 
population. 
 
Elevated GGT and UA levels independently more than doubled the odds of having MetS. 
Surprisingly, elevated hsCRP did not independently increase the odds of one having MetS. 
Elevated GGT is known to occur in non-alcoholic fatty liver disease (NAFLD) which represents 
the hepatic component of MetS and its increase may be a physiological response to the increased 
oxidation stress seen in MetS as GGT plays a role in the metabolism of glutathione which is an 
important anti-oxidant (Lee, Blomhoff, & Jacobs, 2004). Matsha et al demonstrated that 
increasing levels of GGT were associated with increasing levels of insulin resistance as well as 
an increase in the number of components of MetS present in a mixed ancestry population in 
South Africa. This was so even in GGT levels within the reference interval. However, additional 
tests of liver enzymes were not performed in this study to enable inferences on the 
pathophysiology behind the increase of GGT in MetS (Tandi Edith Matsha et al., 2014). In our 
study, elevated GGT was associated with an increase in ALT, AST and ALP suggesting that 
MetS may be associated with mild hepatitis and cholestasis. It is known that hepatocyte injury 
does occur in individuals with NAFLD, however, canalicular cholestasis is more common in 
alcoholic liver disease (Takahashi & Fukusato, 2014).  
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Despite the difference in prevalence of Mets in male and female participants not being 
statistically significant, the 10 year CVD risk was significantly higher in male participants with 
10.6% having a > 10% risk compared to 0% among females. This suggests that the presence of 
MetS confers a different CVD risk depending on gender with the risk being lower in females. 
We explored the possibility of over diagnosis of MetS in female participants given the disparity 
in WC between the Caucasian cut-off and the higher values for females reported in studies 
carried out in Africa including our study. However, whereas using a WC cut-off of 86 cm 
reduced the MetS prevalence in females from 26.0% to 23.4%, the difference compared to males 
was still not statistically significant hence this doesn’t explain the observed disparity in CVD 
risk. This is even more surprising when you consider that women had a statistically significant 
higher level of hsCRP than men. This finding further adds to the uncertainty surrounding the use 
of hsCRP in CVD risk prediction (Yousuf et al., 2013). The optimal cut-off for TGs that 
predicted the presence of MetS was 1.27 mmol/L for combined males and females, 1.68 mmol/L 
for males and 1.25 mmol/L for females. Given these findings, we do advocate the adoption of 
separate TG cut-offs for males and females for the diagnosis of MetS in a black African 
population. The higher TG levels and WC in men compared to women is in keeping with the 
known positive correlation between TG levels and visceral adiposity (Taniguchi et al., 2002). 
The MetS 2009 harmonized criterion uses a cut-off of 1.7 mmol/L for both males and females 
which could under estimate the prevalence of hypertriglyceridaemia in female black Africans 
and by extension MetS. Using gender specific TG cut-offs in addition to adjusting the WC cut-
off to 86 cm increased the MetS prevalence in females to 29.7 %. The prevalence in males 
remained at 25.1% which is not surprising given the similarities in our male TG and WC cut-offs 
to those used in the harmonized criterion (Alberti et al., 2009).  
 
Of the lipid parameters that are not included in the MetS definition, cholesterol remnants 
outperformed non-HDL-C, mLDL-C and cLDL-C in predicting the presence of MetS. Calculated 
non-fasting cholesterol remnant has been shown to be an independent risk factor for ischaemic 
heart disease and myocardial infarction in a Caucasian population (Jorgensen et al., 2013; Varbo 
et al., 2013). There is a scarcity of data on the utility of cholesterol remnants and non HDL-C in 
predicting the presence of MetS in black Africans. In our study, the lipid parameters were better 
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predictors in males than in females. Prospective cohort studies are needed to determine whether 
cholesterol remnants are an independent risk factor for CVD in black Africans. 
 
This study has several limitations. It is a cross sectional study hence causal inferences cannot be 
made. The predictive ability of the factors analysed would best be studied in a longitudinal study 
and as such, our findings would need to be validated in a prospective cohort study. However, 
with a sample size of over 528, the study has sufficient power to draw conclusions on optimal 
cut-offs for MetS prediction. We also didn’t collect data on family history of CVD and therefore 
our estimation of CVD risk based on Framingham calculations may have underestimated the 10 
year risk. However, it is unlikely that this omission significantly affected the comparison 
between CVD risk in males and females. Our study was carried out in an urban population hence 
the findings cannot be directly extrapolated to a rural population who are known to have a lower 
prevalence of obesity and MetS. 
Conclusion 
We propose 94 cm and 86 cm as WC cut-offs for males and females respectively for black 
Africans in Kenya when diagnosing MetS. These however need to be validated prospectively in 
other countries in SSA. There is also a need to adopt gender specific MetS TG cut-offs to avoid 
over diagnosing hypertriglyceridaemia in black African women who have a lower TG level 
compared to the 1.7 mmol/L cut-off. The high prevalence of abdominal obesity, hypertension 
and MetS in our subjectively healthy population emphasizes the need for primary healthcare 
interventions to control the epidemic of CVD in Kenya. Urbanization in SSA will continue to 
accelerate the incidence of obesity, diabetes and hypertension all of which can be avoided or at 
least reduced by adopting lifestyle changes such as reduced intake of processed food that is high 
in calories and regular exercise to ensure a reasonable balance between what is consumed and 
what is expended. Unless urgent interventions are put in place to prevent this epidemic, the 
additional morbidity due to CVD will over burden the already stretched healthcare services in 
SSA leading to increased mortality. 
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CHAPTER 4:  COMPARISON OF EQUATIONS FOR ESTIMATING 
GLOMERULAR FILTRATION RATE IN SCREENING FOR 
CHRONIC KIDNEY DISEASE IN ASYMPTOMATIC BLACK 
AFRICANS: A CROSS SECTIONAL STUDY 
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Several equations have been developed to estimate glomerular filtration rate (eGFR). The 
common equations used were derived from populations predominantly comprised of Caucasians 
with chronic kidney disease (CKD). Some of the equations provide a correction factor for 
African-Americans due to their relatively increased muscle mass and this has been extrapolated 
to black Africans. Studies carried out in Africa in patients with CKD suggest that using this 
correction factor for the black African race may not be appropriate.   However, these studies 
were not carried out in healthy individuals and as such the extrapolation of the findings to an 
asymptomatic black African population is questionable. We sought to compare the proportion of 
asymptomatic black Africans reported as having reduced eGFR using various eGFR equations. 
We further compared the association between known risk factors for CKD with eGFR 
determined using the different equations. 
Methods 
We used participant and laboratory data collected as part of a global reference interval study 
conducted by the Committee of Reference Intervals and Decision Limits (C-RIDL) under the 
International Federation of Clinical Chemistry (IFCC). Serum creatinine values were used to 
calculate eGFR using the Cockcroft-Gault (CG), re-expressed 4 variable modified diet in renal 
disease (4v-MDRD), full age spectrum (FAS) and chronic kidney disease epidemiology 
collaboration equations (CKD-EPI). CKD classification based on eGFR was determined for 
every participant. 
Results 
A total of 533 participants were included comprising 273 (51.2%) females. The 4v-MDRD 
equation without correction for race classified the least number of participants (61.7%) as having 
an eGFR equivalent to CKD stage G1 compared to 93.6% for CKD-EPI with correction for race. 
Only age had a statistically significant linear association with eGFR across all equations after 
performing multiple regression analysis. The multiple correlation coefficients for CKD risk 
factors were higher for CKD-EPI determined eGFRs. 




This study found that eGFR determined using CKD-EPI equations better correlated with a 
prediction model that included risk factors for CKD and classified fewer asymptomatic black 




MDRD, CKD-EPI, Cockcroft-Gault, FAS, eGFR 
 
4.2 Background 
Routine reporting of estimated glomerular filtration rate (eGFR) by medical laboratories for 
every serum creatinine request has been encouraged as a way of screening for chronic kidney 
disease (CKD) and has been shown to increase the absolute number of appropriate referrals to 
nephrologists (Noble et al., 2008). Patients with early CKD may be asymptomatic and therefore 
reporting eGFR may help in early detection and appropriate interventions to stop or reverse 
progression of the disease (Levey, Atkins, et al., 2007).  
 
The use of eGFR equations instead of creatinine clearance (CrCl) is preferred due to the 
difficulties associated with accurately collecting a 24 hour urine sample. The most popular 
equations for estimating GFR are Cockcroft-Gault (CG), 4 variable modified diet in renal disease 
(4v-MDRD) and chronic kidney disease epidemiology collaboration (CKD-EPI). The CG 
equation was derived from an inpatient population comprising predominantly male patients with 
CKD (Cockcroft & Gault, 1976). The equation doesn’t correct for race and one requires the 
patient’s height and weight to correct for body surface area (BSA) in order to accurately classify 
CKD. The 4v-MDRD equation was derived from a population with kidney disease comprising a 
predominantly white population. Despite the low percentage of African-Americans in this study, 
they determined a correction for race (Levey et al., 1999). It has been assumed, given the 
ancestral linkage between African Americans and black Africans that this correction should 
apply to black Africans. However, a study carried out in South Africa that measured GFR in 
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black South Africans with established CKD or risk factors for developing CKD concluded that 
eGFR based on the 4v-MDRD equation without correction for race better correlated with 
measured GFR (mGFR) and had less bias (van Deventer et al., 2008). A similar study carried out 
in Ghana in a rural African population arrived at a similar conclusion, however, this study 
compared eGFR to creatinine clearance (Eastwood et al., 2010). Both CG and 4v-MDRD have 
been shown to underestimate normal and high mGFR values with a greater negative bias seen 
with CG (Ibrahim et al., 2005; Vervoort, Willems, & Wetzels, 2002). One of the drawbacks of 
the 4v-MDRD equation is that it doesn’t accurately classify patients with early CKD, in 
particular those with values > 60ml/min/1.73m2. This is not surprising given that it was derived 
from patients with CKD who had a mean eGFR of 39.8 ml/min/1.73m2. The utility of this 
equation in screening for CKD in an asymptomatic patient with no known risk factors for CKD 
is questionable given that subjectively healthy individuals generally have an eGFR in the range 
where the 4v-MDRD equation is inaccurate. The CKD-EPI equation has been found to better 
correlate with mGFR especially in those with eGFR > 60 ml/min/1.73m2 (Levey et al., 2009). In 
a study carried out in Kenya amongst HIV patients with a median mGFR of 115 ml/min/1.73m2, 
both CKD-EPI and 4v-MDRD performed better without correction for race with CKD-EPI 
estimates being more precise  (Wyatt et al., 2013). A new equation called the full age spectrum 
(FAS) equation has been developed by Pottel et al which factors in correction for race, age and 
gender by including population specific mean or median serum creatinine values in the 
determination of eGFR. This equation has the advantage of being applicable across different age 
groups from children as young as 2 years to the elderly above 65 years of age. The equation is 
yet to be validated in a black African population and was derived from population datasets 
largely comprising Caucasians (Hans Pottel et al., 2016). Most of the studies done in Africa that 
have concluded that correcting for race is not necessary for a black African population were 
carried out in populations comprising patients with CKD or at a high risk of developing CKD. 
The extrapolation of this finding to an asymptomatic population should not be done without 
evidence that this observation is consistent. 
 
None of the eGFR equations that are routinely used were derived from a black African 
population and as such their appropriateness in assessing kidney function in this population 
needs to be evaluated. Since creatinine generation is determined primarily by muscle mass and 
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dietary intake (Stevens, Coresh, Greene, & Levey, 2006), it is reasonable to assume that the 
performance of eGFR equations will be influenced by the extent to which the  body habitus of an 
African population differs from the reference populations used when deriving them. Given the 
paucity of data on the performance of these equations in a subjectively healthy population, we 
compared eGFR determined using various eGFR equations and assessed which eGFR values best 
correlated with known risk factors for CKD and the proportion of asymptomatic black Africans 




We determined eGFR using single measurements of serum creatinine from Kenyans 
participating in a cross-sectional multicenter, multinational, global reference interval study which 
is part of an initiative by the Committee of Reference Intervals and Decision Limits (C-RIDL) 
under the auspices of the International Federation of Clinical Chemistry (IFCC). The aim of the 
study is to determine reference intervals for common laboratory tests across different 
geographical regions and populations, and to explore determinants of variation in reference 
intervals. Kenya is one of the 3 participating countries in Africa, the other ones being Nigeria 
and South Africa. For the Kenyan study, we recruited subjectively healthy black African adults 
who met the inclusion criteria as spelt out in the published protocol (Ozarda et al., 2013). 
Participants were recruited from Nairobi which is the capital city, Kiambu county which is in 
central Kenya, Kisii which is in the western part of Kenya, and Nakuru county which is in the 
Great Rift valley. Recruitment was carried out between January and October 2015. All 
participants had undergone an overnight fast and written informed consent was sought from each 
participant after giving a written and verbal explanation of the study. Recruitment was stratified 
into 4 age groups: 18-29, 30-39, 40-49 and 50-65 years with almost similar numbers of males 
and females in each age strata. The recruitment procedure, sample handling and analysis has 
previously been described (Omuse, Maina, Hoffman, et al., 2017). Briefly, all participants had 
measurements of blood pressure (BP), abdominal circumference and body mass index (BMI) 
done, samples were collected and centrifuged within 4 hours after collection and stored at -80oc 
until shipment on dry ice to the Pathcare reference laboratory in South Africa. As part of the 
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reference interval study, all participating laboratories used a common mini-panel of sera with 
assigned values to ensure accuracy of reported results and alignment of values if any biases were 
identified. Urine samples to test for haematuria and proteinuria were not collected. Serum 
creatinine was determined using a standardized kinetic colour test (Jaffé method) and fasting 
plasma glucose (FPG) by an enzymatic UV test (hexokinase method) both measured on a 
Beckman AU5800 (Schizuoka, Japan).  
 
Calculation of body surface area (BSA) was done using the DuBois method (DuBois D, 1916): 
BSA (m2) = [71.84 x weight (kg)0.425  x height (cm)0.725]/10 000.  
 
Calculation of eGFR (mL/min/1.73 m2) was done using the following equations: 
Re-expressed 4-v MDRD (Levey, Coresh, et al., 2007)  
175 x [S-Cr (µmol/L)/88.4]-1.154 x age (years)-0.203 x (0.742 if female) x (1.212 if African 
American) 
 
Cockcroft-Gault normalized to 1.73m2 (Cockcroft & Gault, 1976)  
[(140 x age in years) x weight (kg) x (0.85 if female) x 1.73 (m2)]/[S-Cr(µmol/L)x 0.814 x BSA 
(m2)] 
 
CKD-EPI for blacks (Levey et al., 2009)  
Female with Creatinine ≤ 62 μmol/L; 166 × (Scr/61.9)
-0.329 × (0.993)Age 
Female with Creatinine > 62 μmol/L; 166 × (Scr/61.9)
-1.209 × (0.993)Age 
Male with Creatinine ≤ 80 μmol/L; 163 × (Scr/79.6)
-0.411 × (0.993)Age 
Male with Creatinine > 80 μmol/L; 163 × (Scr/79.6)
-1.209 × (0.993)Age 
 
CKD-EPI for other races (Levey et al., 2009)  
Female with Creatinine ≤ 62 μmol/L; 144 × (Scr/61.9)
-0.329 × (0.993)Age 
Female with Creatinine > 62 μmol/L; 144 × (Scr/61.9)
-1.209 × (0.993)Age 
Male with Creatinine ≤ 80 μmol/L; 141 × (Scr/79.6)
-0.411 × (0.993)Age 
Male with Creatinine > 80 μmol/L; 141 × (Scr/79.6)
-1.209 × (0.993)Age 
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FAS equation (Hans Pottel et al., 2016)  
2-40 years;   107.3/ (Scr/Q) 
> 40 years;    (107.3/ [Scr/Q])0.988Age-40 
Where Scr is serum creatinine, Q is the mean or median population specific serum creatinine, 
Age is in years 
 
Classification of CKD based on eGFR was done using the 2012 Kidney Disease: Improving 
Global Outcomes (KDIGO) clinical practice guidelines as follows (KDIGO, 2013):  
  
GFR category GFR (ml/min/1.73m2) Terms 
G1   ≥90    Normal or high 
G2   60–89    Mildly decreased 
G3a   45–59    Mildly to moderately decreased 
G3b   30–44    Moderately to severely decreased 
G4   15–29    Severely decreased 
G5   <15    Kidney failure 
 
A cut off-of 75 ml/min/1.73m2 was also used to define reduced eGFR for participants less than 
40 years of age as proposed by Pottel et al (H. Pottel, Hoste, & Delanaye, 2015).  Sample size 
calculation for the primary study was based on recommendations from the Clinical Laboratory 
Standards Institute (CLSI) which requires a minimum of 120 study participants per stratification 
in order to get 90% confidence limits around the upper and lower limits of a reference interval 
(CLSI, 2008). Since we had 4 age stratifications, a minimum sample size of 480 was required to 
achieve the primary objective for the reference interval study.  
Statistical analysis 
Descriptive and inferential statistics were performed using SPSS version 20 (IBM corp, Armonk, 
New York, USA). Medians and interquartile ranges (IQR) were calculated for continuous 
variables before and after stratification based on gender. Comparison of medians or mean ranks 
between males and females was done using the Mann-Whitney U test.  Classification of eGFR 
was reported as proportions. Multiple regression analysis (MRA) was also performed to 
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determine the extent to which the CKD risk factors independently added to the eGFR regression 
model. Calculation of eGFR, BSA and classification of CKD was done using Microsoft excel 
2010 (Redmond, USA). A p-value less than 0.05 was considered statistically significant. 
 
4.4 Results 
A total of 533 participants were included comprising 260 (48.8%) males and 273 (51.2%) 
females. The median age, BMI and FPG between males and females wasn’t statistically different 
neither was eGFR except when determined using CG corrected for BSA. Males had higher 
serum creatinine values. Five participants didn’t have FPG assayed due to insufficient samples. 








Table 4.1: Descriptive characteristics of participants 
















Age (years) 39 (18) 20-65 39 (21) 18-64 39 (20) 18-65 0.971 
Height (cms) 172 (8) 156-191 160 (9) 143-191 167 (13) 143-191 0.000 
Weight (kg) 74 (19) 46-116 68 (16) 38-109 70 (18) 38-116 0.000 
BMI (kg/m2) 24.9 (5.6) 16.3-34.9 26.1 (6.3) 17.1-38.1 25.5 (5.9) 16.3-38.1 0.051 
BSA (m2) 1.88 (0.24) 1.44-2.36 1.72 (0.20) 1.27-2.24 1.78 (0.22) 1.27-2.36 0.000 
Abd. Circ. (cm) 91 (15) 65-124 86 (16) 64-115 89 (17) 64-124 0.005 
BP Systolic 
(mmHg) 
127 (18) 84-179 128 (18) 118 (20) 124 (21) 77-194 0.000 
BP Diastolic 
(mmHg) 
81 (12) 56-101 79 (14) 57-112 80 (14) 56-112 0.003 
*FPG (mmol/L) 4.9 (0.8) 3.0-15.6 4.8 (0.7) 3.3-19.5 4.9 (0.8) 3.0-19.5 0.191 
Creatinine 
(µmol/L) 
80 (20) 50-126 61 (15) 30-93 70 (21) 30-126 0.000 
4v-MDRD eGFR 
(mL/min/1.73m2) 
114 (34) 61-184 118 (34) 69-251 115 (33) 61-251 0.126 
4v-MDRD^ eGFR 
(mL/min/1.73m2) 
94 (28) 50-152 97 (28) 57-207 95 (28) 50-207 0.126 
CKDEPI eGFR 
(mL/min/1.73m2) 
118 (25) 60-151 124 (25) 71-168 121 (25) 60-168 0.090 
CKDEPI eGFR^ 
(mL/min/1.73m2) 
102 (21) 52-130 107 (22) 62-146 105 (22) 52-146 0.061 
CG eGFR^^ 
(mL/min/1.73m2) 
103 (26) 55-163 163 (45) 85-345 128 (61) 55-345 0.000 
FAS eGFR 
(mL/min/1.73m2) 
100 (23) 51-163 104 (25) 58-200 102 (25) 51-200 0.309 
KEY: IQR-Interquartile range, Abd.Circ.-Abdominal circumference, BMI-Body Mass Index, BP-Blood pressure, FPG-Fasting 
plasma glucose (*5 males didn’t have this test done), ^Not corrected for race, ^^Corrected for body surface area 
 
Overall, women had higher eGFR compared to men. Of the 6 equations, the 4v-MDRD equation 
without correction for race had the lowest median eGFR and classified the least number of 
participants (61.7%) as having an eGFR ≥ 90 mL/min/1.73m2 compared to 93.4% by CKD-EPI 
with correction for race as shown in table 2. The 4v-MDRD equation without correction for race 
classified the highest percentage of participants (0.9%) as having an eGFR <60 ml/min/1.73m2. 
The number of individuals with an eGFR <60 ml/min/1.73m2 was less than 1% regardless of the 
equation used. Using a cut off of 75 ml/min/1.73m2, the 4v-MDRD equation without correction 
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for race also classified the highest proportion of participants under the age of 40 years (7.8%) as 
having reduced eGFR as shown in Table 4.2. 
 
After multiple regression analysis, only age had an unstandardized coefficient (B) that was 
statistically significantly different from zeroacross all the 6 equations.  Overall, the correlation 
between eGFR and risk factors for CKD varied depending on which equation was used. The 6 
CKD risk factors evaluated had a stronger association with the CKD-EPI determined eGFRs as 
evidenced by higher multiple correlation coefficients as shown in Table 4.2.  
 
  




Table 4.2: CKD classification and correlation of eGFR with risk factors 
  CG^^ 4v-MDRD 4v-MDRD^ CKD-EPI CKD-EPI^ FAS 
CKD classification based on 
eGFRNo. (%) 
          
G1 478 (89.7%) 473 (88.7%) 329 (61.7%) 499 (93.6%) 433 (81.2%) 402 (75.4%) 
G2 54 (10.1%) 60 (11.3%) 199 (37.3%) 34 (6.4%) 99 (18.6%) 129 (24.2%) 
G3a 1 (0.2%) 0 (0.0%) 5 (0.9%) 0 (0.0%) 1 (0.2%) 2 (0.4%) 
No. (%) <40 years with eGFR <75 
ml/min/1.73m2(n=270) 
0 (0.0%) 0 (0.0%) 21 (7.8%) 0 (0.0%) 1 (0.4%) 5 (1.9%) 
eGFR (ml/min/1.73m2) mean(SD)       
18-29 years (n=135) 149.0 (40.9) 129.5 (21.8) 106.8 (18.0) 135.3 (15.6) 117.2 (13.5) 108.9 (15.5) 
30-39 years (n=135) 136.7 (39.2) 112.1 (20.2) 92.6 (16.7) 119.1 (15.8) 103.2 (13.7) 102.9 (15.8) 
40-49 years (n=132) 139.8 (43.6) 117.0 (25.4) 96.6 (20.9) 117.6 (14.8) 101.8 (12.8) 106.7 (19.8) 
50-65 years (n=131) 120.8 (35.1) 111.9 (25.0) 92.3 (20.6) 107.6 (15.2) 93.2 (13.1) 92.2 (18.4) 
Multiple correlation coefficient (R) 0.563 0.305 0.306 0.568 0.568 0.350 
Unstandardized (B) coefficients 
(standard error) 
      
Age -0.621*(0.151) -0.322*(0.102) -0.267*(0.084) -0.673*(0.067) -0.579*(0.058) -0.403*(0.077) 
BMI 7.418*(0.567) -0.596(0.382) -0.491(0.315) -0.188(0.252) -0.129(0.218) -0.405(0.289) 
Systolic BP -0.485*(0.140) -0.121(0.094) -0.099(0.078) -0.116(0.062) -0.102(0.054) -0.119(0.071) 
Diastolic BP 0.237(0.202) 0.139(0.136) 0.115(0.112) 0.142(0.090) 0.124(0.078) 0.117(0.103) 
Abd.Circ. -2.049*(0.231) -0.178(0.156) -0.148(0.128) -0.184(0.103) -0.172(0.089) -0.028(0.118) 
FPG 0.579(1.170) 1.106(0.788) 0.912(0.650) 0.610(0.519) 0.500(0.450) 0.807(0.596) 
KEY: Abd.Circ.-Abdominal circumference, BP-Blood pressure, BMI-Body Mass Index, CKD-Chronic kidney disease, FPG-Fasting plasma glucose, ^Not corrected for race, 
^^Corrected for body surface area, * Significant at a p-value < 0.05 
 




The prevalence of eGFR < 60 ml/mim/1.73 m2 was less than 1% according to the 6 equations evaluated 
in this study which is reflective of the deliberate recruitment of healthy individuals for the reference 
interval study. In a randomly selected rural and urban adult population in Cameroon, Kaze et al found 
that 10.9% had a CKD-EPI determined eGFR <60 ml/min/1.73m2 with this being more common in the 
urban population (Kaze et al., 2015). Both the CKD-EPI and 4v-MDRD equations with correction for 
race did not classify any participant as having a reduced eGFR in our study largely comprised of an 
urban population. Assuming that a healthy population should predominantly have an eGFR > 90 
ml/min/1.73m2, the CKD-EPI equation with correction for race classified more participants into stage 
G1 suggesting that it could be a more ideal equation when estimating eGFR in an asymptomatic 
population not known to have risk factors for CKD. Unlike the MDRD equation which was derived 
from individuals with CKD, CKD-EPI was derived from a heterogeneous population that included 
healthy individuals (Levey et al., 2009). Rule et al used different equations to screen for CKD in a 
general population and found that equations derived from a CKD population gave higher estimates of 
CKD prevalence compared to equations derived from a population that included healthy individuals 
(Rule et al., 2006). It is therefore not surprising that the CKD-EPI equation classified less participants 
as having a reduced eGFR compared to the 4v-MDRD equation. 
 
There has been a debate as to the suitability of the 60 ml/min/1.73m2 eGFR cut off for defining CKD in 
young adults and the elderly. Pottel et al suggested that a cut off of 75 ml/min/1.73m2 would be more 
ideal in young adults under 40 years of age given that one would require a serum creatinine almost 1.8 
times above the mean value for this population to achieve an eGFR less than 60 ml/min/1.73m2 making 
this cut off quite insensitive to early increments in serum creatinine (H. Pottel et al., 2015). Gharbi et al 
demonstrated that in an Arabic-Berber adult population in Morocco, using a cut off of 60 
ml/min/1.73m2 resulted in under diagnosis of CKD in younger adults and over diagnosis in the elderly 
population (Benghanem Gharbi et al., 2016). In our study, based on a cut off of 75 ml/min/1.73m2, no 
one under the age of 40 years had reduced eGFR when determined using CG corrected for BSA, 4v-
MDRD or CKD-EPI equations corrected for race. The FAS equation that can be applied across a wide 
age spectrum classified 5 (1.9%) individuals less than 40 years of age as having a reduced eGFR 
compared to 21 (7.8%) for the 4v-MDRD equation without correction for race. In the absence of 
mGFR, testing for albuminuria or demonstrating persistence of reduced eGFR for at least 3 months, it 
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is difficult to conclude which individuals truly had CKD and which equation was correctly classifying 
them as such. 
 
We determined eGFR correlation with known risk factors for CKD such as age, BMI, BP, glycaemia 
and abdominal circumference. We assumed that in the absence of mGFR, the multiple correlation 
coefficient would serve as indirect proof of appropriateness for routine reporting of eGFR in an 
asymptomatic population as it is a measure of linear association between the predicted eGFR after 
factoring in the CKD risk factors and eGFR determined using the various equations. The CKD-EPI and 
CG corrected for BSA equations had the highest multiple correlation coefficients suggesting that the 
the model best fitted these equations. However, given that age is one of the components of the CG 
equation and both height and weight are used in the calculation of BMI and BSA, there is a possibility 
that the CG multiple correlation coefficient after correction for BSA is inaccurate due to possible 
collinearity.  Age remained the only risk factor that showed a statistically significant linear association 
with eGFR across all eGFR equations s. Matsha et al demonstrated that age, gender and known history 
of hypertension were determinants of CKD stage 3-5 in a mixed ancestry population in South Africa. 
Surprisingly, this was not the case for FPG, BMI, systolic and diastolic BP. However, this study did not 
correlate eGFR with these potential risk factors but rather used logistic regression to determine the 
odds of having a reduced eGFR (Tandi E. Matsha et al., 2013). Kaze et al concluded that in a rural and 
urban population in Cameroon, elevated systolic BP, presence of hypertension and diabetes were the 
main predictors of albuminuria and CKD (Kaze et al., 2015). In the Democratic Republic of Congo, a 
study by Sumaili et al found that age above 65 years and hypertension were independently associated 
with increased risk of CKD stage 3-5 (Sumaili et al., 2009). 
 
The issue of whether or not one should correct for the black African race when using eGFR equations 
has not been settled. Deventer et al concluded that correction for the African race was not necessary 
when using the 4v-MDRD equation after they compared eGFR with mGFR in 100 black African 
patients with CKD and found a greater bias after correcting for race (van Deventer et al., 2008). The 
mean weight of the participants in this study was 69.5 kg with a BSA of 1.76 m2 compared to a weight 
of 79.6 kg and BSA of 1.91 m2 for the MDRD population which included only 197 (12.1%) African 
Americans (Levey et al., 1999). The adjustment for the African race is extrapolated from the African-
American MDRD study population who had a higher mean weight and BSA compared to the 
Caucasian population necessitating a correction of the original 4v-MDRD eGFR equation by a factor of 
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1.18 that was further adjusted to 1.212 after standardization of the creatinine assay. Since serum 
creatinine levels are affected by muscle mass, it is not surprising that the 4v-MDRD equation without 
correction for race better approximated mGFR in the South African population given a closer similarity 
in weight and by extension muscle mass of their study population to the Caucasian population used in 
deriving the equation. A study carried out in Ghana in a rural population of black Africans also 
concluded that correction for race was unnecessary for both the 4v-MDRD and CKD-EPI equations. 
This study compared eGFR to CrCl and the mean weight of the participants was 54.4 kg (Eastwood et 
al., 2010). Flamant et al compared CKD-EPI and 4v-MDRD derived eGFR to mGFR in African 
Europeans originating from West Africa and concluded that a correction factor of 1.08 was required. 
However, most of the patients in this study had CKD with a mean mGFR of 57.6 ml/min/1.73m2 
(Flamant et al., 2013). Delanaye et al has argued that the correction factor for race when using the 4v-
MDRD or CKD-EPI equations should vary depending on whether it is being applied in individuals 
with CKD and an eGFR <60 ml/min/1.73m2 or healthy subjects due to the inherent difference in how 
these 2 populations handle serum creatinine even within the same race (Delanaye, Mariat, Maillard, 
Krzesinski, & Cavalier, 2011). In our study we didn’t compare eGFR to either mGFR or CrCl but 
rather compared the proportion of healthy black Africans classified as having a reduced or normal 
eGFR across the different equations and eGFR correlation with a prediction mode comprising risk 
factors for CKD. Since the correction factor for race for both 4v-MDRD and CKD-EPI is greater than 
one, it is not surprising that correction for race resulted in higher eGFRs. However, the CKD EPI 
equation had a higher median eGFR and proportion of individuals with eGFR >90 ml/min/1.73m2 
compared to 4v-MDRD or FAS as well as better correlation with risk factors for CKD. This is not 
surprising as CKD-EPI is more accurate than the 4v-MDRD equation in individuals with a GFR  >60 
ml/min/1.73m2 and would be expected to be more appropriate for the subjectively healthy population 
recruited in this study (Levey et al., 2009). The presence of a larger proportion of healthy individuals in 
the CKD-EPI dataset makes it more suitable for reporting eGFR in healthy subjects (Rule et al., 2006). 
The FAS equation was developed to overcome the potential differences in eGFR associated with 
adoption of different equations. The equation incorporates population normalized serum creatinine 
levels and therefore gets rid of the need for further age, gender and race correction. This equation has 
been shown to be less biased than the CKD-EPI equation when applied on data sets largely comprised 
of a Caucasian population and therefore requires validation in an ethnic black African population (Hans 
Pottel et al., 2016). In our study, the FAS determined eGFR had similar correlation coefficients with 
CKD risk factors as the 4v-MDRD equation and demonstrated a similar pattern in change of mean 
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eGFR with age where, the mean eGFR in the age group 40-49 years was higher than in the age group 
30-39 years. Of the 6 equations, only the CKD-EPI derived mean eGFRs showed a consistent decline 
with increase in age across the 4 age stratifications in line with the expected reduction of eGFR 
associated with progressive loss of nephrons above the age of 30 years (Glassock & Rule, 2016). 
 
The median eGFR for female participants calculated using the various equations was consistently 
higher than male participants in our study though this difference was not statistically significant except 
for eGFR determined using CG corrected for BSA. This is in contrast to the Ghanaian study by 
Eastwood et al where the female participants had a lower mean eGFR when determined using both the 
4v-MDRD and CKD-EPI equations with and without correcting for race but not when CG corrected for 
BSA was used. Similar to our study, the Ghanaian women had a higher BMI but lower weight and 
blood pressure compared to the men (Eastwood et al., 2010). No obvious explanation is forthcoming 
for the relatively better eGFR seen in women compared to men in our study. The Ghanaian rural 
population had a significantly higher percentage (13.2%) of individuals with reduced eGFR (< 60 
ml/min/1.73m2) compared to < 1% in our study population which can partially be explained by the fact 
that we recruited a younger population ranging from 18-65 years compared to 40-75 years for the 
Ghanaian population with 50.8% of our study population being under the age of 40 years. We also had 
a strict inclusion and exclusion criteria to ensure that as far as possible only healthy individuals were 
recruited.  
 
A major limitation of our study is that we didn’t measure GFR and as such our comparison of various 
eGFR equations is not validated against a gold standard. In the absence of mGFR, we chose to use 
correlation with a prediction model of markers known to increase risk of CKD but are not included in 
the eGFR equations as a basis of comparison. Our assumption was that equations whose eGFR 
calculations best correlated with these risk factors were potentially better equations to be used when 
screening for CKD in an asymptomatic black African population.  This is not equivalent to mGFR and 
therefore limits the extent to which conclusions can be made as to which equation is better. Another 
major limitation is that we didn’t carry out any test for albuminuria neither did we repeat serum 
creatinine measurements after 3 months hence we cannot accurately comment on the prevalence of 
CKD in this population. Gharbi et al found that 32%  of the subjects classified as having CKD stage 3a 
and 7.4% of those classified as 3b had an eGFR >60 ml/min/1.73 m2 when reinvestigated after 3 
months or longer (Benghanem Gharbi et al., 2016). However, the proportion of participants with an 
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eGFR < 60 ml/min/1.73 m2 in our study was less than 1% hence the risk of over diagnosing CKD in 
this healthy population was extremely low. What is more likely is that we may have under diagnosed 
CKD due to failure to test for albuminuria. We also assumed that diabetes and hypertension are the 
commonest risk factors for CKD in our population which may not necessarily be the case as 
demonstrated by Stanifer et al in Northern Tanzania where 49.1% of individuals with CKD didn’t have 
hypertension, diabetes or HIV (Stanifer et al., 2015). We also didn’t measure cystatin C which has been 
shown by Meeusen et al to significantly improve eGFR estimation across different patient groups 
including healthy kidney donors when incorporated into the CKD-EPI equation (Meeusen, Rule, 
Voskoboev, Baumann, & Lieske, 2015).  
Conclusion 
The CKD-EPI equation with correction for race classified the highest proportion of asymptomatic 
healthy black Africans as having an eGFR >90 ml/min/1.73m2 and its eGFR better correlated with risk 
factors for CKD. For this reason, we recommend the use of the CKD-EPI equation with correction for 
race for routine reporting of eGFR in an asymptomatic black African population with a low prevalence 
of risk factors for CKD. Comparing eGFR to mGFR would be the best way to determine the most 
appropriate equation for CKD screening in an asymptomatic black African population. However, 
measurement of GFR is a complex and expensive process which serves as a barrier for the validation of 
eGFR equations especially in sub Saharan Africa. In the absence of mGFR, other ways of evaluating 
the potential utility and performance of eGFR equations in routine screening for CKD in asymptomatic 
populations need to be evaluated. 
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CHAPTER 5:  COMPLETE BLOOD COUNT REFERENCE INTERVALS 
FROM A HEALTHY ADULT URBAN POPULATION IN KENYA 
Omuse, G., Maina, D., Mwangi, J., Wambua, C., Radia, K., Kanyua, A., . . . Erasmus, R. (2018). 
Complete blood count reference intervals from a healthy adult urban population in Kenya. PLOS ONE, 
1-19.  
Stellenbosch University  https://scholar.sun.ac.za
74 
 
Geoffrey Omuse1,7*, Daniel Maina1, Jane Mwangi2, Caroline Wambua2, Kiran Radia2, Alice Kanyua3, 
Elizabeth Kagotho1, Mariza Hoffman7, Peter Ojwang4, Zul Premji5, Kiyoshi Ichihara6, Rajiv Erasmus7 
 
1Department of Pathology, Aga Khan University Hospital Nairobi, Nairobi, Kenya 
 
2PathCare Kenya Limited, Nairobi, Kenya 
 
3Karen Hospital, Nairobi, Kenya 
 
4Department of Pathology, Maseno University, Maseno, Kenya 
 
5Formerly of Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania 
 
6Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine, Ube, Japan 
 





E-mail: g_omuse@yahoo.com (GO) 
  
Stellenbosch University  https://scholar.sun.ac.za
75 
 
5.1 Abstract  
Background 
There are racial, ethnic and geographical differences in complete blood count (CBC) reference intervals 
(RIs) and therefore it is necessary to establish RIs that are population specific. Several studies have 
been carried out in Africa to derive CBC RIs but many were not conducted with the rigor 
recommended for RI studies hence limiting the adoption and generalizability of the results. 
Method 
By use of a Beckman Coulter ACT 5 DIFF CP analyser, we measured CBC parameters in samples 
collected from 528 healthy black African volunteers in a largely urban population. The latent abnormal 
values exclusion (LAVE) method was used for secondary exclusion of individuals who may have had 
sub-clinical diseases. The RIs were derived by both parametric and non-parametric methods with and 
without LAVE for comparative purposes. 
Results 
Haemoglobin (Hb) levels were lower while platelet counts were higher in females across the 4 age 
stratifications. The lower limits for Hb and red blood cell parameters significantly increased after 
applying the LAVE method which eliminated individuals with latent anemia and inflammation. We 
adopted RIs by parametric method because 90% confidence intervals of the RI limits were invariably 
narrower than those by the non-parametric method. The male and female RIs for Hb after applying the 
LAVE method were 14.5−18.7 g/dL and 12.0−16.5 g/dL respectively while the platelet count RIs were 
133−356 and 152−443 x103 per µL respectively.  
Conclusion 
Consistent with other studies from Sub-Saharan Africa, Hb and neutrophil counts were lower than 
Caucasian values. Our finding of higher Hb and lower eosinophil counts compared to other studies 
conducted in rural Kenya most likely reflects the strict recruitment criteria and healthier reference 
population after secondary exclusion of individuals with possible sub-clinical diseases.  
 
  




Reference intervals (RIs) play an important role in guiding the interpretation of laboratory results. 
However, several factors influence RIs with the notable sources of variation being age, sex, race, body 
mass index (BMI) and ethnicity (Ichihara, Ceriotti, Tam, et al., 2013; Ichihara et al., 2008). Use of 
inappropriate RIs can result in misclassification of patients and subsequent mismanagement (Hershman 
et al., 2003). For this reason, it is recommended that laboratories determine RIs that are appropriate for 
the population they serve or at the very least verify any proposed RIs (CLSI, 2008).  
 
Few studies have been carried out in Africa to derive RIs and these have been done mainly while 
conducting HIV related clinical trials since adopting inappropriate RIs may result in unnecessary 
exclusion of potential trial volunteers and makes assessment of laboratory adverse events difficult. It is 
known that there are racial differences in complete blood count (CBC) parameters. Beutler et al. clearly 
demonstrated that African-Americans had lower haemoglobin (Hb), haematocrit (Hct), white blood cell 
count (WBC) and absolute granulocyte count compared to European-Americans but higher lymphocyte 
counts (Beutler & West, 2005). Karita et al. carried out a study to determine RIs for common 
haematology and chemistry tests in Kenya, Uganda, Zambia and Rwanda. The study found lower Hct, 
Hb, WBC and neutrophil counts compared to RIs from the United States (US) while eosinophil counts 
were found to be higher (Karita et al., 2009). A similar study was carried out in Kericho, a rural area 
situated in the highlands of the Great Rift Valley in Kenya. The derived RIs for males and females 
were 8.3–11.3g/dL and 5.9–10.0 g/dL respectively. A number of participants were found to have 
relatively low mean corpuscular volume (MCV) and haemoglobin (MCH), values consistent with iron 
deficiency especially in women of child bearing age. Lower neutrophil and higher eosinophil counts 
compared to Caucasians were also found (Kibaya et al., 2008). A genetic deletion of the Duffy antigen 
receptor for chemokines (DARC-null genotype), a receptor for Plasmodium vivax,  is thought to 
contribute to the benign neutropenia seen in Africans and African-Americans (Thobakgale & Ndung'u, 
2014). The eosinophilia is thought to be related to increased exposure to environmental allergens and 
possibly parasite infections but there isn’t strong evidence to support this hypothesis.  
 
These studies demonstrate the need to establish population specific RIs. However, establishment of RIs 
should follow a rigorous process of identifying reference individuals, standardization of sample 
handling and analysis as well as the use of appropriate statistical methods (Ozarda et al., 2013). Despite 
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all attempts to ensure that only healthy individuals are included in a RI study, this can never be 
achieved due to the presence of subclinical disease in subjectively healthy individuals. Reference 
individuals are also quite heterogeneous in their state of health and there isn’t a perfect standard to 
define health or normality (Petitclerc, 2004). Statistical methods such as latent abnormal values 
exclusion (LAVE) have been devised in order to secondarily exclude healthy individuals participating 
in an RI study but who have multiple related laboratory test values outside their RIs suggesting the 
possibility of sub-clinical diseases (Ichihara, 2014).  
 
A criticism of RI studies especially those done in economically disadvantaged areas is that the recruited 
population may not necessarily be representative of an ideal reference population. There are different 
motivators to volunteer in a study and these can result in a selection bias hence compromising the 
external validity of the study results (McGrath et al., 2001; Tarimo et al., 2011).  We set out to 
determine RIs for complete blood counts (CBCs) in Kenya using data from carefully selected healthy 
individuals recruited as part of a multicenter, multi-country, global RI study conducted by the 
Committee of Reference Intervals and Decision Limits (C-RIDL) under the auspices of the 
International Federation of Clinical Chemistry (IFCC). Further, we compared our RIs with those 




The study was carried out in Kenyan urban towns located in the counties of Nairobi, Thika, Kiambu, 
Nakuru and Kisii. Recruitment was largely done from colleges, universities, churches, hospitals, 
corporations and shopping malls. Awareness of the study was created through use of posters, flyers, 
emails, church announcements and engaging administrators in the various organizations. 
Recruitment 
A strict recruitment criteria was used when enrolling individuals for the study as stipulated in the 
published study protocol and standard operating procedures (Ozarda et al., 2013). Briefly, subjectively 
healthy black African adults aged 18-65 years who had undergone an overnight fast were recruited 
between January and October 2015. No financial inducements were given, however, snacks were 
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provided to those who participated. Recruitment was stratified into 4 age groups: 20-29, 30-39, 40-49 
and 50-65 years with a similar distribution of males and females in each age strata. Exclusion criteria 
included individuals with a body mass index (BMI) greater than 35 kg/m2, consumption of ethanol 
greater than or equal to 70 g per day [equivalent to 5 alcoholic drinks], smoking more than 20 tobacco 
cigarettes per day, taking regular medication for a chronic disease (diabetes mellitus, hypertension, 
hyperlipidemia, allergic disorders, depression), recent (less than 15 days) recovery from acute illness, 
injury or surgery requiring hospitalization, known carrier state of Hepatitis B, Hepatitis C or HIV, 
pregnant or within 1 year after childbirth. Written informed consent was sought from each participant 
after giving a written and verbal explanation of the study. Individuals with any chronic disease were 
excluded except for the age group 50-65 years where individuals with well controlled hypertension 
taking no more than 2 drugs were recruited. All participants had measurements of blood pressure (BP), 
abdominal circumference and BMI done.  
Pre-analytical sample handling 
CBC samples were collected by a trained phlebotomist using an evacuated tube system comprising a 
sterile multi-sample needle, needle holder and plastic evacuated tubes containing ethylene diamine 
tetra-acetic acid (EDTA) (BD Vacutainer® Blood Collection Tube, US). The samples were transported 
at refrigerated temperature and analyzed within 12 hours after collection. Serum and plasma samples 
requiring centrifugation were spun within 4 hours after collection and stored at -80oC until shipment on 
dry ice to the reference laboratory in South Africa for analysis of tests that were part of the global RI 
study. All samples arrived in the reference laboratory frozen and were only thawed once prior to 
sample analysis. 
Sample analysis 
All the sample analysis for the biochemistries and immunoassays were performed in the PathCare 
reference laboratory in Cape Town, South Africa, which is an International Organization for 
Standardization (ISO) 15189 accredited laboratory. All participating countries in Africa had their 
general biochemistry and immunoassays done in this laboratory so as to standardize analysis, ensure 
alignment and comparison of results by using a common panel of sera across all participating 
laboratories globally. The CBC parameters included red blood cell count (RBC), Hb, Hct, MCV, MCH, 
mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), WBC, 
platelet (PLT), leukocyte differential counts of neutrophil (Neu), lymphocyte (Lym), monocyte (Mon), 
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eosinophil (Eos), basophil (Bas). The differential counts were recorded as both % of WBC and absolute 
count (abs).  The CBC was analysed using a Beckman Coulter ACT 5 DIFF CP analyser (Brea, 
California, US) in the PathCare Kenya laboratory based in Nairobi which is also ISO 15189 accredited 
by the South African National Accreditation Service (SANAS).  
 
Iron (Fe), transferrin (Tf), albumin (Alb), and ultrasensitive c-reactive protein (hsCRP) were analysed 
using a Beckman Coulter AU5800 analyser while ferritin levels were determined using a Beckman 
Coulter DXI analyser. The globulin fraction (Glb) was calculated by subtracting Alb from total protein 
(TP). These non-CBC parameters were used as part of reference tests in the LAVE procedure for 
secondary exclusion of individuals with latent anemia or inflammation. 
Ethics approval 
The study was approved by the Aga Khan University Hospital Nairobi, Health research ethics 
committee (2014/REC-46) and was carried out in accordance with the Declaration of Helsinki. 
Statistical analysis 
The sample size from each country participating in the global RI study was set at a minimum of 500 
(male and female: 250 × 2), so that country-specific RIs would be obtained in a more reproducible 
manner. This number was deemed adequate to make between-country comparisons of test results with 
a power of detecting a difference of two means equivalent to 0.25 times the standard deviation 
comprising the RI (SDRI), which corresponds to a bias of 0.25 times between-individual variation, 
allowing errors of α less than 0.05 and β less than 0.2 in the statistical hypothesis testing done 
separately for each sex. According to the CLSI guideline (CLSI, 2008), at least 120 individuals are 
required to determine RIs using non-parametric methods for each defined population group and for 
parameters not influenced by sex (60 females and 60 males). For parameters that are influenced by sex, 
the minimum recommended number is 240 reference individuals (120 females and 120 males). 
Therefore, the sample size of 500 well exceeds what is recommended by the CLSI and allows 
derivation of RIs with higher precision (narrower 90% confidence intervals of the RI limits, or LL and 
UL). For comparative purposes, RIs were determined using both parametric and non-parametric 
methods before and after applying the LAVE method as described by Ichihara et al. (Ichihara & Boyd, 
2010; Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017). Briefly, for the non-parametric method, the 
reference values coinciding with the 2.5th and 97.5th percentiles after arranging the data in ascending 
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order were used to identify the RI lower and upper limits (LL and UL). For the parametric method, the 
data was transformed into a Gaussian form by using a modification of the original Box-Cox power 
transformation formula as described by Ichihara (Ichihara, 2014), ascertaining the mean and SD, and 
finally determining the RI as the mean ± 1.96SD, which corresponds to the central 95% limits or LL 
and UL under transformed scale. Then, the limits are reverse transformed to get the LL and UL in the 
original scale.     
 
The LAVE method is an iterative optimization procedure which is applied in a situation where 
mutually related analytes were tested simultaneously. Initially, RIs are determined for each analyte 
independently using either a parametric (mean ± 1.96 SD after Gaussian transformation) or non-
parametric (mid 95% range) method. From the second computation, any individual who has two or 
more results outside the RIs derived in the previous computation among the reference tests (see below) 
is excluded. This process was repeated six times at which point the RIs were nearly stable. Of note is 
that need for exclusion of a reference value is determined using a set of pre-defined reference tests but 
not the test whose RI is being determined (Ichihara, 2014). In this study we chose the following 11 
analytes as the reference tests:  Alb, Glb, hsCRP, Fe, Tf, ferritin, Hb, Hct, MCV, WBC, and PLT which 
can help identify individuals with latent anemia and/or inflammation.  
 
For judging the need to partition reference values by sex and age, we computed the standard deviation 
ratio (SDR) which represents a ratio of between-subgroup SD (variation of the subgroup means from 
grand mean) to between-individual SD (approximately 1/4 the width of RI). We performed 2-level 
nested ANOVA to compute between-sex SD and between-age group SD after partitioning age as 18-29 
years, 30-39 years, 40-49 years and 50-65 years. The SDR for between-sex SD (SDRsex) and for 
between-age SD (SDRage) were computed as a ratio to residual SD (or between-individual SD). Since 
between-age variation changes by sex, we also computed  SDRage for each sex by one way ANOVA.  
We considered SDR ≥ 0.40 as a guide for judging the need for partitioning reference values by sex or 
age (Ichihara, 2014). For analysing the relationship between Hb and PLT, we performed least-square 
linear regression analysis and the degree of the association was expressed by Pearson’s correlation 
coefficient. We quantified the magnitude of change in RI lower limit (LL) and upper limit (UL) before 
and after applying the LAVE procedure using the formulas SDR-LL = |LL+ － LL-|/ ((UL+ － 
LL+)/3.92)  and SDR-UL = |UL+ － UL-|/ ((UL+ － LL+))/3.92} where LL+, UL+ are the RI limits 
with application of LAVE, while LL-, UL- are RI limits without application of LAVE (Borai et al., 
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2016). We set 0.3 as a critical value to define a significant change in LL or UL after application of 
LAVE. Analysis was carried out using a general purpose statistical software, StatFlex version 6.0 




A total of 596 individuals volunteered to participate in the study out of which 63 were excluded for 
various reasons as shown in Fig 5.1.  Out of 533 eligible participants, only 528 had CBC results 
available with 254 (48.1%) being males. Five individuals were excluded because CBCs were 
performed at a different laboratory using different equipment.  
 
Fig 5.1: Flow diagram for recruitment 
Key-BMI: body mass index, CBC: complete blood count, DM: diabetes mellitus, HIV: Human Immunodeficiency Virus, 
HTN: hypertension  
*On antibiotics, blood donation in past 3 months, on treatment for hypothyroidism, > 65 years, > 65 years and hypertensive, 
rheumatic heart disease, prostate cancer 
 
The median age for the included participants was 39 years with the youngest and oldest being 18 and 
65 years respectively as shown in Table 5.1. The number of participants in the four age groups were 
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134 (18-29 years), 136 (30-39 years), 131 (40-49 years) and 127 (50-65 years). The number of smokers 
was low with only 2 (0.7%) and 13 (5.1%) women and men respectively.  
 
Table 5.1: Descriptive characteristics of participants (Median, 2.5~97.5 percentile) 
Parameter  Male (n=255) Female (n=273) Total (n=528) 
Age (years) 38.0 (21.0~64.0) 39.0 (20.0~61.7) 39.0 (20.0~63.0) 
BMI (kg/m2) 24.9 (18.3~33.6) 26.1 (18.5~34.9) 25.5 (18.3~34.2) 
SBP (mmHg) 81.0 (61.0~99.0) 79.0 (61.0~98.7) 80.0 (61.0~99.0) 
DBP (mmHg) 127.0 (103.9~151.3) 118.0 (96.3~156.0) 123.5 (98.7~155.0) 
Key-BMI: body mass index, DBP: diastolic blood pressure, SBP: systolic blood pressure 
Sex and age related changes in reference values 
Using a cut-off of 0.4, SDRs revealed that sex was a significant source of variation for RBC count, Hb, 
Hct, PLT count, absolute monocyte count and percentage while age was a significant source of 
variation only for absolute monocyte count and percentage in females as shown in Table 5.2. For all 
other CBC parameters, age and sex did not appear to be major sources of variation hence we chose not 
to partition their RIs.  
 
Table 5.2: Complete blood count standard deviation ratios for age and sex 
Item SDR-sex SDR-age SDR-age M SDR-age F 
RBC 1.02 0.05 0.08 0.00 
Hb 1.28 0.10 0.15 0.00 
Hct 1.28 0.14 0.22 0.00 
MCV 0.00 0.00 0.00 0.17 
MCH 0.04 0.00 0.00 0.10 
MCHC 0.19 0.00 0.00 0.15 
RDW 0.13 0.00 0.00 0.00 
WBC 0.00 0.13 0.12 0.14 
Neu % 0.34 0.16 0.18 0.14 
Lym % 0.16 0.08 0.19 0.00 
Mon % 0.46 0.39 0.33 0.53 
Eos % 0.13 0.14 0.14 0.13 
Bas % 0.27 0.00 0.00 0.05 
Neu Abs 0.22 0.00 0.00 0.04 
Lym Abs 0.00 0.19 0.21 0.17 
Mon Abs 0.33 0.42 0.34 0.53 
Eos Abs 0.12 0.17 0.22 0.07 
Bas Abs 0.20 0.08 0.00 0.20 
PLT 0.41 0.00 0.00 0.00 
Key-%: Percentage, RBC: red blood cell count, Hb: haemoglobin, MCV: mean corpuscular volume, MCH: mean 
corpuscular haemoglobin, MCHC: mean corpuscular haemoglobin concentration, RDW: red cell distribution width, WBC: 
white blood cell count, Neu: neutrophil, Lym: lymphocyte, Mon: monocyte, Eos: eosinophil, Bas: basophil, Abs: absolute 
count, Plt: platelet count, SDR: standard deviation ratio, M: male, F: female. SDRs > 0.4 are in bold 




Reference values (RVs) of Hb, Hct and RBC were considerably lower in female participants compared 
to males while PLT counts were higher in female participants. For the non CBC parameters, RVs of 
serum iron and ferritin were lower in female participants but those of transferrin were higher as shown 
in Fig 5.2.  
 
 
Fig 5.2: Sex and age-related changes for representative parameters 
Key-F: female, Ferr: ferritin, Hb: haemoglobin, M: male, MCV: mean corpuscular volume, Plt: platelet count, RBC: red 
blood cell count, SDR: standard deviation ratio, Tf: transferrin 
 
There was a negative correlation between Hb level and platelet count with the magnitude of the 
correlation coefficient being greater in females (r=−0.336) than compared to males (r=−0.226) as 
shown in Fig 5.3.  




Fig 5.3: Relationship between platelet count and haemoglobin level 
Key-Hb: haemoglobin, Plt: platelet 
 
Derivation of reference intervals 
Without application of the LAVE method, RIs derived using the non-parametric method generally 
showed wider ranges and 90% CIs of the RI limits compared to the parametric method. This tendency 
was more prominently seen in female participants especially for RBC, Hb, Hct, MCV, MCH, RDW 
and PLT as shown in the graphical representation of RIs in Fig 5.4 and Fig S5.1.  




Fig 5.4: Distribution of reference values and reference intervals for selected CBC parameter 
Key-F: female, Hb: haemoglobin, LAVE: latent abnormal value exclusion, M: male, MCV: mean corpuscular volume, Plt: 
platelet count, RBC: red blood cell count, RDW: red cell distribution width, WBC: white blood cells 
 
The LAVE procedure had a greater effect in females where it significantly raised the LLs and narrowed 
the RIs for Hb, Hct, MCV, MCH and MCHC compared to males where the LAVE resulted in a minor 
change in the LLs of RBC parameters. Table S1 shows the SDRs for the change in LLs and ULs after 
application of the LAVE method. An SDR greater than 0.3 was considered a significant change in LL 
or UL by use of the LAVE method. On the other hand, the LAVE method didn’t significantly alter LLs 
for WBC parameters but reduced ULs for absolute basophil and neutrophil counts.  
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The parametrically derived female RI for Hb before applying the LAVE method was 10.6-16.5 g/dL 
but changed to 12-16.5 g/dL after applying the method. In males, the LAVE method changed the 
parametrically derived Hb RI from 14.2-18.7 g/dL to 14.5-18.7 g/dL. RIs for RBC related parameters 
were consistently lower in females as shown in Table 3.  RIs for PLT were consistently higher in 
females with or without the LAVE method as shown in Table 5.3, Fig S5.2 and Table S5.2. The RIs 
that we chose to adopt based on whether sex was a major source of variation are highlighted in bold in 
Table 5.3. 
 
Table 5.3: Parametric complete blood count reference intervals after latent abnormal value 
exclusion 
 Male + Female Male Female 
Item N LL- UL N LL-UL N LL-UL 
RBC (x10^12/L) 463 4.41-6.48 226 4.94-6.52 229 4.31-5.76 
Hb (g/dL) 470 12.8-19.0 232 14.5-18.7 236 12.0-16.5 
Hct (L/L) 471 0.38-0.55 232 0.43-0.55 237 0.36-0.49 
MCV (fl) 466 75.7-95.6 228 76.5-95.5 232 73.4-95.8 
MCH (pg) 462 24.8-32.8 227 25.1-32.8 230 24.4-32.7 
MCHC (g/dL) 461 32.2-35.2 227 32.4-35.4 230 32.0-35.0 
RDW (%) 460 11.3-15.2 225 11.3-14.7 228 11.4-15.8 
WBC (x10^9/L) 464 3.08-7.83 229 3.13-8.10 232 2.89-7.72 
Neu (%) 463 28.0-63.3 227 27.4-60.3 230 29.5-65.4 
Lym (%) 463 27.2-60.0 227 28.2-60.3 230 25.5-59.3 
Mon (%) 461 3.4-13.3 226 3.5-14.3 229 3.2-11.0 
Eos (%) 455 1.1-11.9 225 1.2-11.8 227 0.8-9.4 
Bas (%) 456 0.30-1.10 224 0.40-1.20 228 0.30-1.00 
Neu (x10^9/L) 460 1.05-4.08 227 1.02-3.92 229 1.07-4.42 
Lym (x10^9/L) 461 1.29-3.40 226 1.36-3.58 230 1.22-3.24 
Mon (x10^9/L) 462 0.14-0.74 227 0.15-0.76 229 0.14-0.68 
Eos (x10^9/L) 460 0.04-0.59 226 0.05-0.64 228 0.04-0.49 
Bas (x10^9/L) 461 0.01-0.07 226 0.01-0.08 224 0.01-0.06 
PLT (x10^9/L) 464 144-409 231 133-356 232 152-443 
Key-%: percentage, LL: lower limit, UL: upper limit, RBC: red blood cell count, Hb: haemoglobin, MCV: mean 
corpuscular volume, MCH: mean corpuscular haemoglobin, MCHC: mean corpuscular haemoglobin concentration, RDW: 
red cell distribution width, WBC: white blood cell count, Neu: neutrophil, Lym: lymphocyte, Mon: monocyte, Eos: 
eosinophil, Bas: basophil, Abs: absolute count, Plt: platelet count. Recommended RIs are shown in bold. 
 
A graphical representation of CBC RIs for selected studies carried out in SSA is given in Figs 5.5 and 
5.6 to enable comparison with our derived RIs.  A summary of the same is provided as Tables S3 and 
S4. 




Fig 5.5: Graphical comparison of reference intervals (RIs) for RBC related parameters 
 
Three bars for each study represent RIs for male+female (MF) in grey, male (M) in blue, and female (F) in red. RIs of this 
study is shown on top of each panel. The background shades in blue and pink represent RIs of this study for males and 
females. 
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Key-LL: lower limit, UL: upper limit, RBC: red blood cell count, Hb: haemoglobin, Ht: haematocrit, MCV: mean 
corpuscular volume, MCH: mean corpuscular haemoglobin, MCHC: mean corpuscular haemoglobin concentration 
 
1Exclusion criteria: BMI > 35 kg/m2, consumption of ethanol ≥ 70 g per day, smoking more than 20 tobacco cigarettes per 
day, chronic illness, recent recovery from acute illness, injury or surgery requiring hospitalization, known carrier state of 
HBV, HCV or HIV, pregnant or within 1 year after child birth. CBC analyser: Beckman Coulter ACT 5 DIFF CP analyser 
(Brea, California, US).  
2Exclusion criteria: Febrile, pregnant, HIV seropositive, screen positive for syphilis and malaria. CBC analyser: ACT 
5Diff CP instrument (Beckman Coulter, Fullerton, CA, USA) (Kibaya et al., 2008). 
3Exclusion criteria: HIV positive, pregnant. CBC analyser: Coulter ACT 5Diff CP analyser (Beckman Coulter, France) 
(Odhiambo et al., 2015). 
4 Exclusion criteria: HIV positive, moribund, mentally ill, institutionalized persons, missing personal or laboratory data. 
CBC analyser: Act 5 Diff instrument (Beckman Coulter) (Lugada et al., 2004). 
5 Exclusion criteria: Acutely ill, significant findings on physical examination or if laboratory tests revealed that they were 
pregnant, HIV antibody positive, had evidence of hepatitis B or C infection or suspected syphilis. CBC analyser: Beckman 
Coulter AcT 5 diff CP (Beckman Coulter, USA) (Karita et al., 2009). 
6 Exclusion criteria: HIV positive, presence of any illness as defined by the World Health Organization staging systems for 
HIV infection and disease. CBC analyser: Coulter counter T540 (Tsegaye et al., 1999). 
7 Exclusion criteria: HIV positive, pregnant or on medication, body temperature ≥37.50C or if clinical assessment revealed 
other signs or symptoms of disease that could influence the laboratory parameters of interest. CBC analyser: Sysmex KX-
21N analyser (Sysmex Corp., Kobe, Japan) (Saathoff et al., 2008). 
8 Exclusion criteria: Alcohol abuse, medication, smoking, pregnant, breastfeeding, on oral contraception, on menses. CBC 
analyser: Coulter AcT 5diff and Sysmex KX-21N (Sysmex Corporation, Kobe, Japan) (Gahutu, 2013). 
9 Exclusion criteria: Acute or chronic respiratory, cardiovascular, gastrointestinal, hepatic or genitourinary conditions, 
blood donation or transfusion within the past 3 months, hospitalisation within past 1 month, any findings that would 
compromise laboratory parameters, pregnant or lactating mothers. CBC analyser: Micros 60 analysers (Horiba-ABX, 
Montpellier, France) (Dosoo et al., 2012). 
10 Exclusion criteria: HIV, HBV, and HCV viral infection, malaria, abnormal haemoglobin electrophoresis screening, 
presence of hypochromia. CBC analyser: Sysmex SF-3000 (Sysmex, Kobe, Japan) (Kueviakoe, Segbena, Jouault, Vovor, 
& Imbert, 2011). 
11 Exclusion criteria: HIV, current clinical symptoms, immunosuppressive or corticosteroid medication, chemotherapy, 
hospitalizations, surgery or blood transfusions in the six months prior to screening, splenomegaly, pregnant, Hb < 12 g/dL. 
Menstruating women returned in 2 weeks. CBC analyser: Beckman Coulter LH 750 (Beckman Coulter, Fullerton, CA, 
USA) (Lawrie et al., 2009). 





Fig 5.6: Graphical comparison of reference intervals (RIs) for WBC related parameters and 
platelets 
 
Three bars for each study represent RIs for male+female (MF) in grey, male (M) in blue, and female (F) in red. RIs of this 
study is shown on top of each panel. The background shades in blue and pink represent RIs of this study for males and 
females.  
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Key-WBC: white blood cell count, Neu: Neutrophil, Lym: lymphocyte, Mon: monocyte, Eos: eosinophil, abs-absolute 
count, Plt-platelet count 
 
1Exclusion criteria: BMI > 35 kg/m2, consumption of ethanol ≥ 70 g per day, smoking more than 20 tobacco cigarettes per 
day, chronic illness, recent recovery from acute illness, injury or surgery requiring hospitalization, known carrier state of 
HBV, HCV or HIV, pregnant or within 1 year after child birth. CBC analyser: Beckman Coulter ACT 5 DIFF CP analyser 
(Brea, California, US).  
2Exclusion criteria: Febrile, pregnant, HIV seropositive, screen positive for syphilis and malaria. CBC analyser: ACT 
5Diff CP instrument (Beckman Coulter, Fullerton, CA, USA) (Kibaya et al., 2008). 
3Exclusion criteria: HIV positive, pregnant. CBC analyser: Coulter ACT 5Diff CP analyser (Beckman Coulter, France) 
(Odhiambo et al., 2015). 
4 Exclusion criteria: HIV positive, moribund, mentally ill, institutionalized persons, missing personal or laboratory data. 
CBC analyser: Act 5 Diff instrument (Beckman Coulter) (Lugada et al., 2004). 
5 Exclusion criteria: Acutely ill, significant findings on physical examination or if laboratory tests revealed that they were 
pregnant, HIV antibody positive, had evidence of hepatitis B or C infection or suspected syphilis. CBC analyser: Beckman 
Coulter AcT 5 diff CP (Beckman Coulter, USA) (Karita et al., 2009). 
6 Exclusion criteria: HIV positive, presence of any illness as defined by the World Health Organization staging systems for 
HIV infection and disease. CBC analyser: Coulter counter T540 (Tsegaye et al., 1999). 
7 Exclusion criteria: HIV positive, pregnant or on medication, body temperature ≥37.50C or if clinical assessment revealed 
other signs or symptoms of disease that could influence the laboratory parameters of interest. CBC analyser: Sysmex KX-
21N analyser (Sysmex Corp., Kobe, Japan) (Saathoff et al., 2008). 
8 Exclusion criteria: Alcohol abuse, medication, smoking, pregnant, breastfeeding, on oral contraception, on menses. CBC 
analyser: Coulter AcT 5diff and Sysmex KX-21N (Sysmex Corporation, Kobe, Japan) (Gahutu, 2013). 
9 Exclusion criteria: Acute or chronic respiratory, cardiovascular, gastrointestinal, hepatic or genitourinary conditions, 
blood donation or transfusion within the past 3 months, hospitalisation within past 1 month, any findings that would 
compromise laboratory parameters, pregnant or lactating mothers. CBC analyser: Micros 60 analysers (Horiba-ABX, 
Montpellier, France) (Dosoo et al., 2012). 
10 Exclusion criteria: HIV, HBV, and HCV viral infection, malaria, abnormal haemoglobin electrophoresis screening, 
presence of hypochromia. CBC analyser: Sysmex SF-3000 (Sysmex, Kobe, Japan) (Kueviakoe et al., 2011). 
11 Exclusion criteria: HIV, current clinical symptoms, immunosuppressive or corticosteroid medication, chemotherapy, 
hospitalizations, surgery or blood transfusions in the six months prior to screening, splenomegaly, pregnant, Hb < 12 g/dL. 
Menstruating women returned in 2 weeks. CBC analyser: Beckman Coulter LH 750 (Beckman Coulter, Fullerton, CA, 
USA) (Lawrie et al., 2009) 
 
5.5 Discussion 
Several studies carried out in Africa have reported marked differences in some CBC parameters when 
compared to Caucasian populations and even between different populations across Africa as shown in 
S3 and S4 Tables. A fairly consistent finding has been the lower RIs for absolute neutrophil counts in 
black African populations which is thought to be associated with the DARC-null genotype, an 
evolutionary adaptation thought to make Africans less susceptible to Plasmodium vivax infections 
(Thobakgale & Ndung'u, 2014). In contrast to RIs from the US where the absolute neutrophil count RI 
is 1800−7700 cells/µL (Kratz et al., 2004), the parametrically derived neutrophil count RI for males 
and females in our study was significantly lower at 1050−4080 cells/µL, which is in keeping with what 
has been found in other African studies (Karita et al., 2009; Kibaya et al., 2008; Saathoff et al., 2008). 
Neutrophil count RIs with LLs as low as 500 and 840 cells/uL have been reported in Togo and Uganda 
respectively as shown in S4 Table.  




Studies carried out in largely rural populations in SSA have revealed low Hb levels especially in 
women. A study done in Kericho which is a rural town in Kenya located in The Great Rift Valley at an 
altitude of over 2000 metres above sea level derived a Hb lower RI limit in women of 5.9 g/dL (Kibaya 
et al., 2008) while a study by Karita et al. that involved 4 countries in SSA found a LL of 9.1 g/dL 
(Segolodi et al., 2014). It is inconceivable that a Hb of 5.9 g/dL would be accepted as a LL even if 
clinically one is not presenting with symptoms of anaemia. In the study by Karita et al., the Hb values 
from one of the research sites situated in a university teaching hospital in Nairobi, Kenya were 
excluded as they were significantly higher than the other study sites. Other than the comparatively 
higher altitude of Nairobi, the authors hypothesized that the Hbs of participants from Nairobi were 
higher as they comprised mainly medical doctors and students considered to be healthier due to better 
nutrition and access to healthcare. For this reason, the RVs from Nairobi were subsequently excluded 
in the derivation of the consensus RI. This secondary exclusion of ‘healthier’ individuals may partly 
explain the low RI for Hb they derived (Karita et al., 2009). According to the World Health 
Organization (WHO), a woman above 15 years of age with a Hb that is less than 12 g/dl is considered 
anaemic (WHO, 2011a). Therefore, a large proportion of women recruited in a number of studies 
summarized in Fig 5 were anaemic and given the low RIs for MCV and MCH, the anaemia is in 
keeping with a microcytic hypochromic picture commonly seen in iron deficiency. In SSA iron 
deficiency in women is likely due to poor nutrition or blood loss as a result of menses or repeated 
childbirth.  
 
We carefully recruited an urban population for our study using strict recruitment criteria, and derived a 
RI for Hb in women of 12.0−16.5 g/dL after application of the LAVE method. This RI for women is 
higher than that reported in most SSA studies but similar to published RIs from the US of 12.0−16.0 
g/dL (Kratz et al., 2004). The UL for the parametrically derived RI for male Hb after LAVE was 18.7 
g/dL which is significantly higher than what has been reported from most studies in SSA but similar to 
the ULs of 18.3 and 18.4 g/dL reported from Ethiopia and Togo respectively (Kueviakoe et al., 2011; 
Tsegaye et al., 1999). This most likely reflects our careful attempt to recruit well-defined healthy 
individuals and secondarily exclude individuals with possible sub-clinical diseases by use of the LAVE 
method. This resulted in an increase in the LLs of RBC parameters and narrowing of RIs especially for 
female participants. This may explain the higher LLs for these parameters in our study compared to 
other SSA studies that didn’t employ strict recruitment criteria or secondary exclusion. The systematic 
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removal of individuals with possible sub-clinical disease makes our results more generalizable to an 
urban healthy black African population in Kenya. The high UL for Hb seen especially in males in this 
study could be attributed to Nairobi’s relatively high altitude of 1700 metres above sea level. 
 
For the comparison of parametric and nonparametric methods, as shown in Table S5.2, the 
nonparametric method generally resulted in a wider RI, and wider 90% CIs of the RI limits. It is 
attributable to the fact that parametric method has a step of exclusion of values outside mean±3.5SD 
(probability: 0.00043 or 0.043%) after Gaussian transformation, as shown by a small reduction in data 
size for the parametric method in most of the CBC parameters. This clearly indicates the presence of 
extreme values not explained by chance, at the periphery of the distribution.  The recommendation by 
CLSI (CLSI, 2008) that the  nonparametric method be used in determining RIs was due to the difficulty 
of the parametric method to ensure successful Gaussian transformation by use of the Box-Cox power 
transformation formula. However, Ichihara and Boyd proved that by use of a modified Box-Cox 
formula with addition of transformation origin in the original formula led to a dramatic change in 
goodness-of-fit of the transformation (Ichihara & Boyd, 2010). Besides, the optimal value of power for 
Gaussian transformation predicted by the parametric method is fairly consistent analyte by analyte 
(Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017), a fact supporting the reliability of the parametric 
method. In fact, for the RVs of all the analytes, the parametric method successfully led to a Gaussian 
shape judged from values of skewness and kurtosis as well as from the linearity in the probability paper 
plot (S3 Fig). These are the reasons for our adoption of RIs derived by the parametric method.  
 
A decline in Hb level was associated with an increase in platelet count. Iron deficiency anaemia (IDA) 
and iron deficient erythropoiesis have been associated with secondary thrombocytosis. Conversely, iron 
supplementation in iron deficient individuals has been shown to increase Hb levels while reducing 
platelet count (Kulnigg-Dabsch et al., 2013). This inverse relationship between Hb level and platelet 
count may explain the higher median platelet count in women in this study as well as some of the other 
published studies from SSA (Kibaya et al., 2008; Saathoff et al., 2008). Schloesser et al. compared 
platelet counts in patients with IDA to healthy controls and found an average platelet count of 
499,000/µL in IDA patients compared to 242,000/µL in controls (Schloesser et al., 1937). The 
mechanism behind the relationship between Hb level and platelet count isn’t well understood. Various 
hypothesis have been put forward including homology between erythropoietin and thrombopoietin 
resulting in proliferation and differentiation of pluripotent erythroid and megakaryocyte precursors, 
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synergistic action of erythropoietin and thrombopoietin in megakaryocyte maturation and a direct effect 
of iron on thrombopoiesis (Bilic & Bilic, 2003; Broudy, Lin, & Kaushansky, 1995). Indeed, serum iron 
and ferritin levels were lower in female participants in our study while transferrin levels were higher, a 
common finding in iron deficient states. Sex was a significant source of variation in platelet counts 
(SDRsex=0.45) in this study and therefore we adopted sex specific RIs for PLT. As shown in Fig 5.6, 
women generally have higher platelet counts than men. 
 
The UL for the parametrically derived absolute eosinophil count in our study was 590 cells/ µL which 
is much lower than that reported by Karita et al. (1530 cells/µL) and Kibaya et al. (1140 cells/ µL) both 
of whom did studies in Kenya but recruited largely a rural population (Karita et al., 2009; Kibaya et al., 
2008). It is possible that the higher eosinophil counts in the rural population is due to a bigger burden 
of parasite infection or greater exposure to environmental allergens. Karita et al. mentions that in a sub-
study done in Lusaka-Zambia, Entebbe-Uganda and Kigali-Rwanda, up to one third of stool samples 
had ova or parasites possibly explaining the higher eosinophil counts (Karita et al., 2009). Given that 
our study population was largely comprised of an urban working population, the prevalence of stool 
parasites would be expected to be low. Measurement of serum IgE levels and evaluation of stool 
samples would have provided objective evidence to explore this hypothesis. 
 
We used SDRs to determine whether sex or age were significant sources of variation necessitating 
partitioning of RIs. This is a method widely adopted in the studies by Ichihara et al. and is useful when 
evaluating more than one source of variation, especially when any source of variation consists of more 
than 2 categories (Ichihara, 2014; Ichihara et al., 2008). An unexpected finding was the decline in 
monocyte levels with increase in age for female participants (Fig S5.1). With lack of reports on similar 
observation, no obvious explanation is forthcoming, hence further studies are required to investigate 
the consistency of this finding and its significance. 
 
RIs are used in developing guidelines for defining laboratory adverse events to be used when enrolling 
and following up patients in a clinical trial. In many HIV clinical trials, the Division of AIDS (DAIDS), 
National Institute of Allergy and Infectious Disease/National Institutes of Health adverse event tables 
are used to evaluate toxicities (NIH, 2014). As highlighted by Karita et al., adopting the 2004 DAIDS 
grading criteria would inadvertently misclassify many healthy study volunteers as having adverse 
events at the time of clinical trial recruitment. In the study, 319 (15.2%) individuals would have been 
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misclassified as having a haematology laboratory adverse event which would have resulted in their 
unnecessary exclusion from the study (Karita et al., 2009). Given the marked variability in certain CBC 
parameters across different populations, population specific RIs should be used when defining 
laboratory based adverse events for clinical trials. Failure to do so will not only result in inappropriate 
exclusion or inclusion of study participants but misreporting on the incidence of toxicities. 
 
The major strength of this study is the careful recruitment of healthy individuals with an even 
distribution of age and sex. Unlike most of the other RI studies conducted in SSA, we had strict 
exclusion criteria and further carried out secondary exclusion which significantly reduced the influence 
of individuals with latent anaemia or inflammation. This increases the external validity of the results in 
so far as extrapolating to an adult urban black African population in Kenya is concerned. 
  
One of the limitations of this study was that sample analysis was done only on a Beckman Coulter 
analyzer hence the transferability of the RIs is limited if between-analyzer bias exists in test results. 
Secondly, our recruitment comprised largely an urban population, the vast majority from the capital 
city Nairobi and surrounding counties whose socio-economic status and lifestyles are different from a 
rural population. Some of the RIs may therefore not be directly applicable to a rural community. 
Another limitation is that we relied on self-reporting of chronic illnesses including those of an 
infectious aetiology. It is possible that some participants may not have provided accurate information 
and as such may have ended up being included inadvertently. We however tried to minimize the effect 
of such inclusion by secondarily excluding individuals whose test results suggested the possibility of 
sub-clinical disease. 
Conclusion 
The present study highlights marked differences in certain CBC parameters such as Hb, eosinophil and 
platelet counts compared to other SSA countries and lower neutrophil counts compared to the US. To 
the best of our knowledge this is the first study from Africa that has used the LAVE procedure to 
determine RIs for CBC and we do believe that the secondary exclusion of individuals with possible 
sub-clinical disease makes our RIs more representative of a healthy urban Kenyan population. Our 
study results can serve as a reference for laboratories in SSA especially in situations where conducting 
a formal RI study may not be feasible. 
 




Jared Oseko and Patricia Ingato of Aga Khan University Hospital Nairobi assisted in sample collection, 
bar coding and processing. Benjamin Matheka, marketing manager PathCare Kenya Limited, assisted 
in participant recruitment and sample collection. Arno Theron carried out sample analysis, quality 
assurance and data handling at the PathCare reference laboratory in Cape Town, South Africa. 
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5.6 Supporting information 




Fig S5.1: Age and sex distribution of anaytes  










Fig S5.2: Reference intervals before and after latent abnormal value exclusion 
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Fig S5.3: Normalization of analyte data 
  




Table S5.1: Standard deviation ratios for change in upper and lower limits of reference intervals 
by use of the LAVE method 







Male Female  
Item LL UL LL UL LL UL LL UL LL UL LL UL 
RBC 0.25 0.09 0.32 0.00 0.30 0.30 0.22 0.06 0.28 0.02 0.47 0.23 
Hb 1.01 0.32 0.28 0.00 1.22 0.00 1.28 0.00 0.37 0.00 1.53 0.09 
Hct 0.69 0.00 0.00 0.00 0.60 0.30 0.98 0.00 0.71 0.00 1.21 0.00 
MCV 0.85 0.00 0.19 0.02 1.00 0.04 1.04 0.00 0.18 0.04 1.10 0.03 
MCH 0.78 0.00 0.31 0.05 1.13 0.00 1.09 0.00 0.28 0.00 1.11 0.04 
MCHC 0.52 0.00 0.13 0.00 0.65 0.00 0.63 0.00 0.00 0.13 0.91 0.13 
RDW 0.20 1.21 0.12 0.23 0.09 1.87 0.00 1.92 0.10 0.83 0.00 2.25 
WBC 0.06 0.09 0.02 0.09 0.00 0.22 0.06 0.18 0.02 0.07 0.02 0.25 
Neu % 0.02 0.09 0.05 0.01 0.02 0.05 0.01 0.03 0.02 0.01 0.10 0.03 
Lym % 0.12 0.01 0.05 0.09 0.06 0.07 0.07 0.02 0.08 0.07 0.02 0.08 
Mon % 0.04 0.08 0.04 0.07 0.00 0.25 0.04 0.04 0.07 0.11 0.05 0.27 
Eos % 0.04 0.15 0.00 0.04 0.00 0.23 0.00 0.19 0.00 0.20 0.00 0.00 
Bas % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Neu Abs 0.04 0.27 0.05 0.05 0.01 0.33 0.05 0.31 0.04 0.18 0.01 0.47 
Lym Abs 0.09 0.07 0.04 0.12 0.14 0.10 0.07 0.13 0.02 0.29 0.07 0.04 
Mon Abs 0.00 0.07 0.00 0.00 0.00 0.07 0.00 0.07 0.00 0.06 0.00 0.07 
Eos Abs 0.00 0.07 0.07 0.13 0.00 0.09 0.00 0.00 0.00 0.21 0.00 0.16 
Bas Abs 0.00 0.00 0.00 0.56 0.00 0.78 0.00 0.56 0.00 0.00 0.00 0.78 
PLT 0.05 0.33 0.07 0.17 0.08 0.33 0.01 0.51 0.06 0.08 0.11 0.26 
Key-%: percentage, LL: lower limit, Me: median, UL: upper limit, RBC: red blood cell count, Hb: haemoglobin, MCV: 
mean corpuscular volume, MCH: mean corpuscular haemoglobin, MCHC: mean corpuscular haemoglobin concentration, 
RDW: red cell distribution width, WBC: white blood cell count, Neu: neutrophil, Lym: lymphocyte, Mon: monocyte, Eos: 
eosinophil, Bas: basophil, Abs: absolute count, Plt: platelet count, SDRs > 0.3 are in bold 
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Table S5.2: Complete blood count reference intervals before and after latent abnormal value 
exclusion 
 
Key-%: percentage, LL: lower limit, Me: Median, UL: upper limit, RBC: Red blood cell count, Hb: Haemoglobin, MCV: 
Mean corpuscular volume, MCH: Mean corpuscular haemoglobin, MCHC: Mean corpuscular haemoglobin concentration, 
RDW: Red cell distribution width, WBC: White blood cell count, Neu: Neutrophil, Lym: Lymphocyte, Mon: Monocyte, 
Eos: Eosinophil, Bas: Basophil, Abs: absolute count, Plt: platelet count, LAVE: Latent abnormal values exclusion. (-): 
without LAVE, (+): with LAVE. Reference tests used in applying the LAVE method were Iron, Ferritin, Transferrin, Hb, 
Hct, MCV, Albumin, Globulins, CRP, WBC and PLT 
Item LAVE n LL UL n LL UL n LL UL
LAVE(-) 528 4.3 6.4 254 4.8 6.5 272 4.2 5.9
LAVE(+) 463 4.4 6.5 226 4.9 6.5 229 4.3 5.8
LAVE(-) 527 11.2 18.5 254 14.2 18.7 272 10.6 16.5
LAVE(+) 470 12.8 19.0 232 14.5 18.7 236 12.0 16.5
LAVE(-) 528 0.35 0.55 253 0.43 0.55 272 0.34 0.50
LAVE(+) 471 0.38 0.55 232 0.43 0.55 237 0.36 0.49
LAVE(-) 527 71.4 95.6 254 75.6 95.4 273 67.7 95.6
LAVE(+) 466 75.7 95.6 228 76.5 95.5 232 73.4 95.8
LAVE(-) 526 23.2 32.8 255 24.5 32.9 272 22.0 32.7
LAVE(+) 462 24.8 32.8 227 25.1 32.8 230 24.4 32.7
LAVE(-) 524 31.8 35.2 254 32.3 35.4 271 31.5 35.0
LAVE(+) 461 32.2 35.2 227 32.4 35.4 230 32.0 35.0
LAVE(-) 517 11.5 16.4 251 11.2 14.9 270 11.5 17.9
LAVE(+) 460 11.3 15.2 225 11.3 14.7 228 11.4 15.8
LAVE(-) 525 3.01 7.94 255 3.15 7.99 270 2.89 7.99
LAVE(+) 464 3.08 7.83 229 3.13 8.1 232 2.89 7.72
LAVE(-) 528 27.8 64.1 255 27.0 60.4 273 29.3 65.9
LAVE(+) 463 28.0 63.3 227 27.4 60.3 230 29.5 65.4
LAVE(-) 528 26.2 59.9 255 28.6 61.0 273 25.0 58.7
LAVE(+) 463 27.2 60.0 227 28.2 60.3 230 25.5 59.3
LAVE(-) 527 3.3 13.1 254 3.6 14.1 272 3.2 11.5
LAVE(+) 461 3.4 13.3 226 3.5 14.3 229 3.2 11.0
LAVE(-) 520 1.0 11.5 253 1.2 11.9 270 0.8 9.9
LAVE(+) 455 1.1 11.9 225 1.2 11.8 227 0.8 9.4
LAVE(-) 520 0.3 1.1 251 0.4 1.2 270 0.3 1.0
LAVE(+) 456 0.3 1.1 224 0.4 1.2 228 0.3 1.0
LAVE(-) 524 1.02 4.29 255 0.98 3.96 271 1.08 4.70
LAVE(+) 460 1.05 4.08 227 1.02 3.92 229 1.07 4.42
LAVE(-) 526 1.24 3.44 254 1.34 3.65 272 1.15 3.29
LAVE(+) 461 1.29 3.40 226 1.36 3.58 230 1.22 3.24
LAVE(-) 527 0.14 0.73 255 0.15 0.76 272 0.14 0.69
LAVE(+) 462 0.14 0.74 227 0.15 0.76 229 0.14 0.68
LAVE(-) 523 0.04 0.58 254 0.04 0.62 270 0.04 0.48
LAVE(+) 460 0.04 0.59 226 0.05 0.64 228 0.04 0.49
LAVE(-) 525 0.01 0.07 253 0.01 0.07 272 0.01 0.07
LAVE(+) 461 0.01 0.07 226 0.01 0.08 224 0.01 0.06
LAVE(-) 525 141 431 254 137 365 272 146 468





















M+F M F 




Key-%: percentage, LL: lower limit, Me: Median, UL: upper limit, RBC: Red blood cell count, Hb: Haemoglobin, MCV: 
Mean corpuscular volume, MCH: Mean corpuscular haemoglobin, MCHC: Mean corpuscular haemoglobin concentration, 
RDW: Red cell distribution width, WBC: White blood cell count, Neu: Neutrophil, Lym: Lymphocyte, Mon: Monocyte, 
Eos: Eosinophil, Bas: Basophil, Abs: absolute count, Plt: platelet count, LAVE: Latent abnormal values exclusion. (-): 
without LAVE, (+): with LAVE. Reference tests used in applying the LAVE method were Iron, Ferritin, Transferrin, Hb, 
Hct, MCV, Albumin, Globulins, CRP, WBC and PLT 
Item LAVE n LL UL n LL UL n LL UL
LAVE(-) 528 4.3 6.4 255 4.8 6.6 273 4.2 5.9
LAVE(+) 463 4.4 6.4 227 4.9 6.6 230 4.3 5.8
LAVE(-) 528 10.8 18.5 255 14.0 18.6 273 10.2 16.5
LAVE(+) 470 12.7 18.5 232 14.4 18.6 237 12.0 16.6
LAVE(-) 528 0.34 0.54 255 0.41 0.54 273 0.32 0.49
LAVE(+) 471 0.38 0.54 232 0.43 0.54 237 0.36 0.49
LAVE(-) 528 68.1 95.2 255 72.7 95.0 273 64.9 95.2
LAVE(+) 466 73.8 95.2 228 73.7 95.2 232 71.6 95.4
LAVE(-) 528 22.0 32.6 255 23.5 32.6 273 20.7 32.6
LAVE(+) 463 24.3 32.6 227 24.1 32.6 230 23.3 32.5
LAVE(-) 528 31.6 35.2 255 32.3 35.3 273 31.2 35.0
LAVE(+) 463 32.1 35.2 227 32.3 35.4 230 31.9 34.9
LAVE(-) 528 11.2 17.9 255 11.2 15.9 273 11.3 18.7
LAVE(+) 463 11.2 15.7 227 11.3 15.1 230 11.3 16.0
LAVE(-) 528 3.01 8.42 255 3.18 7.87 273 2.92 9.1
LAVE(+) 467 3.09 8.18 230 3.15 7.96 234 2.95 8.73
LAVE(-) 528 26.7 63.1 255 26.2 59.9 273 28.0 66.0
LAVE(+) 463 26.8 62.8 227 26.4 60.0 230 28.9 65.7
LAVE(-) 528 26.2 60.6 255 27.7 61.2 273 25.0 59.7
LAVE(+) 463 26.8 60.8 227 27.0 60.6 230 25.2 60.4
LAVE(-) 528 3.3 13.3 255 3.5 13.7 273 3.3 12.4
LAVE(+) 463 3.4 13.2 227 3.3 14.0 230 3.2 11.8
LAVE(-) 528 0.9 10.9 255 1.1 11.2 273 0.7 9.5
LAVE(+) 463 0.9 11.4 227 1.1 10.7 230 0.7 9.5
LAVE(-) 528 0.3 1.2 255 0.3 1.3 273 0.3 1.0
LAVE(+) 463 0.3 1.2 227 0.3 1.3 230 0.3 1.0
LAVE(-) 528 1.00 4.62 255 0.99 4.05 273 1.03 5.18
LAVE(+) 463 1.04 4.36 227 1.02 3.92 230 1.04 4.74
LAVE(-) 528 1.23 3.47 255 1.29 3.73 273 1.18 3.34
LAVE(+) 463 1.27 3.40 227 1.28 3.56 230 1.22 3.32
LAVE(-) 528 0.15 0.73 255 0.16 0.78 273 0.14 0.69
LAVE(+) 463 0.15 0.74 227 0.16 0.77 230 0.14 0.68
LAVE(-) 528 0.04 0.61 255 0.04 0.64 273 0.04 0.52
LAVE(+) 463 0.04 0.61 227 0.04 0.61 230 0.04 0.54
LAVE(-) 528 0.01 0.07 255 0.01 0.08 273 0.01 0.07
LAVE(+) 463 0.01 0.08 227 0.01 0.08 230 0.01 0.06
LAVE(-) 528 141 450 255 130 373 273 142 480





















M+F M F 
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Table S5.3: Summary of selected reference interval studies for erythrocyte related parameters in sub-Saharan Africa 
 
Key-LL: lower limit, UL: upper limit, RBC: red blood cell count, Hb: haemoglobin, MCV: mean corpuscular volume, MCH: mean corpuscular haemoglobin, MCHC: 
mean corpuscular haemoglobin concentration, RDW: red cell distribution width, LAVE: latent abnormal values exclusion 
n LL UL n LL UL n LL UL n LL UL n LL UL n LL UL n LL UL
M+F 463 4.41 6.48 470 12.8 19.0 471 0.38 0.55 466 75.7 95.6 462 24.8 32.8 461 32.2 35.2 460 11.3 15.2
M 226 4.94 6.52 232 14.5 18.7 232 0.43 0.55 228 76.5 95.5 227 25.1 32.8 227 32.4 35.4 225 11.3 14.7
F 229 4.31 5.76 236 12.0 16.5 237 0.36 0.49 232 73.4 95.8 230 24.4 32.7 230 32.0 35.0 228 11.4 15.8
M+F 1541 4.00 6.20 1541 6.7 11.1 1541 0.30 0.50 1541 68.8 97.2 1541 22.4 33.5 1541 32.2 35.3
M 1020 4.40 6.30 1020 8.3 11.3 1020 0.40 0.50 1020 71.4 98.2 1020 23.3 33.8 1020 32.4 35.3
F 521 3.70 5.60 521 5.9 10.0 521 0.30 0.50 521 66.0 95.7 521 21.3 33.0 521 32.2 35.2
M+F
M 389 4.60 6.60 389 12.6 17.2 389 0.38 0.52 389 67.4 93.6
F 322 4.00 5.80 322 9.0 14.9 322 0.29 0.44 322 59.3 93.2
M+F
M 410 3.80 6.00 410 11.1 16.8 410 0.32 0.48 410 69.9 95.2
F 435 3.70 5.30 435 10.1 14.3 435 0.30 0.41 435 67.7 92.6
M+F 2105 68.0 98.0
M 1083 4.00 6.40 1083 12.2 17.7 799 0.35 0.51
F 846 3.80 5.60 1022 9.5 15.8 846 0.29 0.45
M+F
M 280 4.30 5.90 280 13.9 18.3 280 0.42 0.55
F 205 3.70 5.20 205 12.2 16.6 205 0.35 0.49
M+F 272 4.01 6.12 276 11.7 17.2 276 0.37 0.53 274 77.6 98.1 272 23.6 33.1 275 30.6 34.9
M 145 4.41 6.27 148 13.7 17.7 149 0.40 0.54 149 76.4 98.8 147 23.1 33.2 148 30.6 35.1
F 127 3.84 5.59 128 11.1 15.7 127 0.36 0.47 125 77.7 97.9 125 24.2 33.1 127 30.4 34.8
M+F 296 77.0 95.0 296 26.0 33.0 296 32.0 37.0
M 206 4.20 6.30 206 12.7 17.5 206 0.38 0.54
F 90 3.40 5.50 90 11.0 16.0 90 0.36 0.48
M+F 623 3.39 5.83 624 9.8 16.0 625 0.29 0.49 625 72.0 97.0 623 22.6 33.5 620 30.5 36.2 625 11.5 16.7
M 316 3.79 5.96 316 11.3 16.4 316 0.33 0.51 316 70.0 98.0 316 22.7 33.5 315 30.6 36.0 316 11.5 16.7
F 307 3.09 5.30 308 8.8 14.4 309 0.26 0.45 309 73.0 96.0 307 22.3 33.6 305 30.4 36.5 309 11.4 16.8
M+F 1349 3.10 6.40 1349 10.0 18.4 1349 0.28 0.54 1349 80.0 99.0 1349 25.0 37.0 1349 29.0 41.0
M 1047 3.30 6.40 1047 10.0 18.4 1047 0.28 0.54 1047 80.0 99.0 1047 25.0 36.0 1047 29.0 39.0
F 302 3.10 6.00 302 10.3 17.1 302 0.28 0.47 302 80.0 95.0 302 25.0 37.0 302 30.0 41.0
M+F
M 88 4.19 5.85 88 13.4 17.5 88 0.39 0.51 88 83.1 101.6 88 27.8 34.8 88 33.0 35.0 88 12.1 16.3
F 631 3.93 5.40 631 11.6 16.4 631 0.34 0.48 631 78.9 98.5 631 26.1 33.5 631 32.7 34.9 631 12.4 17.3
Hb (g/dL)
Study Inclusion criteria Statistical method Sex
RBC (x 10^12/L) Hct (L/L) MCV (fl) MCH (pg) MCHC (g/dL) RDW (%)
1Kenya (Nairobi, Thika, Kiambu, Nakuru, Kisii), 
Jan-Oct 2015, (This study)
Healthy volunteers, 18-65 years, urban towns in Kenya Parametric + LAVE method
2
Kenya (Kericho), Jul-Dec 2004, Kibaya et al
Healthy participants of a natural history cohort evaluating 
HIV-1 infection, 18-55 years
Parametric or non-parametric (mid 
95%) depending on distribution of 
data
3Kenya (Kisumu), Jan 2007-Jun 2010  (Results 
for 18-34 years), Odhiambo et al
Healthy sexually active individuals participating in a 
prospective study estimating the incidence of HIV 
seroconversion, 16-34 years
Non-parametric (mid 95%) 
4Uganda (Eastern Uganda), Jan-Sep 2002 
(Results for > 24 years), Lugada et al
Healthy individuals participating in a study to investigate 
risk factors for human herpes virus 8 infection, 1 week-92 
years
Non-parametric (mid 90%) 
5Kenya (Nairobi, Kilifi), Uganda(Entebe, 
Masaka) Zambia (Lusaka), Rwanda (Kigali), Dec 
2004-Oct 2006, Karita et al
Healthy volunteers, participating in studies prior to HIV 
vaccine safety and efficacy trials, 18–60 years, HIV-
negative test
Non-parametric (mid 95%) , for some 
parameters certain study sites were 
excluded as outliers
6
Ethiopia (Akaki) , Published in 1998, Tsegaye 
et al
Healthy factory workers,  15-45 years Non-parametric (mid 95%) 
7
Tanzania (Mbeya),  Dec 2004-Jul 2005  Saathof 
et al
Healthy volunteers, 19-48 years, participating in a larger 
study called COPE that employed population based 
sampling
Non-parametric (mid 95%)  after 
removal of outliers
8Rwanda (Buhanda,Ruhango, Nyaruteja, 
Butare), Aug-Dec 2011, Gahutu et al
Blood donors, 18-40 years
Non-parametric (mid 95%) after 
removal of outliers
11South Africa (Gauteng), Published in 2009, 
Lawrie et al
Healthy volunteers involved in a study assessing 
morbidity prior to HIV vaccine trials, 18-60 years
Non-parametric (mid 95%) 
9Ghana (Kintampo), published in 2012, Dosoo 
et al
Healthy individuals randomly selected from a Health and 
Demographic Surveillance System (HDSS)
Non-parametric (mid 95%)  after 
removal of outliers
10Togo (Lome), Apr-Sep 2008, Kueviakoe et al Blood donors, 17-58 years
Non-parametric (mid 95%)  after 
removal of outliers
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1Exclusion criteria: BMI > 35 kg/m2, consumption of ethanol ≥ 70 g per day, smoking more than 20 tobacco cigarettes per 
day, chronic illness, recent recovery from acute illness, injury or surgery requiring hospitalization, known carrier state of 
HBV, HCV or HIV, pregnant or within 1 year after child birth. CBC analyser: Beckman Coulter ACT 5 DIFF CP analyser 
(Brea, California, US).  
2Exclusion criteria: Febrile, pregnant, HIV seropositive, screen positive for syphilis and malaria. CBC analyser: ACT 
5Diff CP instrument (Beckman Coulter, Fullerton, CA, USA) (Kibaya et al., 2008). 
3Exclusion criteria: HIV positive, pregnant. CBC analyser: Coulter ACT 5Diff CP analyser (Beckman Coulter, France) 
(Odhiambo et al., 2015). 
4 Exclusion criteria: HIV positive, moribund, mentally ill, institutionalized persons, missing personal or laboratory data. 
CBC analyser: Act 5 Diff instrument (Beckman Coulter) (Lugada et al., 2004). 
5 Exclusion criteria: Acutely ill, significant findings on physical examination or if laboratory tests revealed that they were 
pregnant, HIV antibody positive, had evidence of hepatitis B or C infection or suspected syphilis. CBC analyser: Beckman 
Coulter AcT 5 diff CP (Beckman Coulter, USA) (Karita et al., 2009). 
6 Exclusion criteria: HIV positive, presence of any illness as defined by the World Health Organization staging systems for 
HIV infection and disease. CBC analyser: Coulter counter T540 (Tsegaye et al., 1999). 
7 Exclusion criteria: HIV positive, pregnant or on medication, body temperature ≥37.50C or if clinical assessment revealed 
other signs or symptoms of disease that could influence the laboratory parameters of interest. CBC analyser: Sysmex KX-
21N analyser (Sysmex Corp., Kobe, Japan) (Saathoff et al., 2008). 
8 Exclusion criteria: Alcohol abuse, medication, smoking, pregnant, breastfeeding, on oral contraception, on menses. CBC 
analyser: Coulter AcT 5diff and Sysmex KX-21N (Sysmex Corporation, Kobe, Japan) (Gahutu, 2013). 
9 Exclusion criteria: Acute or chronic respiratory, cardiovascular, gastrointestinal, hepatic or genitourinary conditions, 
blood donation or transfusion within the past 3 months, hospitalisation within past 1 month, any findings that would 
compromise laboratory parameters, pregnant or lactating mothers. CBC analyser: Micros 60 analysers (Horiba-ABX, 
Montpellier, France) (Dosoo et al., 2012). 
10 Exclusion criteria: HIV, HBV, and HCV viral infection, malaria, abnormal haemoglobin electrophoresis screening, 
presence of hypochromia. CBC analyser: Sysmex SF-3000 (Sysmex, Kobe, Japan) (Kueviakoe et al., 2011). 
11 Exclusion criteria: HIV, current clinical symptoms, immunosuppressive or corticosteroid medication, chemotherapy, 
hospitalizations, surgery or blood transfusions in the six months prior to screening, splenomegaly, pregnant, Hb < 12 g/dL. 
Menstruating women returned in 2 weeks. CBC analyser: Beckman Coulter LH 750 (Beckman Coulter, Fullerton, CA, 
USA) (Lawrie et al., 2009). 
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Table S5.4: Summary of selected reference interval studies for platelets and white blood cell related parameters in sub-Saharan 
Africa 
 
Key-LL: lower limit, UL: upper limit, RBC: red blood cell count, Hb: haemoglobin, MCV: mean corpuscular volume, MCH: mean corpuscular haemoglobin, MCHC: 
mean corpuscular haemoglobin concentration, RDW: red cell distribution width, LAVE: latent abnormal values exclusion 
n LL UL n LL UL n LL UL n LL UL n LL UL n LL UL n LL UL
M+F 464 3.08 7.83 460 1.05 4.08 461 1.29 3.40 462 0.14 0.74 460 0.04 0.59 461 0.01 0.07 464 144 409
M 229 3.13 8.10 227 1.02 3.92 226 1.36 3.58 227 0.15 0.76 226 0.05 0.64 226 0.01 0.08 231 133 356
F 232 2.89 7.72 229 1.07 4.42 230 1.22 3.24 229 0.14 0.68 228 0.04 0.49 224 0.01 0.06 232 152 443
M+F 1541 2.80 8.20 1541 0.91 4.72 1541 1.14 3.45 1541 0.13 0.60 1541 0.03 1.14 1541 0.01 0.08 1541 120 411
M 1020 2.70 7.50 1020 0.87 4.32 1020 1.12 3.16 1020 0.13 0.59 1020 0.03 1.08 1020 0.01 0.09 1020 115 366
F 521 3.00 9.10 521 0.99 5.56 521 1.29 3.96 521 0.16 0.64 521 0.03 1.22 521 0.01 0.07 521 124 444
M+F
M 389 3.30 9.60 389 1.30 5.20 389 1.20 3.40 389 0.20 0.70 389 0.04 1.60 389 0.01 0.14 389 126 356
F 322 3.70 9.10 322 1.30 5.00 322 1.40 3.80 322 0.20 0.80 322 0.04 1.20 322 0.02 0.09 322 147 454
M+F 845 3.40 8.70 845 0.84 3.37 845 1.40 4.20 845 0.17 0.59 845 0.13 2.11 845 0.01 0.07
M 410 80 288
F 435 100 297
M+F 2105 3.10 9.10 2103 1.00 5.30 2105 1.20 3.70 2103 0.20 0.78 2104 0.04 1.53 1750 0.01 0.15 2105 126 438
M
F
M+F 485 3.00 10.20 485 98 337
M 280 97 324
F 205 98 352
M+F 279 3.00 7.90 276 1.10 4.70 278 1.10 3.00 274 150 395
M 150 2.80 7.90 150 1.10 4.80 149 1.10 2.80 147 147 356
F 129 3.20 8.00 126 1.20 5.40 129 1.10 3.10 127 151 425
M+F 296 2.90 7.11 296 1.00 4.10 296 1.10 3.20 296 0.20 0.60 296 0.05 0.74 296 0.01 0.08
M 206 115 336
F 90 134 408
M+F 620 3.40 9.20 624 1.20 4.40 624 0.20 1.00 625 89 380
M 311 3.50 9.20 316 1.20 5.20 316 0.20 1.40 316 88 352
F 309 3.40 9.30 308 1.20 4.40 308 0.20 0.90 309 89 403
M+F 1349 1.90 10.10 1349 0.50 5.40 1349 1.10 4.30 1349 0.05 0.80 1349 0.00 0.50 1349 1349 120 443
M 1047 1.90 10.10 1047 0.50 5.40 1047 1.10 4.30 1047 0.05 0.80 1047 0.00 0.50 1047 120 443
F 302 2.20 7.80 302 0.50 4.40 302 1.20 4.30 302 0.05 0.80 302 0.00 0.50 302 150 436
M+F
M 88 3.92 10.40 88 1.60 6.98 88 1.40 4.20 88 0.30 0.80 88 0.00 0.95 88 0.00 0.10 88 171 388
F 631 3.90 12.60 631 1.60 8.30 631 1.40 4.50 631 0.20 0.80 631 0.00 0.40 631 0.00 0.10 631 186 454
Study Inclusion criteria Statistical method Sex
Healthy volunteers, 18-65 years, urban towns in Kenya
11South Africa (Gauteng), Published in 2009, 
Lawrie et al
Healthy volunteers involved in a study assessing 
morbidity prior to HIV vaccine trials, 18-60 years
Non-parametric (mid 95%) 
1Kenya (Nairobi, Thika, Kiambu, Nakuru, Kisii), 
Jan-Oct 2015, (This study)
2Kenya (Kericho), Jul-Dec 2004, Kibaya et al
3
Kenya (Kisumu), Jan 2007-Jun 2010  (Results 
for 18-34 years), Odhiambo et al
5Kenya (Nairobi, Kilifi), Uganda(Entebe, 
Masaka) Zambia (Lusaka), Rwanda (Kigali), Dec 
2004-Oct 2006, Karita et al
Healthy volunteers, participating in studies prior to HIV 
vaccine safety and efficacy trials, 18–60 years, HIV-
negative test
Non-parametric (mid 95%) , for some 
parameters certain study sites were 
excluded as outliers
Parametric + LAVE method
Healthy participants of a natural history cohort evaluating 
HIV-1 infection, 18-55 years
Parametric or non-parametric (mid 
95%) depending on distribution of 
data
Healthy sexually active individuals participating in a 
prospective study estimating the incidence of HIV 
seroconversion, 16-34 years
Non-parametric (mid 95%) 
4Uganda (Eastern Uganda), Jan-Sep 2002 
(Results for > 24 years), Lugada et al
Healthy individuals participating in a study to investigate 
risk factors for human herpes virus 8 infection, 1 week-92 
years
Non-parametric (mid 90%) 
6
Ethiopia (Akaki) , Published in 1998, Tsegaye 
et al
Healthy factory workers,  15-45 years Non-parametric (mid 95%) 
7Tanzania (Mbeya),  Dec 2004-Jul 2005  Saathof 
et al
Healthy volunteers, 19-48 years, participating in a larger 
study called COPE that employed population based 
sampling
Non-parametric (mid 95%)  after 
removal of outliers
10Togo (Lome), Apr-Sep 2008, Kueviakoe et al Blood donors, 17-58 years
Non-parametric (mid 95%)  after 
removal of outliers
8Rwanda (Buhanda,Ruhango, Nyaruteja, 
Butare), Aug-Dec 2011, Gahutu et al
Blood donors, 18-40 years
Non-parametric (mid 95%) after 
removal of outliers
9Ghana (Kintampo), published in 2012, Dosoo 
et al
Healthy individuals randomly selected from a Health and 
Demographic Surveillance System (HDSS)
Non-parametric (mid 95%)  after 
removal of outliers
Mon Abs (x 10^9/L) Eos Abs (x 10^9/L) Bas Abs (x 10^9/L) Plt (x 10^9/L)WBC (x 10^9/L) Neu Abs (x 10^9/L) Lym Abs (x 10^9/L)
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1Exclusion criteria: BMI > 35 kg/m2, consumption of ethanol ≥ 70 g per day, smoking more than 20 tobacco cigarettes per 
day, chronic illness, recent recovery from acute illness, injury or surgery requiring hospitalization, known carrier state of 
HBV, HCV or HIV, pregnant or within 1 year after child birth. CBC analyser: Beckman Coulter ACT 5 DIFF CP analyser 
(Brea, California, US).  
2Exclusion criteria: Febrile, pregnant, HIV seropositive, screen positive for syphilis and malaria. CBC analyser: ACT 
5Diff CP instrument (Beckman Coulter, Fullerton, CA, USA) (Kibaya et al., 2008). 
3Exclusion criteria: HIV positive, pregnant. CBC analyser: Coulter ACT 5Diff CP analyser (Beckman Coulter, France) 
(Odhiambo et al., 2015). 
4 Exclusion criteria: HIV positive, moribund, mentally ill, institutionalized persons, missing personal or laboratory data. 
CBC analyser: Act 5 Diff instrument (Beckman Coulter) (Lugada et al., 2004). 
5 Exclusion criteria: Acutely ill, significant findings on physical examination or if laboratory tests revealed that they were 
pregnant, HIV antibody positive, had evidence of hepatitis B or C infection or suspected syphilis. CBC analyser: Beckman 
Coulter AcT 5 diff CP (Beckman Coulter, USA) (Karita et al., 2009). 
6 Exclusion criteria: HIV positive, presence of any illness as defined by the World Health Organization staging systems for 
HIV infection and disease. CBC analyser: Coulter counter T540 (Tsegaye et al., 1999). 
7 Exclusion criteria: HIV positive, pregnant or on medication, body temperature ≥37.50C or if clinical assessment revealed 
other signs or symptoms of disease that could influence the laboratory parameters of interest. CBC analyser: Sysmex KX-
21N analyser (Sysmex Corp., Kobe, Japan) (Saathoff et al., 2008). 
8 Exclusion criteria: Alcohol abuse, medication, smoking, pregnant, breastfeeding, on oral contraception, on menses. CBC 
analyser: Coulter AcT 5diff and Sysmex KX-21N (Sysmex Corporation, Kobe, Japan) (Gahutu, 2013). 
9 Exclusion criteria: Acute or chronic respiratory, cardiovascular, gastrointestinal, hepatic or genitourinary conditions, 
blood donation or transfusion within the past 3 months, hospitalisation within past 1 month, any findings that would 
compromise laboratory parameters, pregnant or lactating mothers. CBC analyser: Micros 60 analysers (Horiba-ABX, 
Montpellier, France) (Dosoo et al., 2012). 
10 Exclusion criteria: HIV, HBV, and HCV viral infection, malaria, abnormal haemoglobin electrophoresis screening, 
presence of hypochromia. CBC analyser: Sysmex SF-3000 (Sysmex, Kobe, Japan) (Kueviakoe et al., 2011). 
11 Exclusion criteria: HIV, current clinical symptoms, immunosuppressive or corticosteroid medication, chemotherapy, 
hospitalizations, surgery or blood transfusions in the six months prior to screening, splenomegaly, pregnant, Hb < 12 g/dL. 
Menstruating women returned in 2 weeks. CBC analyser: Beckman Coulter LH 750 (Beckman Coulter, Fullerton, CA, 
USA) (Lawrie et al., 2009). 
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Background: Due to a lack of reliable reference intervals (RIs) for Kenya, we set out to determine 
RIs for 40 common chemistry and immunoassay tests as part of the IFCC global RI project. 
Methods:  Apparently healthy adults aged 18-65 years were recruited according to a harmonized 
protocol and samples analyzed using Beckman-Coulter analyzers. Value assigned serum panels were 
measured to standardize chemistry results. The need for partitioning reference values by sex and age was 
based on between-subgroup differences expressed as standard deviation ratio (SDR) or bias in lower or 
upper limits (LLs and ULs) of the RI. RIs were derived using a parametric method with/without latent 
abnormal value exclusion (LAVE). 
Results: Sex-specific RIs were required for uric acid, creatinine, total bilirubin (TBil), total cholesterol 
(TC), ALT, AST, CK, GGT, transferrin, transferrin saturation (TfSat) and immunoglobulin-M. Age-
specific RIs were required for glucose and triglyceride for both sexes, and for urea, magnesium, TC, 
HDL-cholesterol ratio, ALP, and ferritin for females. LAVE was effective in optimizing RIs for AST, 
ALT, GGT iron-markers and CRP by reducing influence of latent anemia and metabolic diseases. 
Thyroid profile RIs were derived after excluding volunteers with anti-thyroid antibodies. Kenyan RIs 
were comparable to those of other countries participating in the global study with a few exceptions such 
as higher ULs for TBil and CRP.  
Conclusions: Kenyan RIs for major analytes were established using harmonized protocol from well-
defined reference individuals. Standardized RIs for chemistry analytes can be shared across sub-Saharan 
African laboratories with similar ethnic and life-style profile.  
 
  




Reference intervals (RIs) are an integral part of laboratory reports as they assist clinicians in 
interpretation of results. RIs should be population specific to ensure appropriate interpretation. 
Unfortunately, many  clinical laboratories in sub-Saharan Africa (SSA) adopt RIs provided by 
manufacturers of laboratory reagents/equipment without verifying them as recommended by the 
Clinical Laboratory Standards Institute (CLSI) (CLSI, 2008). This could result in inaccurate 
interpretation of quantitative laboratory results leading to medical errors. Saathoff et al carried out a 
study in the Mbeya region, south-western Tanzania and found marked differences in RIs from the 
United States (US), Tanzania and other SSA countries. Overall, only 80.9% of reference values (RVs) 
for clinical chemistry tests from healthy individuals in Tanzania would have been classified as normal 
as per the US RIs published by Kratz et al (Kratz et al., 2004). 
 
The International Federation of Clinical Chemistry (IFCC) under its Committee on Reference Intervals 
and Decision Limits (C-RIDL) has been carrying out a global RI study using a protocol that 
harmonizes the pre-analytical, analytical and post-analytical study processes to ensure ease of 
comparison of derived RIs across different regions, countries and ethnicities (Ozarda et al., 2013).  
 
An interim report of the global RI study comprising data from 12 countries identified between ethnic 
group differences in both males and females for serum total protein (TP), albumin (Alb), total bilirubin 
(TBil), high density lipoprotein cholesterol (HDL-C), magnesium (Mg), C-reactive protein (CRP), IgG, 
complement 3 (C3), vitamin B12, and folate. Females were found to generally have more pronounced 
age-related changes in RVs. Ethnic differences in BMI-related changes was also demonstrated. The 
only African country whose data were included in the interim report was South Africa where 
comparisons between black South Africans and Caucasian / mixed race showed much higher levels of 
CRP in the black South Africans (Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017). 
 
The Kenyan study was undertaken to explore sources of variation of RVs, to derive country specific 
RIs and to standardize the RIs by use of a value-assigned panel of sera (Ichihara, Ozarda, Barth, Klee, 
Qiu, et al., 2017) intended for nationwide use and international comparison.  
  
Stellenbosch University  https://scholar.sun.ac.za
120 
 
6.3 Materials and methods 
The methodology used in recruiting participants for the study, sample collection, handling and analysis 
has previously been published (Omuse et al., 2018). The study was approved by the Aga Khan 
University Hospital Nairobi (2014/REC-46) and Stellenbosch University (S16/10/219) Health Research 
Ethics Committees. The study was conducted in conformity with the Declaration of Helsinki. 
Study population 
Recruitment of study participants in Kenya was carried out between January and October 2015 in 
several counties. Majority were urban dwellers from the capital city Nairobi, Kiambu county in central 
Kenya, Kisii County in western Kenya, and Nakuru County based in the Great Rift Valley.  
Inclusion and exclusion criteria 
Inclusion of participants was limited to healthy adults aged 18-65 years stratified into 4 age groups: 18-
29, 30-39, 40-49 and 50-65 years. Exclusion criteria included individuals with a body mass index 
(BMI) >35 kg/m2, consumption of ethanol ≥70 g per day, smoking >20 cigarettes per day, taking 
regular medication for a chronic disease (diabetes mellitus, hypertension, hyperlipidemia, allergic 
disorders, depression), recent (< 15 days) recovery from acute illness, injury or surgery requiring 
hospitalization, carrier of HBV, HCV or HIV, pregnant or within 1 year after delivery. Written 
informed consent was obtained after written/verbal explanation of the study. Those with any chronic 
disease were excluded except for individuals aged 50-65 years who had well controlled hypertension 
taking up to 2 drugs. A single measurement of blood pressure, abdominal circumference and BMI was 
done after filling the study questionnaire.  
Blood collection and handling 
Blood samples were collected by trained phlebotomists into a serum separator tube for all analytes 
tested in serum, lithium heparin tube for troponin I, sodium fluoride tube for plasma glucose. Serum 
and plasma samples requiring centrifugation were spun 2-4 hours after collection and stored at −80oC 
at the Aga Khan University Hospital, Nairobi (AKUHN). Centrifugation was done at 2000g, for 10 
mins in a non-refrigerated centrifuge (Beckman coulter, Allegra X-30, Brea, California, US) These 
were subsequently shipped frozen to the PathCare reference laboratory in Cape Town, South Africa for 
analysis. We also drew 2mL of whole blood for testing hematology parameters using Beckman-Coulter 
ACT5-DIFF-CP analyser (Brea, California, US), tested in PathCare Nairobi. The test results were 
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primarily used for establishing RIs for hematology parameters (Omuse et al., 2018), but they were 
referred to in this study for secondary exclusion of individuals with latent anemia or inflammation. 
Measurements 
The analysis of all serum specimens was performed in batches on the Beckman Coulter AU 5800 
(Brea, California, US) for chemistry assays and DXI (Brea, California, US) for immunoassays as 
summarized in Table 6.1. 
 
  
Stellenbosch University  https://scholar.sun.ac.za
122 
 
Table 6.1: Summary of tests, equipment, assay methods and analytical performance 
 
 
As calculated parameters, globulin (Glb) was computed as TP – Alb; non-HDL-C as TC – HDL-C; 
HDL-C ratio (HDLrat) as TC/HDL-C. 
Analyte Abbreviation Method Units Between Run CV
Sodium Na Ion selective electrode / diluted (indirect) mmol/L 1.3
 Potassium K Ion selective electrode / diluted (indirect) mmol/L 3.8
Chloride Cl Ion selective electrode / diluted (indirect) mmol/L 1.4
Urea Urea Urease mmol/L 2.4
Creatinine Cre Modified kinetic Jaffè µmol/L 1.6
Total Protein TP Biuret g/L 4.6
Albumin Alb Bromocresol Green dye binding g/L 2.8
Total Bilirubin TBil Diazonium salt µmol/L 7.7
Gamma-glutamyl transferase GGT Gamma-glutamyl-3-carboxy-4-nitroanilide IU/L 3.3
Alkaline phosphatase ALP P-nitro-phenylphosphate hydrolysis IU/L 4.0
Lactate dehydrogenase LDH Lactate to Pyruvate IU/L 3.2
Calcium Ca Arsenazo III dye mmol/L 1.4
Magnesium Mg Xylidyl blue mmol/L 1.9
Phosphate IP Molybdate hydolysis mmol/L 1.8
Lipase Lip 1, 2-Diglyceride hydrolysis U/L 8.0
Total cholesterol TC Cholesterol oxidase mmol/L 1.2
Triglycerides TG Glycerol phosphate oxidase mmol/L 4.1
High density lipoprotein cholesterol HDL-C Two phase selective accelerator detergent mmol/L 2.0
Low density lipoprotein cholesterol LDL-C Two phase selective accelerator detergent mmol/L 1.6
Uric acid UA Modified Trinder reaction with Uricase mmol/L 1.2
High sensitive c reactive protein CRP Turbidimetry mg/L 1.8
Amylase AMY 2-chloro-4-nitrophenyl-α-D-maltotrioside U/L 8.1
Immunoglobulin A IgA Turbidimetry g/L 1.3
Immunoglobulin G IgG Turbidimetry g/L 1.1
Immunoglobulin M IgM Turbidimetry g/L 7.0
Alanine aminotransferase ALT NADH (without P-5′-P) U/L 28.1
Aspartate aminotransferase AST NADH (without P-5′-P) U/L 5.6
Creatinine kinase CK Creatine phosphate dephosphorilysation U/L 6.5
Iron Fe 2, 4, 6-Tri-(2-pyridyl)-5-triazine chromogen µmol/L 4.2
Transferrin Tf Turbidimetry g/L 2.6
Anti-thyroglobulin TgAb Two-site immune – enzymatic immunoassay IU/ml 4.8
Anti-thyroid peroxidase TPOAb Two-site immune – enzymatic immunoassay IU/ml 28.8
Thyroid stimulating hormone TSH Two-site immune – enzymatic immunoassay mIU/L 13.0
Free thyroxine FT4 Two-site immune – enzymatic immunoassay pmol/L 8.1
Free tri-iodothyronine FT3 Two-site immune – enzymatic immunoassay pmol/L 4.8
Ferritin Fer Turbidimetry µg/L 8.2
Prostate specific antigen PSA Two-site immune – enzymatic immunoassay µg/L 2.3




The PathCare reference laboratory is accredited by the South African National Accreditation System. 
For purposes of the global RI study, all participating laboratories received a panel of sera produced by 
the C-RIDL in 2014 that had assigned values (Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017). This 
panel was measured by participating laboratories to enable recalibration of RVs using linear regression 
analysis. It also allowed for alignment of RVs across different countries by all-pairwise comparison of 
test results. 
Statistical analysis 
In order to assess sex, age and BMI as sources of variation, we adopted the standard deviation ratio 
(SDR), which represents a ratio of between-subgroup SD (variation of the subgroup means from grand 
mean) to between-individual SD (approximately 0.25 the width of RI). For calculating SDRs, we first 
performed 2-level nested ANOVA to compute between-sex SD and between-age SD after partitioning 
age at 30, 40, and 50 years. With the results, the SDR for between-sex SD (SDRsex) and between-age 
SD (SDRage) were calculated as a ratio to the residual SD that corresponds to roughly between-
individual SD or SD comprizing RI (SDRI. Since between-age variation changes by sex, we also 
computed SDRage for each sex by one way ANOVA. We considered SDR≥0.40 as a primary criterion 
for judging the need for partitioning RVs by sex and/or age (Omuse et al., 2018).  
 
However, SDR represents between-subgroup difference at the center of the RV distribution, which may 
not reflect the difference (bias) at LL or UL (∆LL or ∆UL). Therefore, we also evaluated ∆LL or ∆UL 
as its ratio to SD comprising RI (SDRI) [= |UL−LL|/3.92] and expressed it as bias ratio (BR) at LL or 




  ,   BRUL = 
|UL 𝑀－ UL𝐹|
(UL𝑀𝐹 － 𝐿𝐿𝑀𝐹)/3.92
    
where subscripts of MF, M, and F attached to LL or UL indicate the RI without partition by sex (for 
male+female) and the RIs after partition by male and female, respectively (Ozarda et al., 2017). The 
same calculation was done for judging the need for age-specific RIs by setting LL, UL with/without 
partitioning by age. The distinction of the concepts between SDR and BR is illustrated in Fig 6.1.  




SDR represents between-subgroup differences at the center of distributions, while BR represents between-subgroup differences at the 
periphery (LL or UL) of the distributions. The numerator of SDR is between-subgroup SD (or SDsex, if sub-grouped by sex), while that 
of BR is a difference of LLs or ULs. 
 
In setting the threshold for the bias ratios, we followed the convention of allowable limits of bias in 
measurements: √𝑆𝐷𝐼
2 + 𝑆𝐷𝐺
2 ≤0.375, where SDI and SDG represent within-individual and between-
individual SD (7). Since SDRI or the denominator of BR is composed of both SDI and SDG and equal to 
√𝑆𝐷𝐼
2 + 𝑆𝐷𝐺
2 , we set 0.375 as a threshold for BR. This scheme was adopted in recent papers (Borai et 
al., 2020; Evgina et al., 2020). On the other hand, both SDR and BR depend on their common 
denominator, SDRI. For example, when the RI is narrow, both ratios can be inflated. Conversely, when 
the RI is wide, both ratios are suppressed. In order to cope with such situations, we set a pragmatic 
third criterion that between-subgroup bias at LL or UL (∆LL or ∆UL) should be equal to or more than 
3 times the “reporting unit (RU)” to allow partitioning of RVs. RU represents a unit of value for 
reporting test results. If the number of digits below the decimal point in reporting test results is 2, 1, or 
Fig 6.1: SD ratio (SDR) vs. bias ratio (BR) as a measure of between-subgroup differences 
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0, RU is 0.01, 0.1, or 1, respectively. The flow of logic in deciding the need for partitioning by sex or 
age is shown in Fig 6.2. 
 
 
Fig 6.2: Scheme for partitioning RVs by sex and age 
We adopted this flow-chart in judging the needs for partitioning RVs by sex and age. We defined between-sex (or -age) subgroup bias in 
reference to the three points: 1) SDR>0.4 that represents the between-subgroup bias at the center of RV distribution, 2) BR>0.375 that 
represents the between-subgroup bias at the limits (LL or UL) of RV distribution, and 3) the actual difference (bias) ≤ three reporting unit 
(RP). There were eight possible choices for the partitioning. 
 
RIs were determined using both parametric and non-parametric methods before and after applying the 
latent abnormal values exclusion (LAVE) method (Ichihara, 2014; Ichihara & Boyd, 2010). For the 
non-parametric method, the RVs coinciding with the 2.5th and 97.5th percentiles after sorting the data in 
ascending order were used as the lower and upper limits (LL, UL) of the RI. For the parametric 
method, the RVs were transformed into a Gaussian form by the Box-Cox power transformation 
formula, and then mean±1.96 SD was computed as the central 95% limits (LL−UL) under the 
transformed scale, which were then reverse transformed to get the LL and UL in the original scale 
(Ichihara, 2014).    
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As a measure for secondary exclusion of abnormal values, we tried to apply LAVE in deriving the RI 
both by parametric and nonparametric methods (Ichihara, 2014). For LAVE, we primarily used the 
following set of reference tests: Alb, Glb, UA, Glu, non-HDL, TG, ALT, AST, LDH, CK, GGT, and 
CRP, which were meant for excluding individuals with inappropriate values in the nutritional, 
inflammatory, or muscular damage markers. As an exception, for iron related analytes (Fe, Ferr, Tf, 
and TfSat), we set hemoglobin (Hb), hematocrit (Hct), and mid-corpuscular volume (MCV) in addition 
to the four iron markers as the reference tests. For proteins (TP, Alb, Glb, IgG/A/M, CRP), we set all 
the seven tests plus white blood cell and platelet counts as the reference tests.  
 
On the other hand, for determination of RIs for the thyroid panel, the LAVE procedure was not applied 
because reference tests associated with the thyroid panel were not available. Rather, we first estimated 
the cutoff values for anti-thyroglobulin antibody (TgAb), and anti-thyroid peroxidase antibody 
(TPOAb) from the probability paper plot drawn with x-axis in logarithmic scale, as an intersection of 
the central linear part with the horizontal line at 97.5 percentile as shown in Fig 6.3.  
 
 
Fig 6.3: Determination of cutoff values for TgAb and TPOAb based on the probability paper plot 
Cutoff values for thyroglobulin antibody (TgAb), and thyroid peroxidase antibody (TPOAb) were empirically determined by use of the 
probability paper plot. Y-axis represents cumulative frequencies of RV distribution, while x-axis was drawn in logarithmic scale. We 
assumed that both antibodies are specific to autoimmune thyroiditis (AIT), and thus extreme values in the tail constitutes a group of 
values from AIT cases. Therefore, we determined the cutoff value as an intersection of central linear part with the horizontal line at 
97.5%. 
For judging the need for adopting LAVE, we computed BRLL and BRUL by setting LLs and ULs of RIs 
with/without LAVE: i.e., SDRI in the denominator was set to the RI by the LAVE procedure. The 90% 
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confidence intervals (CIs) of LL and UL were derived by the bootstrap method with resampling of the 
final set of RVs and repeated computations of LL and UL for 50 iterations. Accordingly, final RIs were 
determined as the averages of LL and UL thus derived. 
 
6.4 Results 
Profile of the subjects 
Out of 596 volunteers, 533 met the inclusion criteria: 260 (48.8%) males and 273 (51.2%) females. The 
main reason for exclusion was hypertension as shown in Fig 6.4.  
 
 
Fig 6.4: Study flowchart 
BMI: body mass index, CBC: complete blood count, DM: diabetes mellitus, HIV: Human Immunodeficiency Virus, HTN: hypertension. 
*On antibiotics, blood donation in past 3 months, on treatment for hypothyroidism, > 65 years, > 65 years and hypertensive, rheumatic 
heart disease, prostate cancer 
 
The median age was 39 years with a range of 18-65 years. The participant characteristics are 
summarized in Table 6.2. 




Sources of variation 
Sex, age and BMI as sources of variation were explored with SDR≥0.4 regarded as being significant as 
shown in Table 6.3.  
Table 6.3: Standard deviation ratios for between sex and age 
 
SDRsex SDRsex
M+F M+F M F M+F M+F M F
TP 0.00 0.36 0.38 0.35 ALT 0.56 0.42 0.31 0.52
Alb 0.50 0.54 0.56 0.53 AST 0.48 0.26 0.09 0.34
Glb 0.32 0.00 0.00 0.00 ALP 0.00 0.47 0.16 0.66
Urea 0.30 0.32 0.21 0.42 AMY 0.05 0.00 0.00 0.00
eGFR 0.00 0.32 0.34 0.29 LDH 0.00 0.22 0.00 0.31
UA 0.89 0.38 0.41 0.33 CK 0.50 0.08 0.02 0.12
Cre 1.19 0.24 0.30 0.14 GGT 0.51 0.28 0.35 0.14
TBil 0.48 0.27 0.21 0.32 Iron 0.39 0.09 0.10 0.08
Na 0.00 0.38 0.14 0.47 Ferr 0.78 0.26 0.22 0.45
K 0.00 0.23 0.22 0.25 TF 0.43 0.18 0.18 0.18
Cl 0.44 0.30 0.38 0.18 TFSat 0.50 0.00 0.00 0.00
Ca 0.16 0.29 0.31 0.26 CRP 0.10 0.31 0.37 0.25
IP 0.21 0.20 0.22 0.17 IgA 0.00 0.24 0.15 0.31
Mg 0.00 0.46 0.38 0.52 IgG 0.10 0.12 0.17 0.07
Glu 0.00 0.41 0.44 0.39 IgM 0.48 0.12 0.15 0.08
TC 0.00 0.41 0.41 0.42 FT3 0.12 0.04 0.00 0.09
TG 0.22 0.58 0.56 0.60 FT4 0.00 0.36 0.35 0.37
HDL-C 0.33 0.00 0.00 0.00 TSH 0.00 0.00 0.00 0.03
HDLrat 0.33 0.38 0.39 0.37 TgAb 0.00 0.28 0.27 0.28
nonHDL 0.00 0.45 0.44 0.46 TPOAb 0.09 0.04 0.06 0.03
LDL-C 0.00 0.42 0.40 0.43 Trop I 0.00 0.08 0.00 0.09
Lip 0.07 0.16 0.17 0.15 PSA 0.39
SDR≧0.4 shown in bold; SDR≧0.5 oange background
SDRage SDRage
Median (IQR) Min-Max Median (IQR) Min-Max Median (IQR) Min-Max
Age (years) 39 (18) 20-65 39 (21) 18-64 39 (20) 18-65
Height (cms) 172 (8) 156-191 160 (9) 143-191 167 (13) 143-191
Weight (kg) 74 (19) 46-116 68 (16) 38-109 70 (18) 38-116
BMI (kg/m2) 24.9 (5.6) 16.3-34.9 26.1 (6.3) 17.1-38.1 25.5 (5.9) 16.3-38.1
BSA (m2) 1.88 (0.24) 1.44-2.36 1.72 (0.20) 1.27-2.24 1.78 (0.22) 1.27-2.36
AC (cm) 91 (15) 65-124 86 (16) 64-115 89 (17) 64-124
BP Systolic (mmHg) 127 (18) 84-179 128 (18) 118 (20) 124 (21) 77-194
BP Diastolic (mmHg) 81 (12) 56-101 79 (14) 57-112 80 (14) 56-112
AC: abdominal  ci rcumference;  BMI: body mass  index;  BSA: body surface area;  IQR: interquarti le range
Male (n=260) Female (n=273) Total (n=533)
Table 6.2: Descriptive characteristics of participants 




Between-sex differences exceeded that level in Alb, UA, Cre, TBil, Cl, ALT, AST, CK, GGT, Ferr, Tf, 
TfSat, and IgM. Similarly, between-age subgroup differences were significant for Alb, Cl, Glu, and TG 
in males, and for Alb, urea, Na, Mg, Glu, TC, TG, HDLrat, LDL-C, ALT, ALP, and Ferr in females. 
BMI was an independent source of variation for UA, Glu, TC, HDLrat, nonHDL-C, LDL-C, ALT, 
AST, LDH, and GGT in males, and for CRP only in females. Graphical representations of reference 
value distribution sub-grouped by sex and age are shown for 12 representative analytes in Fig 6.5 and 
for all analytes in Fig S6.1. 




Fig 6.5: Sex and age-related changes for 12 analytes 
The distributions of reference values are shown based on age and sex stratification for 12 analytes. The SDRsex and SDRage for each sex 
are shown at the top of each analyte chart. No secondary exclusion was performed in plotting the data. The box in each scattergram 
represents central 50% range and the vertical bar in the middle represents a median point. 
 




Generally, the parametric method resulted in similar or lower RI ULs, and narrower 90% CIs for the 
LL and UL of the RIs compared to the non-parametric method as shown in Fig S6.2. Besides, the 
accuracy of Gaussian transformation by the parametric method was confirmed as shown in Fig S6.3. 
Therefore, we adopted the RIs derived by the parametric method exclusively. In addition, we could not 
calculate a RI for Trop I because 94.7% of RVs were below detection limit. For TgAb and TPOAb, we 
determined cutoff values by use of the probability paper plot as 2.5 IU/ml and 5.0 IU/mL respectively 
as shown in Fig 6.3. We regarded individuals who had antibody values exceeding either of the cutoffs 
(7.7% of males and 13.6% of females) as possible autoimmune thyroiditis (AIT), and excluded them 
when calculating RIs for thyroid function tests.  
 
The LAVE method resulted in significant differences in LL or UL (BRUL or BRLL > 0.375) for some 
analytes as shown in Table S6.1. For example, UL lowered for AST, ALT, CRP; LL raised for Fe. 
 
Based on the decision flow chart shown in Fig 6.2, RIs for TP, Alb, Glb, Na, K, Cl, Ca, IP, Glu, TG, 
HDL-C, nonHDL, Lip, AMY, LDH, CRP, Fe, IgG and IgA were not partitioned by sex as shown in 
Table 6.4. For age partitions, although the mean age of menopause for females is about 50 years, we 
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Table 6.4: Proposed reference intervals 
 
 
A comparison of our RIs with those recommended by Beckman coulter and those derived from IFCC 
studies conducted in India, Saudi Arabia and Turkey found much higher RIs for TBil as shown in 
Table 6.5. A similar comparison that also includes studies carried out in other African countries is 
shown in Table S6.2.  
Item Units Age n LL UL n LL UL n LL UL
TP g/L All 526 67 83
~45 349 39 50
45~ 150 39 47
Glb g/L All 524 24 38
All 258 2.4 6.6
~45 145 1.8 5.2
45~ 83 1.8 6.4
UA mmol/L All 259 238 532 272 178 417
Cre µmol/L All 260 58 109 271 45 86
TBil µmol/L All 257 6 43 271 5 27
Na mmol/L All 531 134 142
K mmol/L All 531 3.4 4.8
Cl mmol/L All 501 100 110
Ca mmol/L All 531 2.19 2.57
IP mmol/L All 533 0.78 1.42
All 260 0.73 0.98
~45 174 0.71 0.93
45~ 99 0.76 1.01
~45 345 3.9 5.8
45~ 172 4.4 7.3
All 260 3.1 6.9
~45 174 3.1 6.2
45~ 99 3.2 7.1
~45 289 0.47 2.60
45~ 154 0.55 3.70
HDL-C mmol/L All 530 0.7 1.7
All 259 2.6 7.6
~45 174 2.4 5.9
45~ 98 2.7 6.7
nonHDL mmol/L All 532 2.0 5.6
All 260 1.6 4.8
~45 174 1.5 4.2
45~ 99 1.7 4.9
Lip U/L All 527 9 68
ALT IU/L All 202 10 55 229 7 30
AST IU/L All 206 17 40 227 15 29
All 260 53 153
~45 172 47 130
45~ 99 55 174
AMY IU/L All 530 47 164
LDH IU/L All 530 138 257
CK IU/L All 259 72 460 268 53 260
GGT IU/L All 199 13 90 269 10 50
CRP mg/L All 425 0.21 14.67
Fe µmol/L All 412 8.8 28.9
All 253 10 475
~45 173 2 150
45~ 99 0 222
Tf g/L All 254 1.9 3.2 206 2.0 3.5
TfSat % All 208 15 49 211 10 44
IgG g/L All 525 11.1 20.0
IgA g/L All 526 1.05 4.63
IgM g/L All 254 0.38 2.29 272 0.51 2.77
FT3 pmol/L All 467 3.9 6.3
FT4 pmol/L All 468 7.8 14.1
TSH mIU/L All 461 0.61 4.86










M + F M F
Alb g/L
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Table 6.5: Comparison of reference intervals 
Key: M+F-Male & Female; M-Male; F-Female; 1(AU Reagent Quick Reference Guide, 2018), 2(Borai et al., 2016), 3(Ozarda et al., 2014), 4(S. Shah, Ichihara, Dherai, & Ashavaid, 2018) 
Test Units Age LL UL LL UL LL UL Age LL UL LL UL LL UL Age LL UL LL UL LL UL Age LL UL LL UL LL UL Age LL UL LL UL LL UL
TP g/L 18-65 67 83 NA 66 83 18-65 66 83 20-79 66 82 18-65 68 86
18-65 NA 35 52 18-65 39 50 20-79 41 49 18-65 36 47
18-44 40 51 38 49
45-65 40 47 38 46
18-65 2.4 6.6 NA 2.8 7.2 18-65 2.8 7.3 2.1 6.4 18-65 2.2 6.0
18-44 1.8 5.3 20-49 2.95 7.20 2.21 6.12 18-45 1.9 5.1
45-65 1.9 6.2 50-79 2.85 7.96 46-65 2.4 6.7
UA µmol/L 18-65 243 507 178 417 NA 208.3 428.4 154.7 357 18-65 223 444 148 321 20-79 226 458 166 345 18-65 248 509 159 404
Cre µmol/L 18-65 58 109 45 86 NA 59 104 45 84 18-65 66 111 50 74 20-79 59 92 50 71 18-65 58 95 35 74
TBil µmol/L 18-65 6 43 5 27 NA 5 21 18-65 3.6 22.4 2.2 15.5 20-79 3.8 24.1 2.7 15.9 18-65 6.2 23.7 4 17.3
Na mmol/L 18-65 134 142 NA 136 146 18-65 135 144 20-79 137 144 18-65 135 146
K mmol/L 18-65 3.4 4.8 NA 3.5 5.1 18-65 3.7 4.9 20-79 3.7 4.9 18-65 3.8 5
Cl mmol/L 18-65 100 110 NA 101 109 18-65 101 111 20-79 99 107 18-65 102 113
Ca mmol/L 18-65 2.19 2.57 NA 2.2 2.65 18-65 2.11 2.56 20-79 2.15 2.47 18-65 2.1 2.44
IP mmol/L 18-65 0.78 1.42 NA 0.81 1.45 18-65 0.81 1.44 20-79 0.8 1.4 18-65 0.8 1.43
18-65 0.73 0.98 NA 0.73 1.06 0.77 1.03 18-65 0.71 0.96 20-79 0.77 1.06 18-65 0.77 1.07
18-44 0.71 0.93
45-65 0.76 1.01
18-65 NA 4.1 5.9 18-65 4 5.9 20-79 3.96 5.88 18-65
18-44 3.9 5.8 18-45 4.1 5.5
45-65 4.4 7.3 46-65 4.3 6.0
18-65 NA 5.2 18-65 3.5 6.36 18-65 2.9 6.6
18-45 3.10 6.10 20-49 3.22 6.45 3.20 6.42 3.20 6.38 18-45 3.1 6.2
46-65 3.20 7.20 50-79 3.93 7.92 46-65 2.5 6.7
18-65 NA 1.7 18-65 0.5 3.58 0.39 1.6 18-65 0.6 2.7 0.5 2.1
18-45 0.50 2.88 0.45 2.03 20-49 0.53 3.39 0.46 2.52 18-45
46-65 0.53 3.87 0.55 3.24 50-79 0.64 3.55 46-65
HDL-C mmol/L 18-65 0.70 1.70 NA 1.03 1.55 18-65 0.74 1.76 0.98 2.19 0.85 1.52 0.95 1.56 18-65 0.7 1.5 0.8 1.8
18-65 1.60 4.80 NA 2.60 18-65 1.8 4.34 18-65 1.7 4.4
18-44 1.50 4.20 20-49 1.47 3.92 1.60 4.01 1.32 3.92 18-45
45-65 1.70 4.90 50-79 1.78 4.91 46-65
Lip U/L 18-65 8 75 10 63 NA 67 18-65
ALT IU/L 18-65 10 55 7 30 NA 50 35 18-65 7 39 5 18 9 57 7 28 18-65 15 74 10 37
AST IU/L 18-65 17 40 15 29 NA 50 35 18-65 11 28 10 24 13 30 11 25 18-65 20 53 17 39
18-65 53 153 NA 30 120 39 114 18-65 41 111
18-44 47 130 20-49 38 112 43 116 34 97 18-45 35 100
45-65 55 174 50-79 47 133 46-65 43 117
AMY IU/L 18-65 47 164 NA 22 80 18-65 31 117 34 119 18-65 36 135
LDH IU/L 18-65 138 257 NA 248 247 18-65 10 238 126 220 18-65 104 206
CK IU/L 18-65 72 460 53 260 NA 171 145 18-65 54 266 27 138 48 227 34 131 18-65 48 304 36 184
GGT IU/L 18-65 13 90 10 47 NA 55 38 18-65 11 65 7 21 11 69 7 33 18-65 14 62 11 40
Fe µmol/L 18-65 8.8 28.9 NA 12.5 32.2 10.7 32.2 18-65 7.9 29.6 3.7 26 5.9 31.6 3.5 27.8 18-65 7 33 4 26
18-65 20 457 NA 20 250 10 120 18-79 4.7 136 18-65
18-44 5 150 18-44 13 276 4.3 91
45-65 12 232 45-79 5.9 175
Tf g/L 18-65 1.9 3.2 2.0 3.5 NA 2 3.6 18-65 2 3.2 2.1 3.9 18-79 1.8 3.3 1.8 3.3 1.9 3.5 18-65 2.2 4
TfSat % 18-65 13 47 18-65
CRP mg/L 18-65 0.21 14.7 NA 1 18-65 0.2 11.8 18-65 0.33 7.34 0.35 11.9
IgA g/L 18-65 1.05 4.63 NA 0.7 4 18-65 0.94 4.35
IgG g/L 18-65 11.1 20.0 NA 7 16 18-65 9.1 20.4
IgM g/L 18-65 0.38 2.29 0.51 2.77 NA 0.4 2.3 18-65 0.4 2.54 0.51 3.1
FT3 pmol/L 18-65 3.9 6.3 NA 3.8 6 18-65
FT4 pmol/L 18-65 7.8 14.1 NA 7.86 14.41 18-65
TSH mIU/L 18-65 0.61 4.86 NA 0.38 5.33 18-65









F M+F M F
Alb g/L
F M+F M F M+F M
PRESENT STUDY KENYA BECKMAN AU1 SAUDI ARABIA2 TURKEY3 INDIA4
M+F M F M+F M
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Standardization of the RIs 
Since this study utilized a serum panel provided by C-RIDL which comprised 50 samples with values 
assigned to 25 chemistry analytes, we confirmed the standardized status of the assays as shown in S6.4 
Fig. For the method comparison, major-axis regression was used to express the structural relationship 
between our test results and the panel assigned values by calculating BRLL or BRUL as a difference of 
LL or UL before and after the recalibration using the regression coefficients. As a result, we found it 
necessary to recalibrate our RIs for HDL-C and LDH. For Na, we could not get a good linear 
relationship because of poor precision of the assay with the narrow reference interval. 
 
6.5 Discussion 
There have been controversies over the statistical methods used in deriving RIs. They include: selection 
between parametric and nonparametric methods, how and when to exclude RVs secondarily, and when 
to partition RVs into subgroups by sex and age. In this study we sought optimal options for each. We 
found the nonparametric method of limited use with its wider 90% CI for RIs and frequent bias in UL 
(Fig S6.1), while the parametric method was found to be more reliable after successful Gaussian 
transformation (Fig S6.3) For secondary exclusion, we found LAVE procedure effective for reducing 
the influence of over nutrition for those analytes with high association with BMI such as TG, ALT, 
AST, and CRP. It was also effective in reducing the influence of latent inflammation and anemia on Fe, 
Tf and TfSat.  
 
In order to decide the need for partitioning RVs into subgroups by sex or age, we primarily used SDR, 
but it tended to provide an inflated value when the width of the RI was narrow. Another problem of 
SDR is that it reflects between-subgroup difference at the central part which may not reflect between-
subgroup bias at the LL or UL, hence the use of BRLL or BRUL. Furthermore, we found it necessary to 
confirm the appropriateness of BRLL or BRUL by quantitating the actual difference at LL or UL by use 
of the reporting unit (RU). We chose to adopt partitioned RIs only when the difference at LL or UL 
was ≥3RU. We believe this three-way consideration ensured optimal judgement in partitioning RIs by 
sex and age as shown in Table S6.1. 
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RIs can vary appreciably across different populations as demonstrated in the interim report of the 
global study analyzing RVs of 12 countries (Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017). They 
identified ethnic differences in many analytes such as Alb, urea, TBil, HDL-C, CRP, IgG, C3, and 
PTH. In reference to the RV profiles, we noted certain unique features of Kenyan RIs. For instance, our 
urea RIs are lower than those from Turkey and Saudi Arabia. Although most of our RIs for liver 
function tests were similar to published reports from Saudi Arabia and Turkey (Borai et al., 2016; 
Ozarda et al., 2014), our TBil RI of 6-43 µmol/L for males and 5-27 µmol/L for females is almost 
double what has been reported in published studies from outside the African continent as shown in 
Table S6.2 (Borai et al., 2016; Ichihara, Ceriotti, Kazuo, et al., 2013; Kratz et al., 2004; Ozarda et al., 
2014; S. Shah et al., 2018). We hypothesize that Gilbert’s syndrome, the commonest genetic cause of 
asymptomatic unconjugated hyperbilirubinaemia, could be quite prevalent in our population. Genetic 
studies would thus be useful in elucidating the cause of hyperbilirubinaemia observed in our study. 
 
Our electrolytes didn’t differ much from other published IFCC studies except that Mg levels increased 
with age in females. It has been documented that reduced levels of oestrogen are associated with 
increased Mg levels in post-menopausal women as well as in the follicular phase of the menstrual cycle 
in women of reproductive age (Dullo & Vedi, 2008; Lindsay, Hart, & Forrest, 1980).  
 
Our TC and TG RIs were higher than those reported by Kibaya et al who carried out a similar study in 
a rural Kenyan population (Kibaya et al., 2008). Our study population was primarily composed of 
urban dwellers of whom 25.6% had metabolic syndrome (Omuse, Maina, Hoffman, et al., 2017). 
According to the third report of the National Cholesterol Education Program (NCEP), the desirable 
LDL-C level for low risk adults is <4.1 mmol/L (NCEP, 2001). Our UL for LDL-C in males (4.8 
mmol/L) and in females (4.2 and 4.9 mmol/L) are higher than the NCEP targets. However, the NCEP 
clinical decision limits (CDLs) are used for diagnosis of hyperlipidaemia and serve as treatment targets 
for reducing cardiovascular risk. Aside from the risk of over-nutrition, the RI ULs for TC and LDL-C 
are important in diagnosing cholestatic conditions and hypothyroidism. These are relatively short-term 
conditions unrelated to occurrence of atherosclerosis hence the RIs are more relevant than CDLs in 
their diagnosis. On the other hand, determination of LLs for TC or LDL-C RIs are essential for 
diagnosing malnutrition or thyrotoxicosis. Therefore, we are not replacing the derived RIs with those 
CDLs, rather providing CDLs in the footnote of test result report sheet. 
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We obtained fasting plasma glucose (FPG) RIs of 3.9−5.8 and 4.4−7.3 mmol/L for those aged <45 and 
≥45 years respectively. The former RI is comparable to what was obtained in Turkey (3.96−5.88 
mmol/L) and Saudi Arabia (4.0−5.9 mmol/L) (Borai et al., 2016; Ozarda et al., 2014). The American 
Diabetes Association (ADA) uses FPG ≥ 5.6 and 7.0 mmol/L to define pre-diabetes and diabetes 
respectively. Based on the ADA criteria, a total of 63 out of 528 participants would have been 
classified as having elevated values compared to 20 if the ULs of the derived RIs were used.   
 
Our RIs for immunoglobulins are higher than those derived in the US but very similar to those derived 
in India (Kratz et al., 2004; S. Shah et al., 2018). Karita et al also found high levels of IgG in several 
SSA countries (Karita et al., 2009). We hypothesize that this may be due to inflammation caused by 
increased exposure to either infectious disease agents or environmental allergens. The increased 
inflammation is further evidenced by the very high RI UL for CRP of 14.7 mg/L compared to 1 mg/L 
recommended by Beckman Coulter (AU Reagent Quick Reference Guide, 2018). Ichihara et al in a 
similar study carried out in Asia found that the closer the country or region was to the equator, the 
higher the serum concentrations of positive inflammatory markers (IgG, C3, CRP) a phenomenon they 
ascribed to increased exposure to infectious agents (Ichihara, Ceriotti, Tam, et al., 2013). Similar to the 
IFCC study in India, IgM was significantly higher in female participants requiring the determination of 
sex specific RIs (S. Shah et al., 2018). We hypothesize that this could be linked to the role that estrogen 
plays in enhancing humoral immunity (Taneja, 2018). 
 
Ichihara et al has demonstrated that BMI is a major source of variation in RVs for many analytes and 
that the magnitude of this association varies across different populations (Ichihara, Ozarda, Barth, Klee, 
Shimizu, et al., 2017). For example, a similar change in BMI resulted in a greater decline in HDL 
cholesterol amongst the Japanese (r = −0.39) compared to people from Pakistan (r = −0.05). On the 
other hand, an increase in BMI was associated with a greater increase in ALT values (r=0.48) amongst 
non-black South Africans compared to black South Africans (r=0.02) (Ichihara, Ozarda, Barth, Klee, 
Shimizu, et al., 2017). BMI was a source of variation for several analytes in males especially those 
known to be associated with the presence of metabolic syndrome such as Glu, LDL-C, and ALT. We 
did not partition our RIs by BMI because the influence of BMI was suppressed by use of the LAVE 
method. 
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For iron markers, we also applied LAVE to reduce the influence of latent anemia. Although it was very 
effective in raising their LLs, the female LL for ferritin was still lower than the WHO cutoff value of 
<15 µg/L for iron deficiency (WHO, 2011b). 
 
The strengths of our study include the deliberate recruitment of healthy individuals using a harmonized 
protocol to ensure pre-analytical confounders were minimized, centralized analysis of samples in an 
accredited laboratory with excellent internal quality control, standardization of the RIs by use of a 
value-assigned panel of sera and use of the LAVE procedure to reduce the influence of sub-clinical 
disease on the derived RIs. 
 
The weaknesses include failure to perform infectious serology to rule out chronic infections such as 
HIV, HBV or HCV, and over representation of an urban population hence limiting the generalizability 
of our findings to a rural population.  
Conclusion 
According to the harmonized IFCC-C-RIDL protocol, we established RIs for 40 major chemistry and 
immunoassay tests from well-defined healthy Kenyan volunteers by use of the up-to-date statistical 
methods for the first time in Africa. The LAVE method was effective in reducing the influence on RIs 
of latent anemia and metabolic disorders. Based on SD ratio and bias ratios, we developed a flow chart 
to judge the need for partitioning RVs by sex and age subgroups, which we believe is helpful for the 
future RI study. RIs for chemistry analytes were standardized by use of a value assigned serum panel, 
and thus could be shared across sub-Saharan African laboratories with similar ethnic and life-style 
profile. As a whole, Kenyan RIs were comparable to those of other countries participating in the global 
study with a few exceptions such as higher ULs for TBil and CRP. 
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Fig S6.1: Sex and age-related changes 
The distributions of reference values are shown based on age and sex stratification for all analytes. The SDRsex and 
SDRage for each sex are shown at the top of each analyte chart. No secondary exclusion was performed in plotting the data. 
The box in each scattergram represents central 50% range and the vertical bar in the middle represents a median point. 
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Fig S6.2: Bar-chart comparison of reference interval calculation methods 
The RIs of all analytes were derived in four ways by parametric (P) or nonparametric (NP) method with/without the LAVE 
procedure, separately in males+Females (MF), males, and females. Each horizontal bar represents the range of the RI, and 
the vertical line in the center corresponds to the mid-point. The shades on both ends of the bar represent 90%CI for the 
limits of the RI predicted by the bootstrap method. 
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Fig S6.3: Results of Gaussian transformation by the parametric method 
The accuracy of Gaussian transformation by Box-Cox formula can be assessed from theoretical Gaussian curves in two histograms shown 
on left top (before and after the transformation) of each panel. Accuracy can be also seen from the linearity in probability paper plot on 
the right. The limits of the RI by nonparametric method corresponds to the points where red zigzag line intersect with horizontal 2.5 and 
97.5 % red lines of cumulative frequencies. 
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Fig S6.4: Panel test results for assessment of standardized status of assays 
The panel of sera from 50 healthy volunteers, each of which were value assigned for 40 chemistry analytes were measured. Our measured 
values were plotted on Y-axis and assigned values on X-axis. Major axis linear regression was used as a structural relationship for the 
method comparison. The Y=X line is shown as a diagonal broken line. 
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Table S6.1: Reference intervals and determination of method, sex and age bias 
 






LAVE Age n LL Me UL n LL Me UL n LL Me UL BRLL BRUL BRLL BRUL BRLL BRUL
2 (-) 526 67 74 83 254 68 74 83 271 66 74 84 0.49 -0.25
2 (+) 414 67 74 82 195 68 74 82 215 66 74 82 0.00 0.00 0.00 0.26 0.28 0.49 0.52 0.00
2 (-) 527 38 44 50 255 40 45 51 272 38 43 48 0.65 0.98
2 (+) 423 39 44 50 197 41 45 51 216 38 43 49 -0.36 -0.39 0.00 0.00 0.00 -0.36 1.07 0.71
2 (-) 349 39 44 50 176 40 45 51 173 38 43 49 0.71 0.71 0.00 0.71 0.00 0.78
2 (+) 292 39 44 50 148 40 45 51 145 38 43 49 0.00 0.00 0.00 0.00 0.00 0.00 0.71 0.71 0.00 1.57 0.00 1.07
2 (-) 183 38 43 48 84 40 44 49 99 38 42 47 0.78 0.78
2 (+) 150 39 43 47 66 40 43 47 83 38 42 46 -0.49 0.00 0.00 0.49 1.12 0.49 0.98 0.49
2 (-) 524 24 30 38 255 24 29 36 270 24 31 39 0.00 -0.84
2 (+) 435 24 30 37 204 24 29 36 221 24 31 37 0.00 0.00 0.00 0.30 0.00 0.60 0.00 -0.30
1 (-) 530 2.0 3.5 6.1 258 2.4 3.7 6.6 272 1.9 3.2 5.8 0.48 0.76
1 (+) 395 2.0 3.4 6.0 198 2.3 3.6 6.3 218 1.9 3.2 5.9 0.00 0.10 0.00 0.10 0.29 -0.10 0.39 0.39
1 (-) 349 2.0 3.3 5.8 175 2.4 3.6 6.5 174 1.8 3.1 5.3 0.62 1.24 0.00 -0.47 -0.10 -0.90
1 (+) 284 2.0 3.3 5.6 145 2.4 3.5 6.3 145 1.8 3.0 5.2 0.00 0.00 0.00 0.22 0.20 0.12 0.65 1.20 0.10 0.00 0.00 -1.18
1 (-) 182 2.1 3.7 6.6 84 2.4 3.9 7.0 99 1.9 3.6 6.2 0.44 0.70
1 (+) 149 2.1 3.7 6.4 66 2.3 3.8 6.3 83 1.8 3.6 6.4 0.00 0.10 0.09 0.18 0.69 -0.17 0.46 -0.09
1 (-) 532 183 308 489 259 238 350 532 272 178 268 417 0.77 1.47
1 (+) 407 184 297 459 204 243 349 507 221 178 264 403 -0.01 -0.07 0.00 0.43 0.37 0.24 0.93 1.48
1 (-) 531 47 70 108 260 58 80 109 271 45 61 86 0.84 1.48
1 (+) 394 46 69 105 198 58 81 108 218 44 61 84 0.07 0.00 0.10 0.20 0.08 0.20 0.93 1.59
1 (-) 530 5 11 35 257 6 13 43 271 5 9 27 0.13 2.09
1 (+) 394 5 11 35 197 6 13 40 217 5 10 26 0.00 0.00 0.00 0.00 0.35 0.19 0.13 1.83
1 (-) 531 134 138 142 258 135 138 141 272 134 137 142 0.49 -0.49
1 (+) 394 134 138 142 197 135 138 141 218 134 137 142 0.00 0.00 0.00 0.00 0.00 0.00 0.49 -0.49
1 (-) 348 134 137 141 175 135 138 141 173 134 137 141 0.52 -0.03 0.54 -0.29 -0.05 -0.65
1 (+) 283 134 138 141 144 135 138 141 144 134 137 141 -0.15 -0.06 -0.12 -0.06 0.06 0.03 0.46 -0.05 0.33 -0.11 0.05 -0.65
1 (-) 183 134 138 142 84 134 138 142 99 134 138 143 0.00 -0.46
1 (+) 149 134 138 142 66 134 138 141 83 134 138 143 0.05 -0.24 0.00 0.08 0.21 0.02 0.20 -0.61
1 (-) 531 3.4 3.9 4.8 259 3.3 3.9 4.9 273 3.5 4.0 4.8 -0.49 0.24
1 (+) 394 3.4 3.9 4.8 198 3.4 3.9 4.9 218 3.5 4.0 4.8 0.00 -0.23 0.00 0.00 0.00 0.00 -0.24 0.24
1 (-) 531 100 105 110 258 100 104 109 272 101 106 110 -0.39 -0.39
1 (+) 395 101 105 110 198 100 104 109 218 102 106 110 -0.44 0.00 -0.49 0.00 0.00 0.00 -0.87 -0.44
1 (-) 349 100 105 109 173 101 105.7 110 134 100 104 108 0.10 0.61 -0.62 -0.34 -0.71 -1.22
1 (+) 183 101 106 110 99 102 106.2 111 65 101 106 109 -0.25 -0.13 -0.18 -0.54 -0.52 -0.42 0.22 0.37 -0.35 -0.50 -0.60 -1.19
1 (-) 175 100 104 108 266 101 104.9 109 134 102 106 110 -0.03 -0.38
1 (+) 83 100 105 110 137 101 106 110 79 102 106 111 -0.13 -0.35 0.17 -0.67 -0.52 -0.51 -0.07 -0.40
1 (-) 531 2.19 2.36 2.57 259 2.21 2.38 2.56 273 2.18 2.35 2.57 0.31 -0.10
1 (+) 395 2.20 2.36 2.55 197 2.21 2.38 2.57 219 2.19 2.34 2.54 -0.11 0.00 -0.11 0.22 -0.11 0.34 0.22 0.34
1 (-) 533 0.78 1.10 1.42 260 0.75 1.07 1.38 273 0.82 1.12 1.44 -0.43 -0.37
1 (+) 396 0.77 1.09 1.43 198 0.74 1.06 1.36 219 0.82 1.12 1.44 0.06 0.06 0.00 -0.06 0.13 0.00 -0.48 -0.48
1 (-) 533 0.73 0.85 0.98 260 0.73 0.85 0.98 273 0.72 0.85 0.98 0.16 0.00
1 (+) 396 0.72 0.85 0.98 198 0.73 0.85 0.98 219 0.72 0.85 0.98 0.15 0.00 0.00 0.00 0.00 0.00 0.15 0.00
1 (-) 350 0.72 0.83 0.95 176 0.72 0.83 0.97 174 0.71 0.83 0.93 0.10 0.61 -0.62 -0.34 -0.71 -1.22
1 (+) 285 0.72 0.83 0.95 145 0.73 0.83 0.96 145 0.72 0.83 0.94 0.00 -0.17 -0.05 0.00 0.17 -0.08 0.22 0.37 -0.35 -0.50 -0.60 -1.19
1 (-) 183 0.76 0.88 1.00 84 0.76 0.88 0.99 99 0.76 0.88 1.01 -0.03 -0.38
1 (+) 149 0.76 0.88 1.01 66 0.75 0.88 0.99 83 0.76 0.88 1.02 0.00 0.11 0.06 -0.16 0.00 -0.04 -0.07 -0.40
1 (-) 512 3.9 4.9 6.2 247 4.0 4.9 6.3 268 3.9 4.8 6.1 0.17 0.34
1 (+) 395 3.9 4.8 6.1 195 4.1 4.9 6.4 224 3.9 4.8 6.1 0.00 -0.17 0.00 0.18 -0.17 0.00 0.36 0.53
1 (-) 345 3.9 4.7 5.8 173 3.9 4.8 5.8 172 3.8 4.6 5.7 0.21 0.21 -1.02 -3.75 -0.89 -1.78
1 (+) 287 3.9 4.7 5.7 146 3.9 4.7 5.8 151 3.8 4.6 5.8 0.00 0.00 0.00 0.22 0.00 -0.20 0.22 0.00 -1.02 -4.94 -0.89 -1.43
1 (-) 172 4.4 5.2 7.3 77 4.5 5.3 8.0 97 4.3 5.2 6.7 0.27 1.76
1 (+) 144 4.4 5.2 7.1 62 4.5 5.2 8.7 83 4.3 5.2 6.6 0.00 0.00 0.00 0.29 -0.65 0.17 0.29 3.05
1 (-) 532 3.1 4.6 6.7 260 3.1 4.7 6.9 273 3.1 4.6 6.6 0.00 0.33
1 (+) 396 3.2 4.5 6.6 198 3.2 4.7 6.7 219 3.3 4.6 6.6 -0.12 -0.11 -0.24 0.12 0.22 0.00 -0.12 0.12
1 (-) 350 3.1 4.5 6.4 176 3.1 4.5 6.6 174 3.1 4.4 6.2 0.00 0.48 0.00 -0.83 -0.11 -1.01
1 (+) 285 3.1 4.4 6.1 145 3.2 4.5 6.3 145 3.1 4.3 6.1 0.00 -0.13 0.00 0.39 0.38 0.13 0.13 0.26 -0.34 -1.01 -0.48 -1.07
1 (-) 183 3.2 5.0 7.2 84 3.1 5.1 7.4 99 3.2 4.9 7.1 -0.10 0.29
1 (+) 149 3.5 4.9 6.9 66 3.5 5.0 7.2 83 3.5 4.8 7.0 -0.35 -0.42 -0.34 0.35 0.21 0.11 0.00 0.23
1 (-) 528 0.49 1.03 3.49 258 0.50 1.17 4.14 272 0.47 0.91 2.85 0.04 1.69
1 (+) 403 0.49 0.96 2.95 204 0.52 1.19 3.51 225 0.47 0.89 2.70 0.00 -0.03 0.00 0.86 0.83 0.26 0.08 1.29
1 (-) 346 0.49 0.90 2.99 175 0.51 1.07 3.29 173 0.46 0.78 2.29 0.08 1.57 -0.05 -2.53 -0.15 -1.94
1 (+) 289 0.47 0.86 2.60 149 0.50 1.02 2.88 146 0.45 0.75 2.03 0.04 0.02 0.02 0.72 0.68 0.65 0.09 1.56 -0.04 -1.30 -0.18 -2.13
1 (-) 181 0.55 1.32 4.26 83 0.56 1.49 5.64 99 0.55 1.18 3.47 0.01 2.29
1 (+) 154 0.55 1.25 3.70 71 0.53 1.41 3.87 84 0.55 1.17 3.24 0.00 0.04 0.00 0.70 2.08 0.34 -0.02 0.78
All
Partition by age, LAVE+ ~45
45~
TG mmol/L 0.01 0.23 0.55 0.59
0.41
All





Partition by age, LAVE-~45
45~
TC mmol/L 0.1 0.00 0.37




Glu mmol/L 0.1 0.00 0.62 0.59
All No partiion by sex/age. LAVE-
Mg mmol/L 0.01 0.00 0.37 0.54
All
0.26 All No partiion by sex/age. LAVE-
IP mmol/L 0.01 0.21 0.22 0.16
All
No partiion by sex/age. LAVE- 




Ca mmol/L 0.01 0.15 0.31
0.22 All No partiion by sex/age. LAVE-
Cl mmol/L 1 0.45 0.41 0.21
All
No partiion by sex/age. with 




K mmol/L 0.1 0.00 0.20
Na mmol/L 1 0.00 0.09 0.49
Partition by sex. Use LAVE-
TBil µmol/L 1 0.48 0.21 0.30 All Partition by sex. Use LAVE-
Partition by sex. LAVE-
Cre µmol/L 1 1.21 0.27 0.14 All




UA mmol/L 1 0.94 0.39 0.31 All
No partition by sex/age. LAVE-




Glb g/L 1 0.34 0.00 0.00 All
No partition by sex/age, LAVE-   
Alb g/L 1 0.52 0.55 0.52
All
Partition by age, LAVE- for < 45 
and LAVE + > 45
BRLL BRUL
TP g/L 1 0.00 0.38 0.35 All
btw-age diff
Decision
M + F M F M F
SDR
age
RIs by parametric method LAVE effect on LL LAVE effect on UL
btw-sex diff
btw-age diff
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LAVE Age n LL Me UL n LL Me UL n LL Me UL BRLL BRUL BRLL BRUL BRLL BRUL
1 (-) 530 0.7 1.1 1.7 258 0.7 1.1 1.7 271 0.8 1.2 1.8 -0.39 -0.39
1 (+) 395 0.8 1.2 1.8 198 0.7 1.1 1.7 218 0.8 1.2 1.8 -0.39 0.00 0.00 -0.39 0.00 0.00 -0.39 -0.39
1 (-) 530 2.5 4.0 7.0 259 2.6 4.3 7.6 271 2.5 3.8 6.1 0.09 1.31
1 (+) 396 2.6 3.9 6.3 198 2.8 4.3 7.2 219 2.5 3.8 5.8 -0.11 -0.18 0.00 0.74 0.36 0.36 0.32 1.48
1 (-) 348 2.5 3.9 6.6 175 2.7 4.2 7.2 174 2.4 3.6 5.9 0.29 1.24 0.16 -0.47 -0.33 -0.87
1 (+) 285 2.6 3.8 6.1 144 2.8 4.1 6.7 145 2.4 3.6 5.7 -0.11 -0.10 0.00 0.56 0.50 0.24 0.45 1.12 0.27 -0.53 -0.36 -0.83
1 (-) 182 2.7 4.3 7.5 83 2.5 4.7 7.8 98 2.7 4.0 6.7 -0.16 0.90
1 (+) 149 2.7 4.2 7.4 66 2.5 4.6 7.3 82 2.7 4.0 6.4 0.00 0.00 0.00 0.08 0.41 0.32 -0.17 0.75
1 (-) 532 2.0 3.4 5.6 260 2.1 3.5 5.9 273 2.0 3.3 5.3 0.11 0.65
1 (+) 409 2.0 3.4 5.3 203 2.1 3.5 5.6 223 2.0 3.3 5.2 0.00 0.00 0.00 0.36 0.34 0.12 0.12 0.48
1 (-) 533 1.5 2.8 4.7 260 1.6 2.9 4.8 273 1.6 2.8 4.6 0.00 0.25
1 (+) 396 1.7 2.8 4.5 198 1.7 2.9 4.8 219 1.6 2.8 4.5 -0.28 -0.13 0.00 0.28 0.00 0.14 0.14 0.42
1 (-) 350 1.5 2.7 4.5 176 1.6 2.8 4.7 174 1.5 2.6 4.2 0.13 0.65 -0.12 -0.37 -0.26 -0.91
1 (+) 285 1.6 2.7 4.3 145 1.7 2.8 4.6 145 1.5 2.6 4.1 -0.15 -0.14 0.00 0.29 0.14 0.15 0.29 0.73 -0.25 -0.76 -0.54 -1.08
1 (-) 183 1.7 3.1 5.0 84 1.7 3.2 5.0 99 1.7 3.0 4.9 0.00 0.12
1 (+) 149 1.9 3.1 5.0 66 1.9 3.2 5.2 83 1.9 3.0 4.9 -0.25 -0.24 -0.26 0.00 -0.24 0.00 0.00 0.38
1 (-) 527 9 27 68 257 8 29 75 272 10 25 63 -0.13 0.80
1 (+) 392 9 26 64 194 8 29 71 218 9 24 60 0.00 0.00 0.08 0.29 0.25 0.23 -0.07 0.78
1 (-) 528 8 18 55 259 10 22 64 269 7 15 35 0.25 2.42
1 (+) 412 8 16 39 202 10 22 55 229 7 14 30 0.00 0.00 0.00 2.02 0.78 0.85 0.38 3.16
1 (-) 347 7 16 51 176 9 21 61 173 7 13 33 0.18 2.49 -0.22 -0.65 0.00 -0.42
1 (+) 283 8 15 38 144 9 20 47 144 7 13 29 -0.13 0.00 0.00 1.70 1.44 0.71 0.26 2.35 -0.35 -1.31 -0.17 0.00
1 (-) 181 10 20 60 84 12 25 70 96 7 18 36 0.39 2.67
1 (+) 148 10 19 48 66 13 25 62 81 8 17 29 0.00 -0.08 -0.19 1.24 0.64 1.31 0.52 3.40
1 (-) 525 16 23 39 258 17 25 45 266 15 21 32 0.34 2.22
1 (+) 409 16 22 33 206 17 25 40 227 15 21 29 0.00 0.00 0.00 1.38 0.85 0.84 0.46 2.54
1 (-) 531 50 85 153 260 53 88 153 270 49 83 156 0.15 -0.11
1 (+) 394 50 84 151 198 54 87 153 218 48 81 148 0.00 -0.04 0.04 0.08 0.00 0.31 0.23 0.19
1 (-) 347 50 81 142 176 53 86 153 172 47 77 130 0.26 0.98 0.04 0.08 -0.29 -1.61
1 (+) 282 50 80 142 145 54 87 156 144 47 75 129 0.00 -0.04 0.00 0.00 -0.12 0.05 0.30 1.15 0.16 0.00 -0.24 -1.41
1 (-) 183 54 95 163 84 52 92 151 99 55 100 174 -0.11 -0.83
1 (+) 149 53 94 160 66 50 90 156 83 53 96 165 0.04 0.07 0.07 0.11 -0.18 0.32 -0.11 -0.33
1 (-) 530 47 87 164 258 48 87 163 272 45 85 160 0.10 0.10
1 (+) 394 47 87 154 197 49 90 161 218 44 85 154 0.00 -0.04 0.04 0.37 0.07 0.21 0.18 0.26
1 (-) 530 138 189 257 259 136 187 255 271 139 190 259 -0.10 -0.13
1 (+) 409 136 187 249 207 139 186 250 225 138 189 250 0.07 -0.11 0.04 0.28 0.18 0.32 0.03 0.00
1 (-) 529 61 139 380 259 72 167 460 268 53 119 260 0.23 2.46
1 (+) 406 58 135 332 203 76 172 440 219 54 119 277 0.04 -0.04 -0.02 0.69 0.22 -0.30 0.31 2.33
1 (-) 524 12 25 88 257 12 31 105 269 10 21 50 0.10 2.84
1 (+) 405 11 24 65 199 13 31 90 224 10 21 47 0.07 -0.05 0.00 1.67 0.76 0.32 0.22 3.12
1 (-) 528 0.22 1.22 18.86 255 0.20 1.01 14.35 273 0.23 1.54 20.2 -0.01 -1.23
1 (+) 425 0.21 1.10 14.67 200 0.20 0.97 12.97 216 0.23 1.41 13.9 0.00 0.00 0.00 1.14 0.42 1.82 -0.01 -0.24
3 (-) 526 4.3 15.8 29.0 253 7.7 17.5 29.9 273 3.9 13.7 29.3 0.60 0.10
3 (+) 412 8.8 16.1 28.9 207 9.8 17.4 28.7 207 7.5 14.6 29.3 -0.88 -0.44 -0.65 0.02 0.25 0.00 0.45 -0.12
3 (-) 526 1 63 404 253 10 120 475 272 2 31 184 0.08 2.83
3 (+) 404 9 74 413 202 20 124 457 206 7 38 193 -0.08 -0.09 -0.11 -0.09 0.16 -0.19
3 (-) 348 1 58 358 174 9 121 366 173 2 24 150 0.08 2.37 0.03 -2.54 0.04 -1.55
3 (+) 281 6 71 366 147 18 123 371 141 5 28 150 -0.05 -0.10 -0.08 -0.09 -0.06 0.00 0.02 -2.50 -0.15 -1.73
3 (-) 177 1 71 450 78 6 122 667 99 0 48 222 0.05 3.89
3 (+) 134 13 81 452 65 16 131 650 72 12 62 232 -0.11 -0.06 -0.21 -0.02 0.11 -0.18
3 (-) 525 1.9 2.5 3.7 254 1.9 2.4 3.2 273 2.0 2.7 3.9 -0.22 -1.52
3 (+) 408 1.9 2.5 3.3 203 1.8 2.4 3.1 206 2.0 2.6 3.5 0.00 0.30 0.00 1.12 0.30 1.05
3 (-) 524 5 25 46 252 11 29 48 273 4 20 44 0.67 0.38
3 (+) 416 13 26 47 208 15 28 49 211 10 22 44 -0.92 -0.46 -0.69 -0.12 -0.12 0.00
2 (-) 525 11.1 14.7 20.0 254 11.1 14.6 19.4 270 10.9 15.0 20.5 0.07 -0.52
2 (+) 428 11.1 14.7 19.4 201 11.5 14.7 19.3 218 11.2 14.8 19.5 -0.04 -0.21 -0.10 0.29 0.05 0.51
2 (-) 526 1.05 2.32 4.63 254 1.02 2.37 4.72 273 1.03 2.28 4.54 -0.01 0.20
2 (+) 423 1.02 2.35 4.42 198 0.99 2.40 4.44 218 1.02 2.23 4.35 0.03 0.03 0.01 0.24 0.32 0.22
2 (-) 526 0.41 1.02 2.58 254 0.38 0.85 2.29 272 0.51 1.21 2.77 -0.23 -0.87
2 (+) 417 0.41 1.02 2.60 197 0.40 0.85 2.37 217 0.51 1.20 2.68 0.00 -0.04 0.00 -0.04 -0.16 0.16
FT3 pmol/L 0.12 0.00 0.09 4 (-) All 467 3.9 4.8 6.3 235 4.0 4.9 6.2 233 3.8 4.8 6.4 0.33 -0.33 No partiion by sex or age
FT4 pmol/L 0.00 0.34 0.38 4 (-) All 468 7.8 10.6 14.1 235 7.7 10.7 14.3 234 7.8 10.5 13.8 -0.06 0.31 No partiion by sex or age
TSH mIU/L 0.00 0.00 0.00 4 (-) All 461 0.61 1.60 4.86 231 0.63 1.63 5.10 232 0.51 1.59 4.53 0.11 0.53 No partiion by sex or age
PSA µg/L 0.39 (-) All 243 0.29 0.77 2.92 No partiion by age
All Partition by sex. LAVE-IgM g/L 0.01 0.50 0.16 0.07
No partiion by sex or age. LAVE-
IgA g/L 0.01 0.00 0.15 0.30 All No partiion by sex or age. LAVE-
Partition by sex. LAVE+
IgG g/L 0.1 0.11 0.18 0.00 All
All
Partition by sex. LAVE+ for 
female
TfSat % 1 0.50 0.00 0.00 All




Tf g/L 0.1 0.44 0.15 0.18
All
No partiion by sex or age. 
LAVE+
Ferr µg/L 1 0.81 0.20 0.44
All
Fe µmol/L 0.1 0.39 0.10 0.04
Partition by sex. LAVE+ for 
males. LAVE- females
CRP mg/L 0.01 0.11 0.35 0.17 All
No partiion by sex or age. 
LAVE+
Partition by sex. LAVE-
GGT IU/L 1 0.54 0.29 0.13 All
All No partiion by sex or age. LAVE-
CK IU/L 1 0.52 0.00 0.08 All
0.00 All No partiion by sex or age. LAVE-
LDH IU/L 1 0.00 0.00 0.28
All




AMY IU/L 1 0.02 0.00
0.35 All Partition by sex. LAVE+
ALP IU/L 1 0.00 0.17 0.69
All
Partition by sex, LAVE+.
No partiition by age
~45
45~
AST IU/L 1 0.49 0.00
0.14 All
No partition by sex or age. 
LAVE-
ALT IU/L 1 0.59 0.20 0.51
All




Lip U/L 1 0.06 0.16
0.35 All
No partition by sex or age. 
LAVE-
LDL-C mmol/L 0.1 0.00 0.35 0.43
All
Partition by age (female). LAVE-~45
45~
nonHDL mmol/L 0.1 0.00 0.32
0.00 All
No partition by age or sex. 
LAVE- with its effect of ≤2RU 
HDLrat 0.1 0.34 0.38 0.45




M + F M F M F
SDR
age
RIs by parametric method LAVE effect on LL LAVE effect on UL
btw-sex diff
btw-age diff
Stellenbosch University  https://scholar.sun.ac.za
156 
 
Table S6.2: Comparison of reference intervals 
 
Test Units Age LL UL LL UL LL UL Age LL UL LL UL LL UL Age LL UL LL UL LL UL Age LL UL LL UL LL UL
TP g/L 18-65 67 83 NA 66 83 18-65 66 83 20-79 66 82
18-65 NA 35 52 18-65 39 50 20-79 41 49
18-44 40 51 38 49
45-65 40 47 38 46
18-65 2.4 6.6 NA 2.8 7.2 18-65 2.8 7.3 2.1 6.4
18-44 1.8 5.3 20-49 2.95 7.20 2.21 6.12
45-65 1.9 6.2 50-79 2.85 7.96
UA µmol/L 18-65 243 507 178 417 NA 208.3 428.4 154.7 357 18-65 223 444 148 321 20-79 226 458 166 345
Cre µmol/L 18-65 58 109 45 86 NA 59 104 45 84 18-65 66 111 50 74 20-79 59 92 50 71
TBil µmol/L 18-65 6 43 5 27 NA 5 21 18-65 3.6 22.4 2.2 15.5 20-79 3.8 24.1 2.7 15.9
Na mmol/L 18-65 134 142 NA 136 146 18-65 135 144 20-79 137 144
K mmol/L 18-65 3.4 4.8 NA 3.5 5.1 18-65 3.7 4.9 20-79 3.7 4.9
Cl mmol/L 18-65 100 110 NA 101 109 18-65 101 111 20-79 99 107
Ca mmol/L 18-65 2.19 2.57 NA 2.2 2.65 18-65 2.11 2.56 20-79 2.15 2.47
IP mmol/L 18-65 0.78 1.42 NA 0.81 1.45 18-65 0.81 1.44 20-79 0.8 1.4
18-65 0.73 0.98 NA 0.73 1.06 0.77 1.03 18-65 0.71 0.96 20-79 0.77 1.06
18-44 0.71 0.93
45-65 0.76 1.01
18-65 NA 4.1 5.9 18-65 4 5.9 20-79 3.96 5.88
18-44 3.9 5.8
45-65 4.4 7.3
18-65 NA 5.2 18-65 3.5 6.36
18-45 3.10 6.10 20-49 3.22 6.45 3.20 6.42 3.20 6.38
46-65 3.20 7.20 50-79 3.93 7.92
18-65 NA 1.7 18-65 0.5 3.58 0.39 1.6
18-45 0.50 2.88 0.45 2.03 20-49 0.53 3.39 0.46 2.52
46-65 0.53 3.87 0.55 3.24 50-79 0.64 3.55
HDL-C mmol/L 18-65 0.70 1.70 NA 1.03 1.55 18-65 0.74 1.76 0.98 2.19 0.85 1.52 0.95 1.56
18-65 1.60 4.80 NA 2.60 18-65 1.8 4.34
18-44 1.50 4.20 20-49 1.47 3.92 1.60 4.01 1.32 3.92
45-65 1.70 4.90 50-79 1.78 4.91
Lip U/L 18-65 8 75 10 63 NA 67
ALT IU/L 18-65 10 55 7 30 NA 50 35 18-65 7 39 5 18 9 57 7 28
AST IU/L 18-65 17 40 15 29 NA 50 35 18-65 11 28 10 24 13 30 11 25
18-65 53 153 NA 30 120 39 114
18-44 47 130 20-49 38 112 43 116 34 97
45-65 55 174 50-79 47 133
AMY IU/L 18-65 47 164 NA 22 80 18-65 31 117 34 119
LDH IU/L 18-65 138 257 NA 248 247 18-65 10 238 126 220
CK IU/L 18-65 72 460 53 260 NA 171 145 18-65 54 266 27 138 48 227 34 131
GGT IU/L 18-65 13 90 10 47 NA 55 38 18-65 11 65 7 21 11 69 7 33
Fe µmol/L 18-65 8.8 28.9 NA 12.5 32.2 10.7 32.2 18-65 7.9 29.6 3.7 26 5.9 31.6 3.5 27.8
18-65 20 457 NA 20 250 10 120 18-79 4.7 136
18-44 5 150 18-44 13 276 4.3 91
45-65 12 232 45-79 5.9 175
Tf g/L 18-65 1.9 3.2 2.0 3.5 NA 2 3.6 18-65 2 3.2 2.1 3.9 18-79 1.8 3.3 1.8 3.3 1.9 3.5
TfSat % 18-65 13 47
CRP mg/L 18-65 0.21 14.7 NA 1 18-65 0.2 11.8
IgA g/L 18-65 1.05 4.63 NA 0.7 4
IgG g/L 18-65 11.1 20.0 NA 7 16
IgM g/L 18-65 0.38 2.29 0.51 2.77 NA 0.4 2.3
FT3 pmol/L 18-65 3.9 6.3 NA 3.8 6
FT4 pmol/L 18-65 7.8 14.1 NA 7.86 14.41
TSH mIU/L 18-65 0.61 4.86 NA 0.38 5.33









PRESENT STUDY KENYA BECKMAN AU1 SAUDI ARABIA2 TURKEY3
M+F M M FF M+F
ALP IU/L
M+F M F M+F M F




Key:1(AU Reagent Quick Reference Guide, 2018), 2(Borai et al., 2016), 3(Ozarda et al., 2014), 4(S. Shah et al., 2018), 5(Kratz et al., 2004), 6(Kibaya et al., 2008), 7(Karita et al., 2009)
Test Units Age LL UL LL UL LL UL Age LL UL LL UL LL UL Age LL UL LL UL LL UL Age LL UL LL UL LL UL
TP g/L 18-65 68 86 NA 55 80 18-60 58 88 59 88 58 87
18-65 36 47 NA 35 55 18-55 35.8 48.1 36.9 48.5 34.4 47.5 18-60 35 52 36 52 35 51
18-65 2.2 6.0 NA 3.6 7.1 18-55 1.4 4.6 1.5 4.6 1.4 4.6
18-45 1.9 5.1 NA
46-65 2.4 6.7 NA
UA µmol/L 18-65 248 509 159 404 NA 150 480 90 360
Cre µmol/L 18-65 58 95 35 74 NA 133 18-55 55 102 62 106 51 91 18-60 47 109 52 114 43 99
TBil µmol/L 18-65 6.2 23.7 4 17.3 NA 5.1 17 18-55 4.9 39.9 5.6 41.9 4.4 26.8 18-60 2.9 37 3.6 41.9 2.7 31.5
Na mmol/L 18-65 135 146 NA 136 145 18-55 141 153 142 152 140 155
K mmol/L 18-65 3.8 5 NA 3.5 5.0 18-55 3.9 5.8 3.9 5.8 3.8 5.8
Cl mmol/L 18-65 102 113 NA 98 106 18-55 100.5 112 100 111 101 113
Ca mmol/L 18-65 2.1 2.44 NA 2.2 2.6
IP mmol/L 18-65 0.8 1.43 NA 1.0 1.4
18-65 0.77 1.07 NA 0.8 1.2
18-65 NA 4.2 6.4
18-45 4.1 5.5 NA
46-65 4.3 6.0 NA
18-65 2.9 6.6 NA 18-55 2.6 5.7 2.5 5.5 2.6 5.9
18-45 3.1 6.2 NA
46-65 2.5 6.7 NA
18-65 0.6 2.7 0.5 2.1 NA 1.8 18-55 0.4 2.6 0.4 2.7 0.4 2.5
18-45 NA
46-65 NA
HDL-C mmol/L 18-65 0.7 1.5 0.8 1.8 NA 1.03
18-65 1.7 4.4 NA
18-45 NA
46-65 NA
Lip U/L 18-65 NA 0 160
ALT IU/L 18-65 15 74 10 37 NA 0 35 18-55 9.6 52 10.8 53.9 8.6 47 18-60 8 61 9 67 8 48
AST IU/L 18-65 20 53 17 39 NA 0 35 18-55 13.8 42.3 14.9 45.3 13.1 38.1 18-60 14 60 15 71 13 43
18-65 41 111 NA 30 120 18-60 48 164 48 138 46 179
18-45 35 100 NA
46-65 43 117 NA
AMY IU/L 18-65 36 135 NA 60 180 18-55 38.3 163.0 40.0 171.3 36.0 147.8 18-60 35 159 37 167 33 140
LDH IU/L 18-65 104 206 NA 100 190 18-55 126.0 263.9 124.0 259.0 131.5 295.4 18-60 213 678 209 691 217 652
CK IU/L 18-65 48 304 36 184 NA 60 400 40 150 18-60 53 552 60 709 49 354
GGT IU/L 18-65 14 62 11 40 NA 1 94
Fe µmol/L 18-65 7 33 4 26 NA 9 27
18-65 NA 30 300 10 200
Tf g/L 18-65 2.2 4 NA 2.3 3.9
TfSat % 18-65 NA 20 45
CRP mg/L 18-65 0.33 7.34 0.35 11.9 NA 0.02 8
IgA g/L 18-65 0.94 4.35 NA 0.6 3.09
IgG g/L 18-65 9.1 20.4 NA 6.14 12.95 18-60 7.74 28.33 7.56 28.04 7.92 28.95
IgM g/L 18-65 0.4 2.54 0.51 3.1 NA 0.53 3.34
FT3 pmol/L 18-65 NA 0.22 6.78
FT4 pmol/L 18-65 NA 10.3 35
TSH mIU/L 18-65 NA 0.5 4.7
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CHAPTER 7:  COMPARISON OF REFERENCE INTERVALS AND 
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Introduction: Variation of reference intervals (RIs) across different populations has been well 
documented. Several reasons have been postulated to contribute to these variations including 
differences in population structure, race, environment, diet, sample handling, analytical methods and 
statistical analysis approaches. RI studies published from Africa have highlighted several differences 
across countries even in populations thought to be homogeneous. We set out to compare reference 
values of 31 analytes and their sources of variation between black Africans in Kenya and South Africa 
using data collected as part of the IFCC global study on RIs. 
Methodology: Participants in Kenya and South Africa were enrolled using a harmonized protocol. 
Recruitment was targeted at enrolling adults aged 18-65 years with similar numbers of males and 
females to enable determination of RIs using a parametric approach with sex and age stratification 
where appropriate. Reference values of the two populations were standardized before merging based on 
the test results of the value-assigned serum panel measured in common. Comparison of RIs was done 
by determining bias ratios for RI lower and upper limits.  
Results: A total of 1130 participants had sufficient data for inclusion and further analysis. This 
included 597 and 533 participants from South Africa and Kenya respectively. South African RIs for 
UA, TC, LDL-C, ALT, LDH, ALP, ALB, Mg, TSH and PSA were lower than the Kenyan RIs. Sex 
was an important source of variation for UA, Cre, AST, CK and Tf. Age was a significant source for 
variation for UA, Glu and TG. BMI had a significant positive correlation with UA, TG, ALT and CRP 
for both males and females. 
Conclusion: In conclusion, the findings of this study highlight the difficulties in harmonizing RIs 
even for populations thought to be similar despite standardizing study processes to enable direct 
comparison of RIs. For most analytes, harmonization of RIs between Kenyans and South Africans of 
African ancestry will not be ideal as they could result in misclassification of individuals as either 
diseased or healthy. 
 
  




Variation of reference intervals (RIs) across different populations has been well documented. Several 
reasons have been postulated to contribute to these variations including differences in population 
genetic structure, race and ethnicity, environment, diet, sample handling, analytical methods and 
statistical analysis approaches. In order to explore the possibility of harmonizing RIs globally, the 
International Federation of Clinical Chemistry (IFCC) through its Committee of Reference Intervals 
and Decision Limits (C-RIDL) planned a study to determine RIs using a harmonized protocol 
(Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017; Ichihara, Ozarda, Barth, Klee, Shimizu, et al., 2017; 
Ozarda et al., 2013). In Africa, the first countries to join the study were South Africa, Nigeria and 
Kenya representing South, West and East Africa respectively.  
 
RI studies published from Africa have highlighted several differences across countries even in 
populations thought to be homogeneous. Karita et al determined RIs from Kenya, Uganda, Rwanda and 
Zambia and noted significant differences compared to RIs from the United States of America (USA). 
Differences were also seen across the participating countries such as low haemoglobin levels in women 
from Kilifi in Kenya, increased neutrophil counts in men and women from Nairobi and Kilifi in Kenya, 
increased eosinophil counts and immunoglobulin G (IgG) levels in men and women from Masaka in 
Uganda as well as increased total bilirubin in men and women from Masaka and Entebbe in Uganda 
(Karita et al., 2009). The authors hypothesized that some of the causes for the variations in RIs seen 
include poor nutrition, high prevalence of parasitic infections, differences in altitude and the possibility 
of inherited diseases such as Gilbert’s syndrome. 
 
In South Africa, differences in RIs across races have been described. Francois et al highlighted 
differences in neutrophil counts among people of African, Caucasian and mixed ancestry with Africans 
having significantly lower total white blood cell and neutrophil counts while those of mixed ancestry 
were generally found to have similar blood counts to participants of Caucasian ancestry (Smit et al., 
2019). Ichihara et al compared preliminary data on biochemistry reference values between black and 
non-black South Africans and found that black South Africans had lower median reference values 
(RVs) for creatinine, high density lipoprotein cholesterol (HDL-C) and uric acid (UA) (Ichihara, 
Ozarda, Barth, Klee, Qiu, et al., 2017).  




The main factors considered when partitioning RIs are age and sex which are generally considered 
important sources of variation in reference values. Ichihara et al has shown that RVs vary across 
different countries and that other sources of variation need to be considered given that variations are 
seen even in people of the same race but residing in different countries (Ichihara, Ozarda, Barth, Klee, 
Qiu, et al., 2017). Body-mass index (BMI) has emerged as an important source of variation especially 
for tests such as liver enzymes, glucose, markers of inflammation and lipids which are associated with 
metabolic syndrome. Furthermore, it has been demonstrated that this BMI effect varies across races and 
ethnicities. For instance, in South Africa, an increase in BMI was associated with minimal increase in 
alanine transaminase (ALT) (r=0.02) in blacks compared to non-blacks (r=0.48) (Ichihara, Ozarda, 
Barth, Klee, Shimizu, et al., 2017).   
 
Reference intervals can be derived using either parametric or non-parametric methods. The non-
parametric method is recommended by the Clinical Laboratory Standards Institutes (CLSI) as it is 
simple, doesn’t require transformation of data and often times outlier data is treated as a variation of 
normal as opposed to being abnormal (CLSI, 2010). Parametric method has been used as well but it 
only applies to data whose distribution is Gaussian. This often requires transformation of non-Gaussian 
data which is not always successful. However, Ichihara has demonstrated that any dataset can be 
transformed into a Gaussian distribution provided one defines the origin of the transformation relative 
to the data distribution and not from zero as has been the case for the original Box-Cox transformation 
(Box & Cox, 1964; Ichihara, 2014). 
 
We set out to compare reference values and sources of variation between black Africans in Kenya and 
South Africa using data collected as part of the global study. South Africa is a multi-racial society 
hence the comparison was limited to black South Africans in order to control for race which is a known 
source of variation in RVs. 
 
7.3 Methodology 
Participants in Kenya and South Africa were enrolled using a harmonized protocol (Ozarda et al., 
2013). The specifics of the recruitment process in Kenya and South Africa have previously been 
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published (Omuse, Maina, Hoffman, et al., 2017; Omuse et al., 2018; Smit et al., 2019). In Kenya, 
healthy adults aged 18-65 years from selected counties (Nairobi, Kiambu, Nakuru and Kisii) were 
enrolled. This was done between January and October 2015. For South Africa, the study was conducted 
between October 2012 and February 2015 as a multicenter- study involving three core institutions 
located in three different provinces in South Africa: PathCare Laboratories in Cape Town, Western 
Cape Province, which acted as the central laboratory, Water Sisulu University in Mthatha, Eastern 
Cape Province, and Wits University in Johannesburg, Gauteng Province. Recruitment was stratified 
into 4 age groups: 18-29, 30-39, 40-49 and 50-65 years with a similar distribution of males and females 
in each age strata. In South Africa, a few participants above the age of 65 years were also recruited but 
were excluded for this comparison. Informed consent was obtained from all participants after 
confirming that they had fasted overnight.  Measurement of blood pressure (BP), WC and body mass 
index (BMI) was carried out after filling in a questionnaire which took 15-20 minutes. All blood 
samples were collected and centrifuged within 4 hours and stored at -80oc until shipment on dry ice to 
the Pathcare reference laboratory in Cape town, South Africa.  
 
Ethical approval was obtained from Aga Khan University-Nairobi Health Research Ethics Committee 
(2014/REC-46), Wellness Sciences’ Research and Ethical Committee of Cape Peninsula University of 
Technology (CPUT/NHREC: REC-230408-014) as well as the University of Stellenbosch’s Health 
Research Ethics Committee (S12/05/147).  
 
The chemistry tests were analyzed using an automated Beckman Coulter DXC 700 analyser (Brea, CA 
USA) for specimens obtained between 2012 and 2013 and AU 600 analyser (Beckman Coulter, Tokyo, 
Japan) for the specimens obtained from 2014. Immunoassays were measured using a Beckman Coulter 
DxI 800 analyser (Brea, CA USA). The test abbreviations, methodologies and imprecision are shown 
in Table 7.1.  




In order to allow for direct comparison of reference values, all participating laboratories received a 
panel of sera produced by the C-RIDL in 2011 and in 2014 that had values assigned. This panel was 
measured by participating laboratories to aid with recalibration of reference values using linear 
regression analysis. Further, a mini panel of sera derived from 5 healthy individuals analyzed alongside 
the study samples in order to assess for between-day variations and recalibrate the results if the 
variation exceeded acceptable limits (Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017). 
Statistical analysis 
Continuous variables were presented as medians with their corresponding interquartile ranges. In order 
to compare RIs between South Africa and Kenya, we determined RIs using a parametric approach after 
Table 7.1: Test abbreviations, methodologies and imprecision 
Analyte Abbreviation Method Units Between Run CV
Sodium Na Ion selective electrode / diluted (indirect) mmol/L 1.3
 Potassium K Ion selective electrode / diluted (indirect) mmol/L 3.8
Chloride Cl Ion selective electrode / diluted (indirect) mmol/L 1.4
Urea Urea Urease mmol/L 2.4
Creatinine Cre Modified kinetic Jaffè µmol/L 1.6
Total Protein TP Biuret g/L 4.6
Albumin Alb Bromocresol Green dye binding g/L 2.8
Gamma-glutamyl transferase GGT Gamma-glutamyl-3-carboxy-4-nitroanilide IU/L 3.3
Alkaline phosphatase ALP P-nitro-phenylphosphate hydrolysis IU/L 4.0
Lactate dehydrogenase LDH Lactate to Pyruvate IU/L 3.2
Calcium Ca Arsenazo III dye mmol/L 1.4
Magnesium Mg Xylidyl blue mmol/L 1.9
Phosphate IP Molybdate hydolysis mmol/L 1.8
Lipase Lip 1, 2-Diglyceride hydrolysis U/L 8.0
Total cholesterol TC Cholesterol oxidase mmol/L 1.2
Triglycerides TG Glycerol phosphate oxidase mmol/L 4.1
High density lipoprotein cholesterol HDL-C Two phase selective accelerator detergent mmol/L 2.0
Low density lipoprotein cholesterol LDL-C Two phase selective accelerator detergent mmol/L 1.6
Uric acid UA Modified Trinder reaction with Uricase mmol/L 1.2
High sensitive c reactive protein CRP Turbidimetry mg/L 1.8
Amylase AMY 2-chloro-4-nitrophenyl-α-D-maltotrioside U/L 8.1
Immunoglobulin A IgA Turbidimetry g/L 1.3
Immunoglobulin G IgG Turbidimetry g/L 1.1
Immunoglobulin M IgM Turbidimetry g/L 7.0
Alanine aminotransferase ALT NADH (without P-5′-P) U/L 28.1
Aspartate aminotransferase AST NADH (without P-5′-P) U/L 5.6
Creatinine kinase CK Creatine phosphate dephosphorilysation U/L 6.5
Iron Fe 2, 4, 6-Tri-(2-pyridyl)-5-triazine chromogen µmol/L 4.2
Transferrin Tf Turbidimetry g/L 2.6
Anti-thyroglobulin TgAb Two-site immune – enzymatic immunoassay IU/ml 4.8
Anti-thyroid peroxidase TPOAb Two-site immune – enzymatic immunoassay IU/ml 28.8
Thyroid stimulating hormone TSH Two-site immune – enzymatic immunoassay mIU/L 13.0
Prostate specific antigen PSA Two-site immune – enzymatic immunoassay µg/L 2.3
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latent abnormal value exclusion (LAVE) as described by Ichihara et al (Ichihara, Ozarda, Barth, Klee, 
Qiu, et al., 2017). LAVE was based on the following reference tests: Alb, UA, Glu, TG, HDL-C, LDL-
C, AST, ALT, LDH, GGT, CK and CRP, which were used to exclude individuals with outlier values 
tough to be related to nutrition status, inflammation, or muscular damage. For proteins we set TP, Alb, 
Urea, Cre, Na, Ca, Fe, CRP, IgG, IgA, and Tf as the reference tests when applying LAVE. For 
comparison of RIs, we excluded all individuals with a BMI > 35 kg/m2, missing BMI data and age > 65 
years. 
 
Sources of variation were assessed using standard deviation ratios (SDRs) calculated as between 
country (SDRcountry), between sex (SDRsex) and between age (SDRage). These were computed as a 
ratio to the residual SD (or between-individual SD). Since between-age and between-country variation 
changes by sex, we also computed  SDRage and SDRcountry for males, females and both males and 
females by one way ANOVA.  We considered SDR ≥ 0.40 as a guide for judging the important sources 
of variation for the different analytes. For SDRage, age was stratified as 18-29, 30-39, 40-49 and 50-65 
years. This analysis was carried out using a general purpose statistical software, StatFlex version 6.0 
(Artech Inc., Osaka, Japan). We also evaluated the RI lower limit (LL) and upper limit (UL) biases 









The subscripts of KE and ZA refer to LL or UL of Kenyan and South African RIs respectively and 
KE/ZA refers to combined RIs for Kenya and South Africa.  Multiple regression analysis (MRA) was 
performed to identify factors possibly influencing the test results, including country, age, BMI, 
smoking, exercise and alcohol intake. The level of cigarette smoking was categorized as none, ≤ 20, 
and > 20 cigarettes/day; exercise was categorized as none, 1–7 days/week; alcohol intake was 
categorized as none, <12.5, 12.5−25, 25−50, >50 g ethanol/day. A given explanatory variable was 
considered to be of practical importance when its standardized partial regression coefficient (rp) was ≥ 
0.20 in its absolute value. Linear regression was used to demonstrate the association between BMI and 
selected analytes. This analysis was carried out using a general purpose statistical software SPSS® 
version 23 (IBM, USA). 
 




A total of 1130 participants had sufficient data for inclusion and further analysis. This included 597 and 
533 participants from South Africa and Kenya respectively. Participant characteristics were similar 




Using an SDR cut-off of 0.4 to evaluate sources of variation, sex was an important source of variation 
for UA, Cre, AST, CK and Tf without considering between country variation. Between country 
variation was significant for Alb, Mg, Glu, LDL-C, ALT, GGT, CK and IgM while age was a 
significant source of variation for UA, Glu and TG without partitioning by sex as shown in Table 7.3. 
  
Male Female All Male Female All Male Female All
Age  n 312 285 597 259 274 533 571 559 1130
(Years) Median (IQR) 36 (21) 34 (22) 35 (21) 39 (19) 39 (20) 39 (20) 38 (21) 37 (21) 37 (20)
BMI n 306 273 579 259 274 533 565 547 1112
(Kg/m
2
) Median (IQR) 25.2 (7.3) 26.9 (6.8) 26.3 (7.0) 24.9 (5.6) 26.1 (6.2) 25.5 (5.9) 25.1 (6.3) 26.4 (6.6) 25.8 (6.6)
SBP n 165 232 389 259 274 530 424 506 930
(mmHg) Median (IQR) 127 (21) 123 (24) 125 128 (18) 118 (20) 124 127 (18) 120 (22) 124 (21)
DBP n 165 229 394 259 274 532 424 506 930
(mmHg) Median (IQR) 82 (16) 82 (15) 82 81 (12) 79 (14) 80 81 (13) 80 (15) 80 (14)
n 86 97 183 259 274 533 345 371 716
No. (%) 19 (22%) 11 (11%) 30 (16%) 101 (39%) 73 (27%) 174 (33%) 120 (35%) 84 (23%) 204 (28%)
n 93 117 210 259 274 533 352 391 743
No. (%) 6 (6%) 1 (1%) 7 (3%) 12 (5%) 2 (1%) 14 (3%) 18 (6%) 3 (1%) 21 (3%)
Smoking




Table 7.2: Participant characteristics 
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Table 7.3: Standard deviation ratios for between sex, country and age 
 
 
Key: F-Female, M-Male, MF-Male and Female 
 
MRA revealed that drinking, exercise and smoking had minimal influence on reference values for all 
the analytes. Compared to Kenyan data, reference values for Alb, Na, Cl, Mg, TC, LDL-C, ALT and 
LDH were much lower for the South Africans denoted by rp values less than -0.2. BMI had a 
significant positive correlation (rp>0.2) for UA, TG, ALT and CRP while age had a positive correlation 




SDRsex SDRcountry SDRage 
 MF M F MF M F 
TP 0.000 0.000 0.392 0.000 0.220 0.197 0.237 
Alb 0.000 0.800 0.472 0.769 0.374 0.405 0.339 
Urea 0.187 0.306 0.000 0.341 0.306 0.232 0.362 
UA 0.771 0.000 0.829 0.000 0.406 0.360 0.456 
Cre 1.050 0.025 0.534 0.000 0.158 0.188 0.111 
Na 0.000 0.000 0.261 0.000 0.299 0.328 0.273 
K 0.000 0.211 0.190 0.283 0.154 0.155 0.153 
Cl 0.137 0.000 0.076 0.000 0.242 0.316 0.131 
Ca 0.189 0.141 0.110 0.200 0.221 0.224 0.218 
IP 0.173 0.157 0.000 0.268 0.262 0.324 0.175 
Mg 0.000 0.466 0.427 0.442 0.277 0.277 0.278 
Fe 0.357 0.198 0.000 0.104 0.051 0.114 0.000 
Glu 0.000 0.481 0.000 0.488 0.659 0.655 0.662 
TC 0.000 0.198 0.490 0.000 0.394 0.372 0.418 
TG 0.219 0.000 0.276 0.000 0.551 0.488 0.625 
HDL-C 0.263 0.105 0.453 0.159 0.000 0.057 0.000 
LDL-C 0.000 0.538 0.290 0.435 0.339 0.301 0.375 
AST 0.455 0.000 0.000 0.000 0.254 0.251 0.258 
ALT 0.000 1.154 0.619 1.107 0.269 0.204 0.339 
LDH 0.000 0.636 0.299 0.597 0.126 0.074 0.165 
ALP 0.000 0.394 0.000 0.406 0.376 0.202 0.488 
GGT 0.379 0.272 1.191 0.369 0.314 0.326 0.301 
CK 0.412 0.057 0.670 0.000 0.088 0.114 0.042 
AMY 0.076 0.000 0.379 0.053 0.044 0.051 0.034 
CRP 0.000 0.329 0.134 0.238 0.307 0.292 0.322 
IgG 0.025 0.033 0.085 0.000 0.082 0.043 0.107 
IgA 0.000 0.103 0.000 0.097 0.316 0.234 0.390 
IgM 0.347 0.219 0.406 0.035 0.170 0.088 0.225 
Tf 0.405 0.075 0.060 0.112 0.206 0.168 0.227 
TSH 0.000 0.190 0.107 0.193 0.063 0.057 0.069 
PSA   0.308   0.338  




Key: *used log transformed data; shaded red background rP < -0.2; shaded green background rP > 0.2; DrkLvl-Drink level; SmkLvl-Smoking level; ZA-South Africa
Analyte R ZA Age BMI DrkLvl SmkLvl ExerLvl Analyte R ZA Age BMI DrkLvl SmkLvl ExerLvl
TP 0.294 -0.216 -0.220 0.019 -0.019 -0.035 -0.023 TP 0.280 -0.153 -0.169 -0.044 -0.068 -0.025 0.092
Alb 0.513 -0.436 -0.377 0.013 -0.076 -0.077 0.014 Alb 0.558 -0.453 -0.211 -0.229 -0.082 0.039 0.021
Urea 0.320 0.152 0.156 0.150 0.125 0.054 -0.055 Urea 0.357 0.216 0.290 0.015 0.081 0.035 0.035
UA 0.515 -0.086 0.175 0.393 0.113 0.018 -0.021 UA 0.462 -0.161 0.180 0.295 0.071 0.000 -0.139
Cre 0.298 -0.099 -0.121 0.181 0.162 0.029 0.006 Cre 0.171 -0.044 -0.053 0.112 0.085 -0.045 0.037
Na 0.470 -0.415 0.068 -0.096 0.139 -0.048 -0.027 Na 0.444 -0.353 0.189 -0.110 0.041 0.029 0.007
K 0.311 0.278 0.135 0.016 0.087 0.095 0.024 K 0.338 0.262 0.095 0.132 -0.044 0.028 0.015
Cl 0.510 -0.420 0.228 -0.070 0.070 0.009 -0.092 Cl 0.453 -0.392 0.080 -0.044 0.080 0.030 0.012
Ca 0.283 -0.193 -0.227 0.032 0.003 0.044 0.017 Ca 0.375 -0.308 0.000 -0.100 0.029 0.072 0.044
IP 0.269 -0.165 0.015 0.095 0.137 0.025 0.020 IP 0.307 -0.221 0.099 -0.115 0.103 0.011 0.001
Mg 0.522 -0.376 0.306 -0.017 0.059 0.003 0.015 Mg 0.477 -0.348 0.242 -0.001 -0.104 0.024 0.015
Fe 0.234 -0.202 -0.036 -0.074 -0.061 0.041 -0.084 Fe 0.181 -0.167 -0.025 0.041 0.034 0.009 -0.060
Glu 0.595 -0.114 0.340 0.357 -0.132 -0.044 -0.068 Glu 0.548 -0.114 0.423 0.087 -0.019 -0.028 -0.080
TC 0.520 -0.267 0.223 0.284 0.125 -0.050 -0.002 TC 0.398 0.123 0.308 0.036 0.069 0.043 0.053
TG* 0.560 -0.070 0.315 0.375 0.038 0.051 0.003 TG* 0.519 -0.035 0.342 0.214 -0.105 -0.042 -0.010
HDL-C 0.328 -0.102 0.069 -0.291 0.087 -0.023 0.047 HDL-C 0.298 -0.090 0.083 -0.161 0.020 0.082 0.170
LDL-C 0.551 -0.339 0.202 0.304 0.108 -0.067 -0.010 LDL-C 0.451 -0.229 0.304 0.062 0.089 0.043 0.015
AST* 0.240 -0.061 -0.072 0.224 -0.079 -0.049 -0.012 AST* 0.278 0.043 0.122 0.125 -0.107 -0.042 0.037
ALT* 0.633 -0.546 -0.009 0.383 0.027 0.003 -0.047 ALT* 0.736 -0.654 0.259 0.203 0.056 0.046 0.009
LDH 0.390 -0.355 -0.095 0.165 0.039 0.005 -0.028 LDH 0.401 -0.305 0.080 0.150 0.038 -0.021 0.030
ALP 0.233 -0.225 -0.029 0.021 -0.074 0.006 -0.061 ALP 0.426 -0.196 0.269 0.081 -0.069 -0.035 0.014
GGT* 0.457 0.138 0.061 0.366 0.126 0.044 -0.075 GGT* 0.283 0.215 0.133 0.091 0.058 0.002 0.065
CK* 0.206 0.039 -0.071 0.193 0.002 -0.010 0.046 CK* 0.229 -0.039 0.048 0.155 -0.068 0.029 0.077
AMY 0.218 0.009 -0.014 -0.125 -0.107 -0.089 0.042 AMY 0.183 -0.058 0.014 -0.122 -0.062 0.083 0.037
CRP* 0.473 0.192 0.147 0.330 0.157 0.054 0.006 CRP* 0.529 0.257 0.156 0.394 0.055 0.063 0.159
IgG 0.181 -0.099 -0.056 -0.035 -0.084 -0.096 0.023 IgG 0.137 0.041 -0.092 0.051 -0.080 -0.040 0.036
IgA 0.231 0.046 0.187 0.038 0.081 0.029 -0.026 IgA 0.322 0.044 0.278 0.006 -0.022 0.025 -0.003
IgM 0.222 0.117 -0.076 -0.116 0.042 -0.033 0.027 IgM 0.151 0.081 -0.039 -0.066 -0.062 -0.017 0.062
Tf 0.194 -0.139 0.074 0.035 -0.052 0.018 0.013 Tf 0.260 -0.121 -0.130 -0.060 0.029 -0.015 0.090
TSH 0.210 -0.172 0.027 0.076 -0.004 0.030 0.000 TSH 0.148 -0.098 -0.049 0.079 -0.049 -0.032 0.039
PSA 0.294 -0.039 0.257 -0.067 -0.043 -0.008 -0.076
Male Female
Table 7.4: Multiple regression analysis and partial correlation coefficients for all analytes 
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A comparison of linear regression between Kenya and South African data for selected analytes with 
BMI is shown in Fig 7.1. Both between country and sex differences are seen in the effect of BMI on 
the selected analytes as evidenced by the differences in the slope of the regression lines.  
 
Not all participants had test results for all the analytes hence RIs were determined using available data 
as shown in Table 7.5. South African RIs for UA, TC, LDL-C, ALT, LDH, ALP, ALB, Mg, TSH and 
PSA were lower than the Kenyan RIs as seen by the negative biases for both LLs and ULs. For 
instance, the RIs for Na in Kenyan males and females were 135-141 mmol/L and 134-142 mmol/L 
respectively, while that for South African males and females were 129-144 mmol/L and 129-147 
mmol/L respectively. Glucose was excluded from the RI comparison given the very few reference 
values available from South Africa compared to Kenya (66 vs 522). 
 




Figure 7.1a: Linear regression of UA and BMI in males 
 
Figure 7.1b: Linear regression of UA and BMI in females 
 
Figure 7.1c: Linear regression of logTG and BMI in males 
 
Figure 7.1d: Linear regression of logTG and BMI in females 
 
Figure 7.1e: Linear regression of CRP and BMI in males 
 
Figure 7.1f: Linear regression of CRP and BMI females 
Fig 7.1: Linear regression of BMI and selected analytes




Key: KE-Kenya; ZA-South Africa; Red shade-negative bias; Green shade-positive bias 
Item LL UL LL UL BRLL BRUL LL UL LL UL BRLL BRUL LL UL LL UL BRLL BRUL
UA 248 506 198 468 -0.73 -0.57 175 392 154 406 -0.35 0.24 187 459 160 463 -0.37 0.06
TC 3.19 6.67 2.78 6.35 -0.44 -0.34 3.21 6.50 2.60 6.36 -0.68 -0.15 3.14 6.45 2.66 6.33 -0.55 -0.14
TG 0.54 3.32 0.49 3.42 -0.07 0.14 0.46 2.40 0.44 2.44 -0.04 0.07 0.49 2.82 0.46 3.11 -0.05 0.46
HDL-C 0.76 1.63 0.69 1.62 -0.27 -0.03 0.82 1.78 0.74 1.82 -0.29 0.14 0.78 1.75 0.72 1.75 -0.20 0.02
LDL-C 1.72 4.82 0.92 3.80 -0.99 -1.25 1.57 4.59 0.94 3.96 -0.80 -0.80 1.57 4.57 0.95 3.86 -0.77 -0.88
AST 17 39 15 42 -0.30 0.43 15 29 14 33 -0.19 0.84 15 33 14 40 -0.18 1.24
ALT 10 51 4 25 -0.52 -2.30 7 28 2 17 -0.83 -1.79 8 40 3 21 -0.58 -2.13
LDH 137 248 93 218 -1.33 -0.89 139 252 112 230 -0.84 -0.66 136 247 97 224 -1.20 -0.68
ALP 52 150 43 125 -0.37 -0.99 48 146 39 124 -0.36 -0.90 50 147 39 125 -0.44 -0.92
GGT 14 85 14 92 0.04 0.30 10 45 12 84 0.18 3.09 12 66 13 96 0.09 1.68
CK 75 427 57 505 -0.18 0.76 52 271 46 266 -0.11 -0.08 58 350 50 419 -0.10 0.84
AMY 50 162 48 166 -0.09 0.14 46 162 43 159 -0.10 -0.12 48 161 43 162 -0.15 0.04
TP 67.9 80.7 66.2 82.7 -0.46 0.55 66.2 82.5 66.2 88.4 -0.01 1.28 67.2 81.8 65.7 85.5 -0.35 0.88
Alb 40.1 50.2 37.3 47.7 -0.98 -0.89 37.8 47.8 34.0 47.2 -1.19 -0.18 39.1 49.6 34.9 47.8 -1.29 -0.55
Urea 2.36 6.47 2.66 6.93 0.26 0.41 1.89 5.85 1.99 6.69 0.09 0.75 2.08 6.03 2.26 6.91 0.16 0.78
Cre 57 109 55 108 -0.17 -0.13 44 86 44 86 0.03 0.03 48 107 46 104 -0.11 -0.22
Na 135 141 129 144 -2.53 0.93 134 142 129 147 -1.67 1.67 134 142 128 145 -2.16 1.12
K 3.3 4.8 3.6 5.3 0.66 1.16 3.4 4.8 3.6 5.4 0.43 1.41 3.4 4.8 3.6 5.3 0.52 1.21
Cl 100 109 95 112 -1.82 1.18 102 110 98 115 -1.12 1.79 101 109 96 113 -1.51 1.19
Ca 2.22 2.55 2.17 2.58 -0.56 0.38 2.18 2.54 2.07 2.64 -1.01 0.83 2.22 2.55 2.10 2.60 -1.13 0.51
IP 0.76 1.40 0.76 1.36 -0.01 -0.21 0.83 1.42 0.76 1.38 -0.41 -0.24 0.78 1.42 0.75 1.36 -0.20 -0.33
Mg 0.73 0.99 0.66 0.96 -1.01 -0.37 0.71 0.98 0.47 0.93 -3.26 -0.63 0.73 0.98 0.58 0.95 -2.04 -0.45
Fe 8.9 29.7 7.2 28.8 -0.30 -0.17 3.6 29.0 3.7 26.7 0.03 -0.37 5.6 28.6 4.6 28.3 -0.18 -0.05
CRP 0.19 11.80 0.36 16.68 0.04 1.28 0.22 19.68 0.32 28.70 0.02 1.65 0.22 16.11 0.35 25.83 0.03 1.97
IgG 11.40 18.89 9.96 21.52 -0.61 1.13 11.21 20.53 10.52 26.53 -0.25 2.22 11.22 19.55 10.15 23.25 -0.42 1.44
IgA 0.92 4.74 1.14 5.00 0.22 0.26 1.00 4.35 1.13 5.26 0.14 0.99 0.98 4.54 1.10 5.13 0.13 0.62
IgM 0.37 2.23 0.42 2.57 0.10 0.67 0.50 2.87 0.55 2.92 0.09 0.08 0.40 2.50 0.45 2.78 0.10 0.51
Tf 1.88 3.08 1.83 3.11 -0.17 0.09 2.01 3.90 1.91 3.76 -0.20 -0.30 1.93 3.48 1.85 3.48 -0.20 -0.01
TSH 0.58 4.81 0.41 3.79 -0.16 -0.98 0.51 4.99 0.47 3.01 -0.04 -2.07 0.57 5.02 0.46 3.62 -0.11 -1.38
PSA 0.27 2.87 0.22 2.27 -0.08 -0.91
ZA ZA vs KE
Male Female Male + Female
KE ZA KE ZAZA vs KE ZA vs KE KE
Table 7.5: Comparison of reference intervals between Kenya and South Africa 




We compared RIs between Kenya and South Africa and assessed the extent to which potential 
sources of RI variation impacted reference values. This was an attempt at determining the 
possibility of harmonizing RIs as the 2 countries used a harmonized study protocol including 
analysis of samples in a central laboratory using appropriate quality control procedures to ensure 
comparability of results (Ozarda et al., 2013). A study by Karita et al demonstrated significant 
inter-country variation in RIs for some analytes among East African countries (Karita et al., 
2009). However, there was no harmonization of pre-analytical sample handling and sample 
analysis was not centralized which could have contributed to some of the differences seen. 
Generally, there is scanty published data on chemistry and immunoassay RIs from sub-Saharan 
Africa. Some of the published data was derived from participants screened as part of HIV 
clinical trials and often times the requisite rigor expected of a RI study wasn’t met (Segolodi et 
al., 2014). There are concerns that individuals volunteering to participate in HIV related clinical 
trials may not be representative of a healthy reference population, hence compromising their 
external validity.  The IFCC has a fairly strict criteria that should be followed when identifying 
reference individuals for a RI study (PetitClerc & Solberg, 1987). 
 
In our study, we found several differences in RIs between Kenya and South Africa that we didn’t 
expect. For example, the LL for Na in the South African population was 128 mmol/L for 
combined males and females compared to 134 mmol/L in the Kenyan participants. The LL for Cl 
for both males and females in South Africans was similarly very low at 95 and 98 mmol/L 
respectively compared to 100 and 102 mmol/L for Kenya. The RIs we obtained for electrolytes 
in Kenya are in keeping with what has previously been published (Kibaya et al., 2008). A search 
for published literature on RIs for electrolytes from South Africa didn’t yield citable references 
hence we are unable to find an explanation for the unexpected low Na and Cl. However, a study 
from Botswana which borders South Africa reported RIs for Na (135-143 mmol/L) and Cl (98-
107 mmol/L) that are similar to what has been found in other countries in Africa (Segolodi et al., 
2014). Given that the Na values obtained from South Africa are low enough to be clinically 
relevant and that they are at variance with what has been widely published (Burtis et al., 2005), 
verification of the same is required. Given the association between hyponatremia and 
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tuberculosis, it would be desirable to find out whether some of the participants could have had 
undiagnosed tuberculosis (Jafari et al., 2012). 
 
Lipid levels were consistently lower in the black South Africans compared to Kenyans. Various 
factors can contribute to variations in lipid levels across populations including differences in 
environment, physiology and genetics (Bentley & Rotimi, 2012).  In our study, no significant 
differences were seen in age and BMI between participants from the 2 countries. The impact of 
exercise on reference values for all the tests was also minimal. Therefore, it is unlikely that the 
differences seen in lipid levels can be attributed to differences in age, BMI or exercise. CRP and 
immunoglobulin levels were higher in the South African participants which may partially explain 
the lower cholesterol levels seen given that inflammation may cause a dyslipidemia characterized 
by low HDL-C levels (Esteve, Ricart, & Fernandez-Real, 2005). We have previously published 
analysis of the same Kenyan data set that revealed a prevalence of metabolic syndrome of 25.6% 
(Omuse, Maina, Hoffman, et al., 2017). Metabolic syndrome is associated with increased 
visceral adipose tissue and a dyslipidemia characterized by increased LDL-C, TGs and reduced 
HDL-C. We hypothesize that a high prevalence of metabolic syndrome in the Kenyan 
participants may contribute to the differences seen in lipid levels. Differences in diet have been 
shown to contribute to variation in lipid levels. Kakarmath et al demonstrated that a combination 
of using palm oil for cooking, eating more than one serving of meat per day and fewer than five 
servings of fruits and vegetables per day, was associated with higher serum total cholesterol in 
Dar es Salaam, Tanzania (Kakarmath et al., 2017). We did collect data on food intake however, 
we did not use a standardized and validated questionnaire to objectively determine its association 
with lipid levels. There are also known inter-ethnic variations in genes associated with lipids 
such as APOL1 whose prevalence varies across sub-Saharan Africa and is thought to influence 
the distribution of HDL particles (Freedman et al., 2011). Genetic testing to determine the 
prevalence of the APOL1 gene would aid in further elucidating reasons for the variation in lipid 
levels. Kesswell et al examined differences in body fat distribution between premenopausal 
black and white South African women and found that black women had less central and more 
peripheral (lower-body) but had lower serum lipid concentrations. Central and peripheral fat 
deposition was shown to be independently associated with the presence of insulin resistance in 
both the black and white women, and with TG concentrations in the black women (Keswell, 
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Tootla, & Goedecke, 2016). We did not collect data on body composition hence do not know 
whether this could have contributed to some of the differences seen in lipid levels between 
Kenya and South African blacks. 
 
Differences in liver function tests were found with South Africans having much lower albumin, 
ALT, LDH and ALP levels in both males and females but higher GGT. We didn’t have data on 
total and direct bilirubin from South Africa to be able to evaluate whether the increased GGT 
could be associated with cholestasis or hepatobiliary disease though the low ALP levels make 
this unlikely. Alcohol consumption was lower in South Africans hence would not explain the 
increased GGT. Given that CRP and IgG levels in South Africans were much higher compared to 
Kenyans, the low albumin may be due to inflammation given that it is a negative acute phase 
reactant (Gulhar, Ashraf, & Jialal, 2020). We didn’t test for the presence of viral hepatitis hence 
cannot speculate on whether this may have contributed to the differences in liver enzymes. 
Further studies are recommended to investigate the reasons for the differences in liver function 
tests seen. 
 
Several factors are thought to contribute to intra-ethnic differences in inflammatory markers. We 
found higher levels of CRP and immunoglobulins in the South African participants compared to 
their Kenyan counterparts. It is often assumed that infections contribute to the increased 
inflammation seen in Africans but non-communicable diseases also contribute to chronic 
inflammation especially with urbanization taking root in the continent (Bickler et al., 2018). 
South Africa is a more urbanized country compared to Kenya and differences in diet, lifestyle 
and environment could contribute to the increased inflammation seen. Urbanization is thought to 
influence gene expression through unknown mechanisms. For example, in Morocco, a 
comparison of rural and urban populations demonstrated differences in gene expression of G 
protein-coupled receptors (Bickler, Lizardo, Cauvi, & De Maio, 2016). These receptors impact 
on almost every aspect of biology in humans hence differential expression could possibly 
translate into physiological differences including inflammatory responses. Chronic inflammation 
is a known cardiovascular disease risk factor hence identifying the reason for the increased 
inflammatory markers may provide an opportunity to mitigate this risk. 




Little is known about sources of RI variation in sub-Saharan Africa and whether BMI impacts on 
reference values especially those associated with metabolic syndrome. Not surprisingly, an 
increase in BMI was associated with an increase in TC, TG, LDL-C, UA, CRP, GGT and a 
decrease in HDL-C as seen by absolute rp values > 0.2. Of note was that the slope of the 
regression lines for UA, TG and CRP seen in Fig 7.1 was different between Kenya and South 
Africa indicating that factors beyond ethnicity influence this relationship, further adding to the 
complexity in determining harmonized RIs. Ichihara et al has also demonstrated similar 
variations across several countries with change in BMI having the greatest impact in Asian 
countries compared to other races and ethnicities (Ichihara, 2014). This suggests that BMI should 
be an important consideration when determining RIs, however, there is need for robust evidence 
to guide what BMI cut off should be used as an inclusion or exclusion criteria. 
 
Our study had various limitations. Despite all attempts at standardizing pre-analytical, analytical 
and post-analytical processes, discrepancies were found in the actual implementation of the 
recruitment criteria with individuals with BMIs greater than 35 kg/m2 being recruited so long as 
they were subjectively healthy. However, for purposes of comparing Kenya and South Africa 
data, everyone with a BMI above 35 kg/m2 was secondarily excluded.  Given the challenge of 
coordinating sample collection from various sites, it is possible that sample handling may have 
differed especially with regards to time to centrifugation, aliquoting and storage. Analytes such 
as potassium and glucose which are sensitive to sample handling might have been affected for 
some samples. In order to minimize the impact of any delay in centrifuging on glucose, samples 
for glucose analysis were collected in fluoride tubes. We relied on participants to truthfully 
report on their health status when filling in the questionnaire including whether they had any 
infection such as HIV, HBV and HCV. It is possible that a few of our participants may have been 
recruited as healthy individuals despite this not being true thereby impacting on derived RIs. 
However, we used LAVE to secondarily exclude individuals with outlier values based on a 
combination of analytes used in evaluating nutritional and inflammatory status. 
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In conclusion, the findings of this study highlight the difficulties in harmonizing RIs even for 
populations thought to be similar despite standardizing study processes to enable direct 
comparison of RIs. For most analytes, harmonization of RIs between Kenyans and South 
Africans of African ancestry will not be ideal as they could result in misclassification of 
individuals as either diseased or healthy. We therefore recommend separate RIs for the 
respective reference populations. Furthermore, BMI was shown to be a major source of variation 
and future studies should be sufficiently powered to factor this as an independent variable that 
influences RIs and also determine the ideal BMI to use as an inclusion or exclusion criteria given 
the subjectivity of defining health. 
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CHAPTER 8:  DISCUSSION 
8.1 Integrated summary 
Establishing RIs for any population is a herculean task that requires attention to detail at every 
step of the testing cycle. The global study on reference intervals (RIs) adopted a harmonized 
protocol to enable comparison of results across participating countries by using a panel of sera to 
recalibrate and align reference values (RVs) (Ichihara, Ozarda, Barth, Klee, Qiu, et al., 2017; 
Ozarda et al., 2013). Despite all attempts at ensuring that we recruited healthy individuals, it is 
clear from the prevalence of metabolic syndrome (MetS) of 25.6% that a sizeable proportion had 
increased waist circumference, hypertension, dysglycaemia or dyslipidemia (Omuse, Maina, 
Hoffman, et al., 2017). People with MetS are at an increased risk for cardiovascular disease or 
type 2 diabetes and one would argue that they should have been secondarily excluded when 
determining our RIs. We reduced the influence of MetS and increased body mass index (BMI) 
on derived RIs by use of the latent abnormal value exclusion (LAVE) method as well as 
restricting recruitment to individuals with a BMI ≤ 35 kg/m2. LAVE was effective in optimizing 
RIs for AST, ALT, GGT iron-markers and CRP by reducing the influence of latent anemia and 
metabolic diseases (Omuse et al., 2020). LAVE was also useful in reducing the influence of 
anaemia and inflammation when deriving RIs for complete blood count parameters and this was 
seen by the higher lower limits (LLs) and narrowing of the RIs for red blood cell (RBC) related 
parameters especially for females (Omuse et al., 2018).  
 
Less than 1% of participants recruited in our study had reduced eGFR, a testimony to the 
relatively good health of the recruited individuals and successful effort in recruiting a sample 
representative of an ideal reference population. We found that eGFR determined using Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (with or without correcting for 
race) better correlated with a prediction model that included risk factors for chronic kidney 
disease (CKD) and classified fewer asymptomatic healthy Kenyan adults as having a reduced 
eGFR (Omuse, Maina, Mwangi, et al., 2017). Correction for race further improved the 
correlation hence we recommend the use of the CKD-EPI equation in screening for CKD in 
asymptomatic adults in Kenya. 
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Our derived RIs for CBCs provide a suitable reference for the East African population that can 
be used to guide interpretation of respective laboratory tests given the paucity of well conducted 
RIs studies in the East African region. We have provided a comprehensive comparison with 
similar studies in Africa clearly highlighting the differences and possible explanations for the 
same. Our RIs for haematological parameters such as haemoglobin and haematocrit were higher 
than what has previously been reported from Kenya (Karita et al., 2009). We are cognizant that 
these differences could reflect recruitment of a much healthier population but at the same time 
could be partially explained by the difference in altitude between Nairobi and some of the other 
study sites. Ozarda et al describes regional variations in haematological parameters in Turkey 
attributable to altitude differences despite aefforts at standardizing all aspects of the testing cycle 
(Ozarda et al., 2017). This observation highlights the influence of the environment on RIs and 
may explain some of the geographical differences seen even in populations thought to be fairly 
homogeneous. Similar to other studies, we have demonstrated the need to adjust our RIs for 
neutrophil counts to reflect the inherent low counts in the African population (Omuse et al., 
2018). The use of manufacturer provided RIs or those found in text books which are largely 
derived from Caucasian populations could result in sub-optimal patient management. 
Laboratories should at the very least verify these RIs as recommended by the Clinical Laboratory 
Standards Institute (CLSI, 2010). 
 
Our derived RIs for some of the chemistry and immunoassay tests highlight the need for sex 
specific RIs for analytes which traditionally are reported without sex stratification. These include 
uric acid (UA), creatinine, total bilirubin (TBil), total cholesterol, alanine transaminase (ALT), 
aspartate transaminase (AST), creatinine kinase (CK), gamma-glutamyl transferase (GGT), 
transferrin (Tf), transferrin saturation (TfSat) and immunoglobulin-M (Omuse et al., 2020). 
Whether this proposed change in what has previously been accepted as a norm will be adopted 
by laboratories in Kenya and any other users of our RIs is a question that can only be answered 
over time. Indeed, a lot of effort will be required to explain and convince users on the need for 
sex stratification. Our TBil RI of 6-43 µmol/L for males and 5-27 µmol/L for females is almost 
double what has been reported in published studies from Asia and North America. This finding 
of increased TBil with normal transaminases has been described in other studies carried out in 
East Africa (Kibaya et al., 2008; Saathoff et al., 2008). This needs to be investigated further in 
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order to advise doctors and patients what this finding actually means and to what extent an 
asymptomatic adult with elevated TBil but normal transaminases needs to be investigated. 
 
The differences seen between our RIs between and those from other countries suggests that 
similar differences may be observed with CDLs. Unfortunately, most countries adopting CDLs 
for diagnosis of pre-diabetes and diabetes do so without verifying their appropriateness for their 
respective populations. It is possible that this results in misclassification of individuals as 
diseased or not diseased as shown by Zemlin et al who evaluated the utility of the recommended 
HbA1c cut-off for diagnosing diabetes of 6.5% and found that 6.1% was the most appropriate 
cut-off in mixed ancestry South Africans (Zemlin, Matsha, Hassan, & Erasmus, 2011). Such 
differences emphasize the need for population specific CDLs or at the very least verification of 
what is found in guidelines before adoption. Zemlin et al carried out a study to derive and 
validate a HbA1c cut-off for diagnosing pre-diabetes (Zemlin, Matsha, Kengne, & Erasmus, 
2015). A cut-off of 5.75% was determined to be most optimal which is very similar to the 
American Diabetes Association recommended cut-off of 5.7%. Similarly, the use of CDLs that 
are not population specific for lipid lowering targets may result in treatment dosages that are not 
optimal or inaccurate evaluation of cardiovascular risk when risk scores that incorporate lipid 
values are used. To determine our own CDLs for lipids, longitudinal studies are required where 
various cut-offs and their ability to predict cardiovascular risk are evaluated. 
 
The use of various statistical approaches such as standard deviation ratios (SDRs) and bias ratios 
(BRs) presented challenges when deciding when to partition an RI. Each statistical method has 
its limitations and sometimes may create a dilemma when they give conflicting findings 
(Ichihara, 2014; Ichihara & Boyd, 2010). We used an SDR ≥0.4 to determine the need for 
partitioning of RIs by sex or age. SDR gives an indication of the extent to which a source of 
variation such as sex contributes to the overall (between-individual) imprecision seen in a data 
set but doesn’t provide much information about data at the extremes which is crucial when 
determining lower and upper limits (ULs) of an RI. For this reason, we also adopted lower and 
upper limit bias ratios (BRLL and BRUL) with an absolute cut-off of 0.375 to further guide us on 
the need for partitioning data. BR represents between subgroup differences at the periphery (LL 
or UL) of the distributions. In order to avoid over partitioning, we further added a third criteria 
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based on the absolute bias in relation to the reporting units and published the first paper that 
proposes the use of a partitioning flowchart combining the three criteria (Omuse et al., 2020). 
We do propose the adoption of this scheme when evaluating the need for partitioning data based 
on sources of variation as it takes into consideration variation at the centre and periphery of a 
data set when comparing groups. 
 
The extent to which BMI influences RIs and whether BMI specific RIs should be adopted is an 
ongoing debate. There is no doubt that there is an association between BMI and analytes related 
to MetS such as glucose, lipids, UA and transaminases based on an absolute partial correlation 
co-efficient (rp)> 0.2 as shown in our multiple regression analysis. We did restrict recruitment to 
individuals with a BMI≤35 kg/m2. However, other similar studies used lower BMI cut-offs such 
32 kg/m2 in Saudi Arabia (Borai et al., 2016)  and  28 kg/m2 in Turkey (Ozarda et al., 2014). The 
complexity that arises with incorporating BMI as a source of variation is that its effect on 
analytes varies across populations as demonstrated by Ichihara et al (Ichihara, Ozarda, Barth, 
Klee, Shimizu, et al., 2017). Furthermore, BMI can be influenced by so many variables including 
food intake and activity hence can change quite rapidly over time. It is therefore not practical to 
derive BMI specific RIs as this could further complicate the utility of RIs. Our study was also not 
powered to sufficiently to allow stratification by BMI. 
 
Comparison of our data with data from black South Africans collected using the same study 
protocol including sample analysis done in the same laboratory revealed interesting findings 
some of which require further studies to determine their veracity. For instance, the hyponatremia 
seen in some of the South Africans is inexplicable and requires further verification. What is clear 
from the comparison is that having harmonized RIs will not be possible as the data reveals 
significant sex and age differences. We therefore recommend country specific RIs for Kenya and 
black South Africans. South Africa being a multi-racial country, there is need to analyze the 
effect of race and ethnicity on the derived RIs.  
 
We used both parametric and non-parametric methods to derive the Kenyan RIs but adopted the 
parametric method which resulted in narrower 90% confidence intervals around the LL and UL 
as well as lower ULs for chemistry tests which can be attributed to removal of outliers (Omuse et 
Stellenbosch University  https://scholar.sun.ac.za
187 
 
al., 2020). For CBC parameters, LAVE resulted in an increase in the LLs and narrowing of RIs 
(Omuse et al., 2018). However, the non-parametric method is simpler to use as it simply involves 
listing reference values from the lowest to the highest value and identifying the LL and UL as the 
values corresponding to the 2.5th and 97.5th percentiles. The use of LAVE significantly impacted 
on RIs for analytes associated with the presence of MetS, anaemia or inflammation with ULs for 
analytes such as ALT, AST, Tf, c-reactive protein and triglycerides reducing while LLs for iron 
and TfSat increasing (Omuse et al., 2020). The use of statistical approaches like LAVE to 
secondarily exclude reference individual’s data based on out of range values for related analytes 
further helps in ensuring that RIs are reflective of a healthy population by reducing the likelihood 
of including individuals with sub-clinical or overt disease in a reference data set. We therefore 
advocate its use in derivation of RIs. 
 
The totality of the presented work supports the need for population specific RIs. However, 
beyond sex and age, it is clear that other sources of variation such as BMI and possibly altitude 
need to be considered for specific analytes. The difficulty in identifying an ideal reference 
population is also emphasized given the prevalence of sub-clinical conditions that confer 
increased risk for disease. It is also impossible to rule out all possible disease conditions that may 
impact on an analyte. No inclusion or exclusion criteria can be perfect hence any RIs can only be 
extrapolated to populations that to a large extent are similar to the reference population from 
whom the RIs were derived. 
 
8.2 Future directions 
Our RIs need to be verified and their appropriateness for different populations across Kenya and 
the East African region needs to be determined. Nevertheless, given the rigour with which the 
study was conducted, the published studies will provide a very useful reference for laboratories 
in SSA that are looking for RIs for common haematology, chemistry and immunoassay tests. We 
will carry out transference studies to determine the transferability of our RIs to analyzers from 
other manufacturers given that Beckman analyzers for chemistry and immunoassay aren’t very 
common in Kenya. 
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There is a need to verify widely adopted CDLs and determine how they relate to population 
specific RIs to find out whether population specific RIs for tests like fasting plasma glucose, uric 
acid and lipids may be used to derive population specific CDLs without necessarily carrying out 
a longitudinal study which would are expensive and require long term follow-up to collect 
outcome data. 
 
We did not explore the impact of genetic diversity on RIs given the costs associated with 
carrying out genetic studies. Genetic variation might have contributed to some of the differences 
seen in RIs between Kenya and South Africa given that genetic diversity is thought to be more 
prevalent in the African continent compared to any other continent. Future studies should 
therefore explore the association between genetic diversity at an individual or population level 
and RIs as this would be more scientifically sound as opposed to comparisons based on race 
which is a poor surrogate for genetic diversity. 
 
The utility of our flowchart in determining whether to partition RIs by sex and/or age needs to be 
verified using other datasets. We intend to do so when analyzing data from other countries that 
have participated in the global RI study and evaluate to what extent it impacts on previously 
derived RIs. The impact of adopting our RIs on reporting out of reportable range values in 
comparison to manufacturer recommended RIs needs to be evaluated. This can be assessed by 
monitoring the flagging rate of ‘abnormal’ values using either archived laboratory data or data 
collected prospectively. 
 
Given the rigour, technical expertise, cost and time required to carry out a reference interval 
study, alternative ways of deriving RIs such as use of indirect methods need to be evaluated. 
Indirect methods rely on mining routine laboratory data that is readily available and this can be 
an alternative especially where time and financial resources are constrained as well as for 
deriving RIs for rare sample types like CSF and for populations such as children, expectant 
women and the elderly. 
 
We do intend to engage the Ministry of Health in Kenya and present our RIs for adoption as a 
key reference for both public and private laboratories in Kenya and the East African region. 
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Appendix 6: Informed consent 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
Project Name:  
ESTABLISHING ADULT REFERENCE VALUES FOR SELECTED ANALYTES IN KENYA NIGERIA AND   SOUTH AFRICA 
Project leaders:  Dr Geoffrey Omuse/Dr Daniel Maina 
Address: Department of Pathology, Aga Khan University Hospital, 3rd Parklands Ave, Nairobi, Kenya 
Contact numbers: Dr Geoffrey Omuse  +254724932640 OR +254-20-3662226  
Dr Daniel Maina +254720927338 OR +254-20-3662226  
You are being invited to take part in a research project that is taking place in 18 countries globally which includes 3 from Africa.  Please take some 
time to read the information presented here, which will explain the details of this project.  Please ask the study staff or doctor any questions about 
any part of this project that you do not fully understand.  It is very important that you are fully satisfied that you clearly understand what this 
research entails and how you could be involved.  Also, your participation is entirely voluntary and you are free to decline to participate.  If you 
say no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw from the study at any point, even if you initially 
agree to take part.  This study has been approved by the Scientific and Ethical committees of Aga Khan University Hospital Nairobi and will be 
conducted according to the ethical guidelines and principles of the international Declaration of Helsinki, South African Guidelines for Good Clinical 
Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
The investigators are in the process of reviewing “normal values” for selected blood tests.  Doctors will use these normal values to compare against 
values of patients in order to asses the health of an individual e.g. comparing the blood sugar level of a diabetic patient with that of normal 
individuals. You will be asked about your health status and your activity levels.  It is extremely important that you answer these questions honestly 
and to the best of your ability.  This information will not be shared with anyone outside of this study, but it is very important for us to know so that 
we can correctly determine what is normal for our population. 
All Kenyan born healthy individuals of African Ethnic origin will be considered for the study.  Individuals with the following conditions will not 
be included in the study: 
 Under regular medications for illnesses (e.g. high blood sugar, high blood pressure, allergies and depression) 
 Pregnant females or within 1 year after child birth 
 Alcohol:  more than 5 drinks a day OR 1400ml beer OR 580ml wine OR 175ml whiskey/brandy etc 
 Individuals who had an operation or had to be admitted to hospital for an illness in the past 2 weeks 
 Smoking more than 20 cigarettes per day 
 BMI > 35 kg/m2 (very obese) 
 
Why have you been invited to participate? 
We are interested in enrolling “healthy individuals” and we expect that all your test results will be “normal”.  Therefore we will be able to use your 
test results to calculate “normal values”. 
What will your responsibilities be? 
In order for this project to be a success, healthy individuals are expected to complete a questionnaire and allow for height, weight and blood pressure 
measurement.  A small amount of blood will be collected from selected individuals and this blood will be analysed in Pathcare laboratories in South 
Africa and Kenya. We are only interested in routine tests including tests for normal functioning of liver, kidney and thyroid.  
Will you benefit from taking part in this research? 
Though it will take a few weeks to get results out, we will get these results to you via email.  If results are severely abnormal, a referral letter will 
be written to your local clinic or general practitioner.  There will be no direct financial benefits to individuals involved in the study.  The 
establishment of normal values for our local population will help doctors to better diagnose and treat patients. 
Are there any risks involved in your taking part in this research? 
Apart from slight discomfort at the site of where blood is drawn, there are no risks involved.   
If you do not agree to take part, what alternatives do you have? 
Your participation in this study is completely voluntary and you can withdraw at any stage of the study.  Your participation will not influence any 
treatment you are currently on.  You can withdraw from the study at any stage, in which event your stored samples will be discarded.  
Who will have access to your data? 
Your information will not be made public.  Only the principal and co-investigators in the study will have access to your result.  In addition, once 
we have drawn your blood, your samples and information will be identified with a number only.  If the results of the study are published, your 
identity will not be made known. 
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Declaration by participant 
By signing below, I …………………………………..…………. agree to take part in a research study entitled:   
ESTABLISHING ADULT REFERENCE VALUES FOR SELECTED ANALYTES 
I declare that: 
 I have read or had read to me this information and consent form and it is written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been pressurized to take part. 
 I may choose to leave the study at any time and will not be penalized or prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is in my best interests, or if I do not follow 
the study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....………..  
Signature of participant……………………………………   
Signature of witness…………………………………………… 
Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed above 
 I did/did not use a translator.  (If a translator is used then the translator must sign the declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
 
Signature of investigator…………………………………   
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Appendix 7: Questionnaire 
                        
    INTERNATIONAL  REFERENCE RANGE STUDY 
QUESTIONAIRRE 
          
                        
Study number                 Laboratory number              
(Ichihara Barcode)                (Pathcare Barcode)              
                                    
                        
Date of sampling                 Time of sampling              
       Year/month/Day            hour  :  minutes    
                        
CONTACT DETAILS OF 
PARTICIPANT 
                                   
Name and surname:                                       
ID number:                       Date of Birth:            
Postal address:                                        
                                          
Contact numbers:    Cell: 
  
      Home/Office:         Fax: 
  
         
E-mail address:                                        
                        
INCLUSION CRITERIA                                      
                        
1.  Do you consider yourself healthy?          NO   YES     
2.  Are you at least  20 years of age?          NO   YES     
                                        
EXCLUSION CRITERIA                                      
                                          
1.    Is your BMI > 35 kg/m2?           NO   YES     
2.    Do you drink > 5 glasses of wine/5 beers/5 shots per day?      NO   YES     
3.    Do you smoke > 20 cigarettes/day?          NO   YES     
4.    Do you have/had chronic disease (including diabetes, hypertension,              
       depression etc) requiring regular medication?        NO   YES     
5.    Do you have results from a blood test that point to a severe disease?     NO   YES     
6.    Have you been hospitalized or seriously ill in the past 2 
weeks? 
     NO    YES     
7.    Have you given blood as a donor in the previous 3 months?      NO   YES     
8.    Are you a known carrier of Hepatitis B/C or HIV?        NO   YES     
9.    Are you pregnant or within one year after childbirth?       NO   YES     
10.  Have you participated in a research study involving an investigational    NO   YES     
      drug in the past 12 weeks?                   
                                        
DEMOGRAPHICS                                        
                                          
Are you fasting ?      NO     YES            
       Last food intake:      (AM / PM)        
       Time since last meal      (hours)         
                        
Age:          years              
                        
Gender:        Male 
  
  Female            
                        
Ethnicity:        Caucasian   African   Mixed   Other (specify)    
                        
Occupation:                      
                        
Measurements:  Height     cm    BMI         
   Weight       kg     Waist circumference    cm  
                        
Blood pressure:         mmHg              
                        
ABO blood type:      A+    B+    AB+   O+   not known  
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PERSONAL HABITS                                      
                        
Do you smoke?          NO   YES         
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     If yes, how many per day for how many years?    nr/day   total nr of years       
                        
Do you drink alcohol?        NO 
  
  YES         
      If yes, how often?      Rarely   1x/week   2 - 3x/w   4 -  x/w   every day  
      If yes, how much do you drink in the typical week.                  
       Beer      litres     ✻ Calculation by the investigator:   
       Cider      litres      Amount of alcohol consumption in  
       Wine       glasses (6 glasses/bottle)  gram of ethanol per day and week   
       Spirits    bottles         grams per day    
                   grams per week    
                                      
PHYSICAL ACTIVITIES AND 
EXERCISE 
                                   
                        
Daily activities                      
     Time spent standing/walking        hours/day           
     Time spent sitting          hours/day           
     Time spent sleeping         hours/day           
     Time spent outdoors         hours/day           
                        
Physical activity at work                    
     Does your work involve vigorous activity?         NO   YES     
     If yes, how much time do you spend on the activity (e.g. digging)?     hours   min/typical day   
                        
     Does your work involve moderate intensity activity (e.g. walking)?     NO   YES     
     If yes, how much time do you spend on this activity?       hours   min/typical day   
                        
Physical activity (sports, fitness, recreation) on a regular basis (at least once per week for > 1 year)        
     Do you do any vigorous exercise regularly (e.g. running, aerobics)?     NO   YES     
     If yes, what type?                         
     If yes, frequency and duration       days/wk   hrs + min on a typical day   
                        
     Do you do any moderate-intensity exercise regularly (e.g. brisk walking)?    NO   YES     
     If yes, what type?                         
     If yes, frequency and duration       days/wk   hrs + min on a typical day   
                        
MEAL PATTERN (frequency and amount per 
week) 
                             
                        
  Red Meat       None   1 - 2 x/W   3-4x/W   5-6 x/W   every day  
  Fish        None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
  Vegetables       None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
  Pulses (Beans, Peas, Lentils)    None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
  Milk/diary       None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
  Fruit        None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
  Sweets        None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
  Fried/sauteed       None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
  Salty foods       None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
 Rice        None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
 Ugali (maize flour)      None   1 - 2 x/W   3-4 x/W   5-6 x/W   every day  
                      
CURRENT HEALTH STATUS                                    
                        
Have you suffered from any of the following infections which required treatment in the past 
year? 
        
   Bacterial infection (e.g. pharingitis, pneumonia)    No    once/y   twice/y   three/more  
   Viral infection (e.g. influenza, viral gastroenteritis)    No    once/y   twice/y   three/more  
   Parasite infection         No    treated   currently    untreated  
              <2yrs  treated      
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Do you have air pollution in your living 
environment? 
               
  Polution        None   Mild   Moderate   Fairly   Heavy   
  Source        Car    Factory   Both   Other___________________  
  Time spent outside in air polution    hrs/day               
                        
Are you taking any nutritional supplements regularly?      NO   YES      
  If yes, specify type                               
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Are you taking any medication regularly?        NO   YES      
  If yes, specify ALL DRUGS                             
                                  
                                  
                        
Have you had any of the following allergic disorders in recent 
years? 
             
         Allergic rhinitis     Bronchial asthma       
         Food allergy     Other (Specify):________________________  
         Atopic dermatitis    I have had no allergic disorder     
                        
Have you had chest pain in the past year for which you sought medical attention or was 
hospitalized? 
       
               NO   YES      
                          
VITAMIN D 
STATUS 
                                       
                        
Have you eaten oily fish (e.g. tuna, sardines, snoek, mackerel, salmon, including canned, fresh or smoked) in the 
last week? 
    
               NO   YES      
  If yes, how many times?           times/week        
                        
On an average day, how much time do you spend outdoors between 10 am and 4 
pm? 
          
         < 15 min   15 min   30min   1 hr   2 hrs   
         3 hrs   4 hrs   5 hrs   6 hrs      
                        
When you are outdoors, what parts of your body are exposed and NOT covered?           
         Face   Arms   Hands   Legs   Torso   
                        
WOMEN (If you are post menopausal or have had a hysterectomy you can skip this 
section) 
                 
When was the first day of your last period?        yyyy/mm/dd      
                        
How is your menstrual cycle?    regular   irregular   menopause        
         under hormone therapy or taking contraceptive pills        
                        
If "regular", what is the average length of the cycle?      days       
                        
Do you suffer from hypermenorrhoea (heavy/lasting > 7 days) or hypomenorrhoea (extremely 
light)? 
       
  I suffer from NONE of the above   hypermenorrhoea    hypomenorrhoea       
                        
FOR MEN 
ONLY 
                                         
                        
Have you had any urinary problems in the past 3 months (frequent urge to urinate, burning or painful 
urination or difficulty urinating)? 
     
            NO   YES      
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THANK YOU FOR YOUR COOPERATION. YOUR INFORMATION WILL BE USED SOLELY FOR THIS STUDY  
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